Prestige Consumer Healthcare (PBH) 10-Q 2 Feb 17 2017 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Dec. 31, 2016	Jan. 27, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	Prestige Brands Holdings, Inc.
Entity Central Index Key	1,295,947
Current Fiscal Year End Date	--03-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Common Stock, Shares Outstanding		52,936,255

Consolidated Statements of Inco

Consolidated Statements of Income and Comprehensive Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Revenues
Net sales	$ 216,732	$ 199,485	$ 640,519	$ 596,034
Other revenues	31	710	871	2,358
Total revenues	216,763	200,195	641,390	598,392
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	92,216	83,411	271,287	249,432
Gross profit	124,547	116,784	370,103	348,960
Operating Expenses
Advertising and promotion	30,682	29,935	86,909	84,250
General and administrative	22,131	18,135	60,383	52,186
Depreciation and amortization	5,852	6,071	18,700	17,478
(Gain) loss on divestitures	(3,405)	0	51,552	0
Total operating expenses	55,260	54,141	217,544	153,914
Operating income	69,287	62,643	152,559	195,046
Other (income) expense
Interest income	(46)	(31)	(149)	(91)
Interest expense	18,600	19,493	60,660	62,104
Loss on extinguishment of debt	0	0	0	451
Total other expense	18,554	19,462	60,511	62,464
Income before income taxes	50,733	43,181	92,048	132,582
Provision for income taxes	19,092	15,186	33,743	46,611
Net income	$ 31,641	$ 27,995	$ 58,305	$ 85,971
Earnings per share:
Basic (in USD per share)	$ 0.60	$ 0.53	$ 1.10	$ 1.63
Diluted (in USD per share)	$ 0.59	$ 0.53	$ 1.09	$ 1.62
Weighted average shares outstanding:
Basic (in shares)	52,999	52,824	52,960	52,727
Diluted (in shares)	53,359	53,203	53,339	53,106
Comprehensive income, net of tax:
Currency translation adjustments	$ (8,736)	$ 4,922	$ (11,857)	$ (6,562)
Total other comprehensive (loss) income	(8,736)	4,922	(11,857)	(6,562)
Comprehensive income	$ 22,905	$ 32,917	$ 46,448	$ 79,409

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2016	Mar. 31, 2016
Current assets
Cash and cash equivalents	$ 63,289	$ 27,230
Accounts receivable, net	104,388	95,247
Inventories	100,926	91,263
Deferred income tax assets	12,602	10,108
Prepaid expenses and other current assets	10,005	25,165
Total current assets	291,210	249,013
Property and equipment, net	12,865	15,540
Goodwill	345,485	360,191
Intangible assets, net	2,156,378	2,322,723
Other long-term assets	4,914	1,324
Total Assets	2,810,852	2,948,791
Current liabilities
Accounts payable	45,250	38,296
Accrued interest payable	8,399	8,664
Other accrued liabilities	78,675	59,724
Total current liabilities	132,324	106,684
Long-term debt
Principal amount	1,437,000	1,652,500
Less unamortized debt costs	(21,421)	(27,191)
Long-term debt, net	1,415,579	1,625,309
Deferred income tax liabilities	459,780	469,622
Other long-term liabilities	3,312	2,840
Total Liabilities	2,010,995	2,204,455
Commitments and Contingencies
Stockholders' Equity
Preferred stock - $0.01 par value; Authorized - 5,000 shares; Issued and outstanding - None	0	0
Common stock - $0.01 par value; Authorized - 250,000 shares; Issued - 53,269 shares at December 31, 2016 and 53,066 shares at March 31, 2016	532	530
Additional paid-in capital	455,684	445,182
Treasury stock, at cost - 332 shares at December 31, 2016 and 306 shares at March 31, 2016	(6,594)	(5,163)
Accumulated other comprehensive loss, net of tax	(35,382)	(23,525)
Retained earnings	385,617	327,312
Total Stockholders' Equity	799,857	744,336
Total Liabilities and Stockholders' Equity	$ 2,810,852	$ 2,948,791

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2016	Mar. 31, 2016
Stockholders' Equity:
Preferred stock, par value (in USD per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in USD per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	250,000,000	250,000,000
Common stock, shares issued (in shares)	53,269,000	53,066,000
Treasury stock, (in shares)	332,000	306,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Operating Activities
Net income	$ 58,305	$ 85,971
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	18,700	17,478
Loss on divestitures and sales of property and equipment	51,807	0
Deferred income taxes	(12,530)	31,591
Amortization of debt origination costs	6,129	5,433
Stock-based compensation costs	6,260	7,098
Loss on extinguishment of debt	0	451
Gain on sale or disposal of property and equipment	0	(36)
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	(12,374)	2,453
Inventories	(16,589)	(7,114)
Prepaid expenses and other current assets	11,149	5,472
Accounts payable	7,168	(17,553)
Accrued liabilities	22,323	5,207
Net cash provided by operating activities	140,348	136,451
Investing Activities
Purchases of property and equipment	(1,935)	(2,540)
Proceeds from divestitures	110,717	0
Proceeds from the sales of property and equipment	85	344
Net cash provided by investing activities	110,286	5,041
Financing Activities
Term loan repayments	(130,500)	(50,000)
Borrowings under revolving credit agreement	20,000	15,000
Repayments under revolving credit agreement	(105,000)	(81,100)
Payments of debt origination costs	(9)	(4,211)
Proceeds from exercise of stock options	3,444	6,600
Proceeds from restricted stock exercises	0	544
Excess tax benefits from share-based awards	800	1,850
Fair value of shares surrendered as payment of tax withholding	(1,431)	(2,187)
Net cash used in financing activities	(212,696)	(113,504)
Effects of exchange rate changes on cash and cash equivalents	(1,879)	(333)
Increase in cash and cash equivalents	36,059	27,655
Cash and cash equivalents - beginning of period	27,230	21,318
Cash and cash equivalents - end of period	63,289	48,973
Interest paid	54,615	58,867
Income taxes paid	25,127	9,014
Insight Pharmaceuticals
Investing Activities
Proceeds from previous acquisitions	0	7,237
DenTek Oral Care, Inc.
Investing Activities
Proceeds from previous acquisitions	$ 1,419	$ 0

Business and Basis of Presentat

Business and Basis of Presentation	9 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business and Basis of Presentation	Business and Basis of Presentation Nature of Business Prestige Brands Holdings, Inc. (referred to herein as the “Company” or “we”, which reference shall, unless the context requires otherwise, be deemed to refer to Prestige Brands Holdings, Inc. and all of its direct and indirect 100% owned subsidiaries on a consolidated basis) is engaged in the marketing, sales and distribution of over-the-counter (“OTC”) healthcare and household cleaning products to mass merchandisers, drug stores, supermarkets, club, convenience, and dollar stores in North America (the United States and Canada) and in Australia and certain other international markets. Prestige Brands Holdings, Inc. is a holding company with no operations and is also the parent guarantor of the senior credit facility and the senior notes described in Note 10 to these Consolidated Financial Statements. Basis of Presentation The unaudited Consolidated Financial Statements presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. All significant intercompany transactions and balances have been eliminated in these Consolidated Financial Statements. In the opinion of management, these Consolidated Financial Statements include all adjustments, consisting of normal recurring adjustments, that are considered necessary for a fair statement of our consolidated financial position, results of operations and cash flows for the interim periods presented. Our fiscal year ends on March 31 st of each year. References in these Consolidated Financial Statements or related notes to a year (e.g., “2017”) mean our fiscal year ending or ended on March 31 st of that year. Operating results for the three and nine months ended December 31, 2016 are not necessarily indicative of results that may be expected for the fiscal year ending March 31, 2017 . These unaudited Consolidated Financial Statements and related notes should be read in conjunction with our audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2016 . Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on our knowledge of current events and actions that we may undertake in the future, actual results could differ from those estimates. As discussed below, our most significant estimates include those made in connection with the valuation of intangible assets, stock-based compensation, fair value of debt, sales returns and allowances, trade promotional allowances and inventory obsolescence, and the recognition of income taxes using an estimated annual effective tax rate. Cash and Cash Equivalents We consider all short-term deposits and investments with original maturities of three months or less to be cash equivalents. Substantially all of our cash is held by a large regional bank with headquarters in California. We do not believe that, as a result of this concentration, we are subject to any unusual financial risk beyond the normal risk associated with commercial banking relationships. The Federal Deposit Insurance Corporation (“FDIC”) and Securities Investor Protection Corporation (“SIPC”) insure these balances up to $250,000 and $500,000, with a $250,000 limit for cash, respectively. Substantially all of the Company's cash balances at December 31, 2016 are uninsured, and approximately 58.5% of our consolidated cash balances at December 31, 2016 are located in the United States. Accounts Receivable We extend non-interest-bearing trade credit to our customers in the ordinary course of business. We maintain an allowance for doubtful accounts receivable based upon historical collection experience and expected collectability of the accounts receivable. In an effort to reduce credit risk, we (i) have established credit limits for all of our customer relationships, (ii) perform ongoing credit evaluations of customers' financial condition, (iii) monitor the payment history and aging of customers' receivables, and (iv) monitor open orders against an individual customer's outstanding receivable balance. Inventories Inventories are stated at the lower of cost or market value, with cost determined by using the first-in, first-out method. We reduce inventories for diminution of value resulting from product obsolescence, damage or other issues affecting marketability, equal to the difference between the cost of the inventory and its estimated market value. Factors utilized in the determination of estimated market value include: (i) current sales data and historical return rates, (ii) estimates of future demand, (iii) competitive pricing pressures, (iv) new product introductions, (v) product expiration dates, and (vi) component and packaging obsolescence. Property and Equipment Property and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives: Years Machinery 5 Computer equipment and software 3 Furniture and fixtures 7 Leasehold improvements * *Leasehold improvements are amortized over the lesser of the term of the lease or the estimated useful life of the related asset. Expenditures for maintenance and repairs are charged to expense as incurred. When an asset is sold or otherwise disposed of, we remove the cost and associated accumulated depreciation from the respective accounts and recognize the resulting gain or loss in the Consolidated Statements of Income and Comprehensive Income. Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. An impairment loss is recognized if the carrying amount of the asset exceeds its fair value. Goodwill The excess of the purchase price over the fair market value of assets acquired and liabilities assumed in business combinations is classified as goodwill. Goodwill is not amortized, although the carrying value is tested for impairment at least annually in the fourth fiscal quarter of each year, or more frequently if events or changes in circumstances indicate that the asset may be impaired. Goodwill is tested for impairment at the product group level, which is one level below the operating segment level. Intangible Assets Intangible assets, which are comprised primarily of trademarks, are stated at cost less accumulated amortization. For intangible assets with finite lives, amortization is computed using the straight-line method over estimated useful lives, typically ranging from 10 to 30 years. Indefinite-lived intangible assets are tested for impairment at least annually in the fourth fiscal quarter of each year, or more frequently if events or changes in circumstances indicate that the asset may be impaired. Intangible assets with finite lives are reviewed for impairment whenever events or changes in circumstances indicate that their carrying amounts may exceed their fair values and may not be recoverable. An impairment loss is recognized if the carrying amount of the asset exceeds its fair value. Debt Origination Costs We have incurred debt origination costs in connection with the issuance of our long-term debt. These costs are amortized over the term of the related debt, using the effective interest method for our bonds and our term loan facility and the straight-line method for our revolving credit facility. Revenue Recognition Revenues are recognized when the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) the selling price is fixed or determinable, (iii) the product has been shipped and the customer takes ownership and assumes the risk of loss, and (iv) collection of the resulting receivable is reasonably assured. We have determined that these criteria are met and the transfer of the risk of loss generally occurs when the product is received by the customer, and, accordingly, we recognize revenue at that time. Provisions are made for estimated discounts related to customer payment terms and estimated product returns at the time of sale based on our historical experience. As is customary in the consumer products industry, we participate in the promotional programs of our customers to enhance the sale of our products. The cost of these promotional programs varies based on the actual number of units sold during a finite period of time. These promotional programs consist of direct-to-consumer incentives, such as coupons and temporary price reductions, as well as incentives to our customers, such as allowances for new distribution, including slotting fees, and cooperative advertising. Estimates of the costs of these promotional programs are based on (i) historical sales experience, (ii) the current promotional offering, (iii) forecasted data, (iv) current market conditions, and (v) communication with customer purchasing/marketing personnel. We recognize the cost of such sales incentives by recording an estimate of such cost as a reduction of revenue, at the later of (a) the date the related revenue is recognized, or (b) the date when a particular sales incentive is offered. At the completion of a promotional program, the estimated amounts are adjusted to actual results. Due to the nature of the consumer products industry, we are required to estimate future product returns. Accordingly, we record an estimate of product returns concurrent with recording sales, which is made after analyzing (i) historical return rates, (ii) current economic trends, (iii) changes in customer demand, (iv) product acceptance, (v) seasonality of our product offerings, and (vi) the impact of changes in product formulation, packaging and advertising. Cost of Sales Cost of sales includes product costs, warehousing costs, inbound and outbound shipping costs, and handling and storage costs. Warehousing, shipping and handling and storage costs were $10.7 million and $32.1 million for the three and nine months ended December 31, 2016, respectively, and $10.1 million and $29.2 million for the three and nine months ended December 31, 2015, respectively. Advertising and Promotion Costs Advertising and promotion costs are expensed as incurred. Allowances for distribution costs associated with products, including slotting fees, are recognized as a reduction of sales. Under these new distribution arrangements, the retailers allow our products to be placed on the stores' shelves in exchange for such fees. Stock-based Compensation We recognize stock-based compensation by measuring the cost of services to be rendered based on the grant-date fair value of the equity award. Compensation expense is recognized over the period a grantee is required to provide service in exchange for the award, generally referred to as the requisite service period. Income Taxes Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Income Taxes topic of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740 prescribes a recognition threshold and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The guidance only allows the recognition of those tax benefits that have a greater than 50% likelihood of being sustained upon examination by the various taxing authorities. As a result, we have applied such guidance in determining our tax uncertainties. We are subject to taxation in the United States and various state and foreign jurisdictions. We classify penalties and interest related to unrecognized tax benefits as income tax expense in the Consolidated Statements of Income and Comprehensive Income. Earnings Per Share Basic earnings per share is calculated based on income available to common stockholders and the weighted-average number of shares outstanding during the reporting period. Diluted earnings per share is calculated based on income available to common stockholders and the weighted-average number of common and potential common shares outstanding during the reporting period. Potential common shares, composed of the incremental common shares issuable upon the exercise of outstanding stock options and unvested restricted stock units, are included in the earnings per share calculation to the extent that they are dilutive. In loss periods, the assumed exercise of in-the-money stock options and restricted stock units has an anti-dilutive effect, and therefore these instruments are excluded from the computation of diluted earnings per share. Recently Issued Accounting Standards In January 2017, the FASB issued Accounting Standards Update ("ASU") 2017-04, Intangibles - Goodwill and Other (Topic 350) . The amendments in this update simplify the test for goodwill impairment by eliminating Step 2 from the impairment test, which required the entity to perform procedures to determine the fair value at the impairment testing date of its assets and liabilities following the procedure that would be required in determining fair value of assets acquired and liabilities assumed in a business combination. The amendments in this update are effective for public companies for annual or any interim goodwill impairments tests in fiscal years beginning after December 15, 2019. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements. In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805); Clarifying the Definition of a Business. The amendments in this update clarify the definition of a business to help companies evaluate whether transactions should be accounted for as acquisitions or disposals of assets or businesses. The amendments in this update are effective for public companies for annual periods beginning after December 15, 2017, including interim periods within those periods. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements. In December 2016, the FASB issued ASU 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers . The amendments in this update affect narrow aspects of the guidance issued in ASU 2014-09, Revenue from Contracts with Customers . For public business entities, the amendments in this update are effective for annual reporting periods beginning after December 15, 2017, including interim reporting periods therein. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements. In December 2016, the FASB issued ASU 2016-19, Technical Corrections and Improvements . The amendments in this update affect a wide variety of topics in the Accounting Standards Codification. For public business entities, the amendments in this update are effective for annual periods beginning after December 15, 2017, and interim periods in the annual periods beginning after December 15, 2018. The adoption of ASU 2016-19 is not expected to have a material impact on our Consolidated Financial Statements. In October 2016, the FASB issued ASU 2016-16, Intra-Entity Transfers of Assets Other Than Inventory. The amendments in this update require recognition of the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. For public business entities, the amendments in this update are effective for annual reporting periods beginning after December 15, 2017, including interim reporting periods within those annual reporting periods. The adoption of ASU 2016-16 is not expected to have a material impact on our Consolidated Financial Statements. In August 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments . The amendments in this update provide clarification and guidance on eight cash flow classification issues. For public business entities, the amendments in this update are effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The adoption of ASU 2016-15 is not expected to have a material impact on our Consolidated Financial Statements. In May 2016, the FASB issued ASU 2016-12, Revenue from Contracts with Customers . The amendments do not change the core principle of the guidance in FASB ASC 606, discussed below. Rather, the amendments in this update affect only certain narrow aspects of FASB ASC 606. The effective date and transition requirements for the amendments in this update are the same as the effective date and transition requirements of ASU 2014-09 described below. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements. In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers . The amendments in this update clarify the implementation guidance on identifying performance obligations and licensing in FASB ASC 606. The effective date and transition requirements for the amendments in this update are the same as the effective date and transition requirements of ASU 2014-09 described below. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements. In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting . The amendments in this update involve several aspects of accounting for share-based payment transactions, including income tax consequences, classification of awards, and classification on the statement of cash flows. For public business entities, the amendments in this update are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements. In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers . The amendments in this update clarify the implementation guidance on principals versus agent considerations in FASB ASC 606. The effective date and transition requirements for the amendments in this update are the same as the effective date and transition requirements of ASU 2014-09 described below. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements. In February 2016, the FASB issued ASU 2016-02, Leases. The amendments in this update include a new FASB ASC Topic 842, which supersedes Topic 840. The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. For public business entities, the amendments in this update are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted for all entities as of the beginning of interim or annual reporting periods. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements. In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes . The amendments in this update require that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The amendments in this update may be applied either prospectively to all deferred tax liabilities and assets or retrospectively to all periods presented. For public business entities, the amendments in this update are effective for financial statements issued for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early application is permitted for all entities as of the beginning of interim or annual reporting periods. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements. In July 2015, the FASB issued ASU 2015-11, Simplifying the Measurement of Inventory . The amendments in this update more closely align the measurement of inventory in GAAP with the measurement of inventory in International Financial Reporting Standards, under which an entity should measure inventory at the lower of cost or net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. For public business entities, the amendments are effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The adoption of ASU 2015-11 is not expected to have a material impact on our Consolidated Financial Statements. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers - Topic 606 , which supersedes the revenue recognition requirements in FASB ASC 605. The new guidance primarily states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. In August 2015, the FASB issued ASU 2015-14, which deferred the effective date of ASU 2014-09 from annual and interim periods beginning after December 15, 2016 to annual and interim periods beginning after December 15, 2017. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements.

Acquisitions

Acquisitions	9 Months Ended
	Dec. 31, 2016
Business Combinations [Abstract]
Acquisitions	Acquisitions Acquisition of DenTek On February 5, 2016, the Company completed the acquisition of DenTek Holdings, Inc. (" DenTek "), a privately-held marketer and distributor of specialty oral care products. The closing was finalized pursuant to the terms of the merger agreement, announced November 23, 2015, under which Prestige agreed to acquire DenTek from its stockholders for a purchase price of $226.9 million . The acquisition expands Prestige's portfolio of brands, strengthens its existing oral care platform and increases its geographic reach in parts of Europe. The Company financed the transaction with a combination of available cash on hand, available cash from its asset based loan revolver, and financing of an additional unsecured bridge loan. The DenTek brands are primarily included in the Company's North American and International OTC Healthcare segments. The DenTek acquisition was accounted for in accordance with the Business Combinations topic of the FASB ASC 805, which requires that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based upon their respective fair values at the date of acquisition. We prepared an analysis of the fair values of the assets acquired and liabilities assumed as of the date of acquisition. The following table summarizes our allocation of the assets acquired and liabilities assumed as of the February 5, 2016 acquisition date. (In thousands) February 5, 2016 Cash acquired $ 1,359 Accounts receivable 9,187 Inventories 14,304 Deferred income taxes 3,303 Prepaids and other current assets 6,728 Property, plant and equipment, net 3,555 Goodwill 73,737 Intangible assets, net 206,700 Total assets acquired 318,873 Accounts payable 3,261 Accrued expenses 14,336 Deferred income tax liabilities - long term 74,352 Total liabilities assumed 91,949 Total purchase price $ 226,924 Based on this analysis, we allocated $179.8 million to non-amortizable intangible assets and $26.9 million to amortizable intangible assets. We are amortizing the purchased amortizable intangible assets on a straight-line basis over an estimated weighted average useful life of 18.5 years. The weighted average remaining life for amortizable intangible assets at December 31, 2016 was 17.7 years. In December 2016, as a result of an arbitration settlement and other post-closing adjustments, we recorded a reduction to goodwill of $2.8 million . As a result, we recorded goodwill of $73.7 million based on the amount by which the purchase price exceeded the fair value of the net assets acquired. Goodwill is not deductible for income tax purposes. The pro forma effect of this acquisition on revenues and earnings was not material.

Divestitures

Divestitures	9 Months Ended
	Dec. 31, 2016
Discontinued Operations and Disposal Groups [Abstract]
Divestitures and Assets Held for Sale	Divestitures Divestitures Late in the first quarter of fiscal 2017, the Company was approached and discussed the potential to sell certain businesses. Prior to these discussions, the Company did not contemplate any divestitures, and the Company did not commit to any course of action to divest any of the businesses until entering into an agreement on June 29, 2016 to sell Pediacare , New Skin and Fiber Choice, which were reported under the North American OTC Healthcare segment in the Cough & Cold, Dermatologicals and Gastrointestinal product groups, respectively. On July 7, 2016, we completed the sale of the Pediacare, New Skin and Fiber Choice brands for $40.0 million plus the cost of inventory. As a result, we received approximately $40.1 million including the cost of preliminary inventory of $2.6 million , less certain immaterial holdbacks, which will be paid upon meeting certain criteria as defined in the asset purchase agreement and within approximately 18 months following the closing date of the transaction. During the nine months ended December 31, 2016, we recorded a preliminary pre-tax loss on sale of $56.2 million . The proceeds were used to repay debt and related income taxes due on the dispositions. The following table sets forth the components of the assets sold and the pre-tax loss recognized on the sale in July 2016. (In thousands) July 7, Components of assets sold: Inventory $ 2,380 Intangible assets, net 91,208 Goodwill 2,920 Assets sold 96,508 Total purchase price received 42,380 54,128 Costs to sell 2,018 Pre-tax loss on divestitures $ 56,146 Concurrent with the completion of the sale of these brands, we entered into a transitional services agreement with the buyer, whereby we agreed to provide the buyer with various services, including marketing, operations, finance and other services, from the date of the acquisition through January 7, 2017. We also entered into an option agreement with the buyer to purchase Dermoplast at a specified earnings multiple as defined in the option agreement. The buyer paid a $1.25 million deposit in September 2016 and later notified us of its election to exercise the option. In December 2016, we completed the sales of the Dermpolast and e.p.t brands for an aggregate amount of $59.6 million . As a result, we recorded a pre-tax net gain on these divestitures of $3.9 million . The following table sets forth the components of the assets sold and the pre-tax net gain recognized on the sales of e.p.t and Dermoplast in December 2016. (In thousands) December 2016 Components of assets sold: Inventory $ 2,998 Intangible assets, net 45,870 Goodwill 6,889 Assets sold 55,757 Total purchase price received 59,614 Pre-tax net (gain) on divestitures $ (3,857 )

Accounts Receivable

Accounts Receivable	9 Months Ended
	Dec. 31, 2016
Receivables [Abstract]
Accounts Receivable	Accounts Receivable Accounts receivable consist of the following: (In thousands) December 31, March 31, Components of Accounts Receivable Trade accounts receivable $ 115,967 $ 105,592 Other receivables 289 1,261 116,256 106,853 Less allowances for discounts, returns and uncollectible accounts (11,868 ) (11,606 ) Accounts receivable, net $ 104,388 $ 95,247

Inventories

Inventories	9 Months Ended
	Dec. 31, 2016
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories consist of the following: (In thousands) December 31, March 31, Components of Inventories Packaging and raw materials $ 7,944 $ 7,563 Finished goods 92,982 83,700 Inventories $ 100,926 $ 91,263 Inventories are carried and depicted above at the lower of cost or market value, which includes a reduction in inventory values of $4.1 million and $4.8 million at December 31, 2016 and March 31, 2016 , respectively, related to obsolete and slow-moving inventory.

Property and Equipment

Property and Equipment	9 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment Property and equipment consist of the following: (In thousands) December 31, March 31, Components of Property and Equipment Machinery $ 8,217 $ 7,734 Computer equipment 13,238 12,793 Furniture and fixtures 2,504 2,445 Leasehold improvements 7,347 7,389 31,306 30,361 Accumulated depreciation (18,441 ) (14,821 ) Property and equipment, net $ 12,865 $ 15,540 We recorded depreciation expense of $1.3 million and $4.3 million for the three and nine months ended December 31, 2016, respectively. We recorded depreciation expense of $1.2 million and $3.7 million for the three and nine months ended December 31, 2015, respectively.

Goodwill

Goodwill	9 Months Ended
	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	Goodwill A reconciliation of the activity affecting goodwill by operating segment is as follows: (In thousands) North American OTC Healthcare International OTC Healthcare Household Cleaning Consolidated Balance — March 31, 2016 $ 330,615 $ 22,776 $ 6,800 $ 360,191 Reductions (12,601 ) — (555 ) (13,156 ) Effects of foreign currency exchange rates — (1,550 ) — (1,550 ) Balance — December 31, 2016 $ 318,014 $ 21,226 $ 6,245 $ 345,485 In August 2016, we sold the rights to use of the Comet brand in certain geographic areas (see Note 8 below for further information) and reduced goodwill by $0.6 million as a result. On July 7, 2016, we completed the sale of Pediacare , New Skin and Fiber Choice ( see Note 3 above for further details) for $40.0 million plus the cost of inventory and received $40.1 million including preliminary inventory, less certain immaterial holdbacks, and reduced goodwill by $2.9 million as a result. In addition, as discussed in Note 3, in connection with this sale, the buyer exercised its option to purchase the Dermoplast brand. The sale of Dermoplast was completed on December 30, 2016 and, as a result, we reduced goodwill by $5.5 million . On December 28, 2016, we completed the sale of the e.p.t brand and, as a result, we reduced goodwill by $1.4 million . In addition, in December 2016, we received $1.4 million as a result of an arbitration associated with the DenTek acquisition. As a result, we reduced goodwill by $2.8 million , including other post-closing adjustments of $1.4 million . Under accounting guidelines, goodwill is not amortized, but must be tested for impairment annually, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below the carrying amount. On an annual basis during the fourth quarter of each fiscal year, or more frequently if conditions indicate that the carrying value of the asset may not be recoverable, management performs a review of the values assigned to goodwill and tests for impairment. At February 29, 2016 , during our annual test for goodwill impairment, there were no indicators of impairment under the analysis. Accordingly, no impairment charge was recorded in fiscal 2016. We utilize the discounted cash flow method to estimate the fair value of our reporting units as part of the goodwill impairment test. We also considered our market capitalization at February 29, 2016 , which was the date of our annual review, as compared to the aggregate fair values of our reporting units, to assess the reasonableness of our estimates pursuant to the discounted cash flow methodology. The estimates and assumptions made in assessing the fair value of our reporting units and the valuation of the underlying assets and liabilities are inherently subject to significant uncertainties. Consequently, changing rates of interest and inflation, declining sales or margins, increases in competition, changing consumer preferences, technical advances, or reductions in advertising and promotion may require an impairment charge to be recorded in the future. As of December 31, 2016, no events have occurred that would indicate potential impairment of goodwill.

Intangible Assets

Intangible Assets	9 Months Ended
	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Intangible Assets A reconciliation of the activity affecting intangible assets is as follows: (In thousands) Indefinite Lived Trademarks Finite Lived Totals Gross Carrying Amounts Balance — March 31, 2016 $ 2,020,046 $ 417,880 $ 2,437,926 Reductions (77,248 ) (76,903 ) (154,151 ) Effects of foreign currency exchange rates (5,185 ) (230 ) (5,415 ) Balance — December 31, 2016 1,937,613 340,747 2,278,360 Accumulated Amortization Balance — March 31, 2016 — 115,203 115,203 Additions — 14,412 14,412 Reductions — (7,610 ) (7,610 ) Effects of foreign currency exchange rates — (23 ) (23 ) Balance — December 31, 2016 — 121,982 121,982 Intangible assets, net - December 31, 2016 $ 1,937,613 $ 218,765 $ 2,156,378 Intangible Assets, net by Reportable Segment: North American OTC Healthcare $ 1,755,635 $ 196,391 $ 1,952,026 International OTC Healthcare 80,716 1,004 81,720 Household Cleaning 101,262 21,370 122,632 Intangible assets, net - December 31, 2016 $ 1,937,613 $ 218,765 $ 2,156,378 Historically, we received royalty income from the licensing of the names of certain of our brands in geographic areas or markets in which we do not directly compete. We have had royalty agreements for our Comet brand for several years, which included options on behalf of the licensee to purchase license rights in certain geographic areas and markets in perpetuity. In December 2014, we amended these agreements and we sold rights to use of the Comet brand in certain Eastern European countries to a third-party licensee in exchange for $10.0 million as a partial early buyout of the license. The amended agreement provided that we would continue to receive royalty payments of $1.0 million per quarter for the remaining geographic areas and also granted the licensee an option to acquire the license rights in the remaining geographic areas anytime after June 30, 2016. In July 2016, the licensee elected to exercise its option. In August 2016, we received $ 11.0 million for the purchase of the remaining license rights and, as a result, we recorded a pre-tax gain of $1.2 million and reduced our indefinite-lived trademarks by $9.0 million . Furthermore, the licensee is no longer required to make additional royalty payments to us, and as a result, our future royalty income will be reduced accordingly. On July 7, 2016, we completed the sale of the Pediacare , New Skin and Fiber Choice (see Note 3 above for further details) brands for $40.0 million plus the cost of inventory and received $40.1 million including the cost of preliminary inventory, less certain immaterial holdbacks, and reduced our indefinite and finite-lived trademarks by $37.2 million and $54.0 million , respectively. During the nine months ended December 31, 2016, we recorded a preliminary pre-tax loss of $56.2 million on the sale of these brands. In addition, as discussed in Note 3, in connection with this sale, the buyer exercised its option to purchase the Dermoplast brand. The sale of Dermoplast was completed on December 30, 2016, and we received $48.4 million . As a result, we reduced intangible assets by $31.0 million . In December 2016, we also completed the sale of the e.p.t brand and, as a result, we reduced intangible assets by $14.8 million . Under accounting guidelines, indefinite-lived assets are not amortized, but must be tested for impairment annually, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the asset below the carrying amount. Additionally, at each reporting period, an evaluation must be made to determine whether events and circumstances continue to support an indefinite useful life. Intangible assets with finite lives are amortized over their respective estimated useful lives and are also tested for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable and exceeds its fair value. On an annual basis during the fourth fiscal quarter, or more frequently if conditions indicate that the carrying value of the asset may not be recoverable, management performs a review of both the values and, if applicable, useful lives assigned to intangible assets and tests for impairment. We utilize the excess earnings method to estimate the fair value of our individual indefinite-lived intangible assets. We also considered our market capitalization at February 29, 2016 , which was the date of our annual review. The estimates and assumptions made in assessing the fair value of our reporting units and the valuation of the underlying assets and liabilities are inherently subject to significant uncertainties. Consequently, changing rates of interest and inflation, declining sales or margins, increases in competition, changing consumer preferences, technical advances, or reductions in advertising and promotion may require an impairment charge to be recorded in the future. The weighted average remaining life for finite-lived intangible assets at December 31, 2016 was approximately 12.1 years, and the amortization expense for the three and nine months ended December 31, 2016 was $4.5 million and $14.4 million , respectively. At December 31, 2016 , finite-lived intangible assets are being amortized over a period of 10 to 30 years, and the associated amortization expense is expected to be as follows: (In thousands) Year Ending March 31, Amount 2017 (Remaining three months ending March 31, 2017) $ 4,527 2018 17,945 2019 17,945 2020 17,945 2021 17,522 Thereafter 142,881 $ 218,765

Other Accrued Liabilities

Other Accrued Liabilities	9 Months Ended
	Dec. 31, 2016
Payables and Accruals [Abstract]
Other Accrued Liabilities	Other Accrued Liabilities Other accrued liabilities consist of the following: (In thousands) December 31, March 31, Accrued marketing costs $ 33,786 $ 26,373 Accrued compensation costs 7,686 9,574 Accrued broker commissions 1,277 1,497 Income taxes payable 13,327 3,675 Accrued professional fees 3,142 1,787 Deferred rent 609 836 Accrued production costs 5,216 3,324 Accrued lease termination costs 351 448 Income tax related payable 6,354 6,354 Other accrued liabilities 6,927 5,856 $ 78,675 $ 59,724

Long-Term Debt

Long-Term Debt	9 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Long-Term Debt	Long-Term Debt 2012 Term Loan and 2012 ABL Revolver: On January 31, 2012, Prestige Brands, Inc. (the "Borrower") entered into a new senior secured credit facility, which consists of (i) a $660.0 million term loan facility (the “2012 Term Loan”) with a 7 -year maturity and (ii) a $50.0 million asset-based revolving credit facility (the “2012 ABL Revolver”) with a 5 -year maturity. In subsequent years, we have utilized portions of our accordion feature to increase the amount of our borrowing capacity under the 2012 ABL Revolver by $85.0 million to $135.0 million and reduced our borrowing rate on the 2012 ABL Revolver by 0.25% (discussed below). The 2012 Term Loan was issued with an original issue discount of 1.5% of the principal amount thereof, resulting in net proceeds to the Borrower of $650.1 million . In connection with these loan facilities, we incurred $20.6 million of costs, which were capitalized as deferred financing costs and are being amortized over the terms of the facilities. The 2012 Term Loan is unconditionally guaranteed by Prestige Brands Holdings, Inc. and certain of its domestic 100% owned subsidiaries, other than the Borrower. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company. On February 21, 2013, we entered into Amendment No. 1 ("Term Loan Amendment No. 1") to the 2012 Term Loan. Term Loan Amendment No. 1 provided for the refinancing of all of the Borrower's existing Term B Loans with new Term B-1 Loans (the "Term B-1 Loans"). The interest rate on the Term B-1 Loans under Term Loan Amendment No. 1 was based, at our option, on a LIBOR rate plus a margin of 2.75% per annum, with a LIBOR floor of 1.00% , or an alternate base rate, with a floor of 2.00% , plus a margin. The new Term B-1 Loans would have matured on the same date as the Term B Loans' original maturity date. In addition, Term Loan Amendment No. 1 provided the Borrower with certain additional capacity to prepay subordinated debt, the Company's 8.125% senior notes due in 2020 and certain other unsecured indebtedness permitted to be incurred under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver. In connection with Term Loan Amendment No. 1, during the fourth quarter ended March 31, 2013, we recognized a $1.4 million loss on the extinguishment of debt. On September 3, 2014, we entered into Amendment No. 2 ("Term Loan Amendment No. 2") to the 2012 Term Loan. Term Loan Amendment No. 2 provided for (i) the creation of a new class of Term B-2 Loans under the 2012 Term Loan (the "Term B-2 Loans") in an aggregate principal amount of $720.0 million , (ii) increased flexibility under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver, including additional investment, restricted payment and debt incurrence flexibility and financial maintenance covenant relief, and (iii) an interest rate on (x) the Term B-1 Loans that was based, at our option, on a LIBOR rate plus a margin of 3.125% per annum, with a LIBOR floor of 1.00% , or an alternate base rate, with a floor of 2.00% , plus a margin, and (y) the Term B-2 Loans that was based, at our option, on a LIBOR rate plus a margin of 3.50% per annum, with a LIBOR floor of 1.00% , or an alternate base rate, with a floor of 2.00% , plus a margin (with a margin step-down to 3.25% per annum, based upon achievement of a specified secured net leverage ratio). Also, on September 3, 2014, we entered into Amendment No. 3 ("ABL Amendment No. 3") to the 2012 ABL Revolver. ABL Amendment No. 3 provided for (i) a $40.0 million increase in revolving commitments under the 2012 ABL Revolver and (ii) increased flexibility under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver, including additional investment, restricted payment and debt incurrence flexibility. Borrowings under the 2012 ABL Revolver, as amended, bear interest at a rate per annum equal to an applicable margin, plus, at our option, either (i) a base rate determined by reference to the highest of (a) the Federal Funds rate plus 0.50% , (b) the prime rate of Citibank, N.A., and (c) the LIBOR rate determined by reference to the cost of funds for U.S. dollar deposits for an interest period of one month, adjusted for certain additional costs, plus 1.00% or (ii) a LIBOR rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing, adjusted for certain additional costs. The applicable margin for borrowings under the 2012 ABL Revolver may be increased to 2.00% or 2.25% for LIBOR borrowings and 1.00% or 1.25% for base-rate borrowings, depending on average excess availability under the 2012 ABL Revolver during the prior fiscal quarter. In addition to paying interest on outstanding principal under the 2012 ABL Revolver, we are required to pay a commitment fee to the lenders under the 2012 ABL Revolver in respect of the unutilized commitments thereunder. The initial commitment fee rate is 0.50% per annum. The commitment fee rate will be reduced to 0.375% per annum at any time when the average daily unused commitments for the prior quarter is less than a percentage of total commitments by an amount set forth in the credit agreement covering the 2012 ABL Revolver. We may voluntarily repay outstanding loans under the 2012 ABL Revolver at any time without a premium or penalty. On May 8, 2015, we entered into Amendment No. 3 ("Term Loan Amendment No. 3") to the 2012 Term Loan. Term Loan Amendment No. 3 provided for (i) the creation of a new class of Term B-3 Loans under the 2012 Term Loan (the "Term B-3 Loans") in an aggregate principal amount of $852.5 million , which combined the outstanding balances of the Term B-1 Loans of $207.5 million and the Term B-2 Loans of $645.0 million , and (ii) increased flexibility under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver, including additional investment, restricted payment, and debt incurrence flexibility and financial maintenance covenant relief. The maturity date of the Term B-3 Loans remains the same as the Term B-2 Loans' original maturity date of September 3, 2021. The 2012 Term Loan, as amended, bears interest at a rate per annum equal to an applicable margin plus, at our option, either (i) a base rate determined by reference to the highest of (a) the Federal Funds rate plus 0.50% , (b) the prime rate of Citibank, N.A., (c) the LIBOR rate determined by reference to the cost of funds for U.S. dollar deposits for an interest period of one month, adjusted for certain additional costs, plus 1.00% and (d) a floor of 1.75% or (ii) a LIBOR rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing, adjusted for certain additional costs, with a floor of 0.75% . For the nine months ended December 31, 2016, the average interest rate on the 2012 Term Loan was 4.7% . On June 9, 2015, we entered into Amendment No. 4 (“ABL Amendment No. 4”) to the 2012 ABL Revolver. ABL Amendment No. 4 provided for (i) a $35.0 million increase in the accordion feature under the 2012 ABL Revolver and (ii) increased flexibility under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver, including additional investment, restricted payment, and debt incurrence flexibility and financial maintenance covenant relief and (iii) extended the maturity date of the 2012 ABL Revolver to June 9, 2020, which is five years from the effective date of ABL Amendment No. 4. We may voluntarily repay outstanding loans under the 2012 ABL Revolver at any time without a premium or penalty. For the nine months ended December 31, 2016, the average interest rate on the amounts borrowed under the 2012 ABL Revolver was 2.7% . In connection with the DenTek acquisition on February 5, 2016, we entered into Amendment No. 5 (“ABL Amendment No. 5”) to the 2012 ABL Revolver. ABL Amendment No. 5 temporarily suspended certain financial and related reporting covenants in the 2012 ABL Revolver until the earliest of (i) the date that was 60 calendar days following February 4, 2016, (ii) the date upon which certain of DenTek’s assets were included in the Company’s borrowing base under the 2012 ABL Revolver and (iii) the date upon which the Company received net proceeds from an offering of debt securities. 2013 Senior Notes: On December 17, 2013, the Borrower issued $400.0 million of senior unsecured notes, with an interest rate of 5.375% and a maturity date of December 15, 2021 (the "2013 Senior Notes"). The Borrower may redeem some or all of the 2013 Senior Notes at redemption prices set forth in the indenture governing the 2013 Senior Notes. The 2013 Senior Notes are guaranteed by Prestige Brands Holdings, Inc. and certain of its 100% domestic owned subsidiaries, other than the Borrower. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company. In connection with the 2013 Senior Notes offering, we incurred $7.2 million of costs, which were capitalized as deferred financing costs and are being amortized over the term of the 2013 Senior Notes. 2016 Senior Notes: On February 19, 2016, the Borrower completed the sale of $350.0 million aggregate principal amount of 6.375% senior notes due 2024 (the “2016 Senior Notes”), pursuant to a purchase agreement, dated February 16, 2016, among the Borrower, the guarantors party thereto (the “Guarantors”) and the initial purchasers party thereto. The 2016 Senior Notes are guaranteed by Prestige Brands Holdings, Inc. and certain of its domestic 100% owned subsidiaries, other than the Borrower. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the Guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company. In connection with the 2016 Senior Notes offering, we incurred $5.5 million of costs, which were capitalized as deferred financing costs and are being amortized over the term of the 2016 Senior Notes. The 2016 Senior Notes were issued pursuant to an indenture, dated February 19, 2016 (the “Indenture”). The Indenture provides, among other things, that interest will be payable on the 2016 Senior Notes on March 1 and September 1 of each year, beginning on September 1, 2016, until their maturity date of March 1, 2024. The 2016 Senior Notes are senior unsecured obligations of the Borrower. Redemptions and Restrictions: At any time prior to December 15, 2016, we had the option to redeem the 2013 Senior Notes in whole or in part at a redemption price equal to 100% of the principal amount of notes redeemed, plus an applicable "make-whole premium" calculated as set forth in the indenture governing the 2013 Senior Notes, together with accrued and unpaid interest, if any, to the date of redemption. On or after December 15, 2016, we have the option to redeem some or all of the 2013 Senior Notes at redemption prices set forth in the indenture governing the 2013 Senior Notes. In addition, at any time prior to December 15, 2016, we had the option to redeem up to 35% of the aggregate principal amount of the 2013 Senior Notes at a redemption price equal to 105.375% of the principal amount thereof, plus accrued and unpaid interest, if any, to the redemption date, with the net cash proceeds of certain equity offerings, provided that certain conditions were met. Subject to certain limitations, in the event of a change of control, as defined in the indenture governing the 2013 Senior Notes, the Borrower will be required to make an offer to purchase the 2013 Senior Notes at a price equal to 101% of the aggregate principal amount of the 2013 Senior Notes repurchased, plus accrued and unpaid interest, if any, to the date of repurchase. The Borrower has the option to redeem all or a portion of the 2016 Senior Notes at any time on or after March 1, 2019 at the redemption prices set forth in the Indenture, plus accrued and unpaid interest, if any. The Borrower may also redeem all or any portion of the 2016 Senior Notes at any time prior to March 1, 2019, at a price equal to 100% of the aggregate principal amount of the notes redeemed, plus an applicable "make-whole premium" calculated as set forth in the Indenture, and accrued and unpaid interest, if any, to the date of redemption. In addition, before March 1, 2019, the Borrower may redeem up to 40% of the aggregate principal amount of the 2016 Senior Notes with the net proceeds of certain equity offerings at the redemption price set forth in the Indenture, provided that certain conditions are met. Subject to certain limitations, in the event of a change of control, as defined in the Indenture, the Borrower will be required to make an offer to purchase the 2016 Senior Notes at a price equal to 101% of the aggregate principal amount of the notes repurchased, plus accrued and unpaid interest, if any, to the date of repurchase. The indentures governing the 2013 Senior Notes and the 2016 Senior Notes contain provisions that restrict us from undertaking specified corporate actions, such as asset dispositions, acquisitions, dividend payments, repurchases of common shares outstanding, changes of control, incurrences of indebtedness, issuance of equity, creation of liens, making of loans and transactions with affiliates. Additionally, the credit agreement with respect to the 2012 Term Loan and the 2012 ABL Revolver and the indentures governing the 2013 Senior Notes and the 2016 Senior Notes contain cross-default provisions, whereby a default pursuant to the terms and conditions of certain indebtedness will cause a default on the remaining indebtedness under the credit agreement governing the 2012 Term Loan and the 2012 ABL Revolver and the indentures governing the 2013 Senior Notes and the 2016 Senior Notes. At December 31, 2016, we were in compliance with the covenants under our long-term indebtedness. At December 31, 2016, we had an aggregate of $1.0 million of unamortized debt costs related to the 2012 ABL Revolver included in other long-term assets, and $21.4 million of unamortized debt costs included in long-term debt costs, the total of which is comprised of $4.8 million related to the 2013 Senior Notes, $5.0 million related to the 2016 Senior Notes, and $11.6 million related to the 2012 Term Loan. At March 31, 2016, we had an aggregate of $1.3 million of unamortized debt costs related to the 2012 ABL Revolver included in other long-term assets, and $27.2 million of unamortized debts costs included in long-term debt costs, the total of which is comprised of $5.4 million related to the 2013 Senior Notes, $5.4 million related to the 2016 Senior Notes, and $16.4 million related to the 2012 Term Loan. At December 31, 2016, we had $0.0 million outstanding on the 2012 ABL Revolver and a borrowing capacity of $135.0 million . Long-term debt consists of the following, as of the dates indicated: (In thousands, except percentages) December 31, March 31, 2016 Senior Notes bearing interest at 6.375%, with interest payable on March 1 and September 1 of each year. The 2016 Senior Notes mature on March 1, 2024. $ 350,000 $ 350,000 2013 Senior Notes bearing interest at 5.375%, with interest payable on June 15 and December 15 of each year. The 2013 Senior Notes mature on December 15, 2021. 400,000 400,000 2012 Term B-3 Loans bearing interest at the Borrower's option at either a base rate with a floor of 1.75% plus applicable margin or LIBOR with a floor of 0.75% plus applicable margin, due on September 3, 2021. 687,000 817,500 2012 ABL Revolver bearing interest at the Borrower's option at either a base rate plus applicable margin or LIBOR plus applicable margin. Any unpaid balance is due on June 9, 2020. — 85,000 Total long-term debt (including current portion) 1,437,000 1,652,500 Current portion of long-term debt — — Long-term debt 1,437,000 1,652,500 Less: unamortized debt costs (21,421 ) (27,191 ) Long-term debt, net $ 1,415,579 $ 1,625,309 At December 31, 2016, aggregate future principal payments required in accordance with the terms of the 2012 Term Loan, 2012 ABL Revolver and the indentures governing the 2016 Senior Notes and the 2013 Senior Notes are as follows: (In thousands) Year Ending March 31, Amount 2017 (remaining three months ending March 31, 2017) $ — 2018 — 2019 — 2020 — 2021 — Thereafter 1,437,000 $ 1,437,000

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Dec. 31, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements For certain of our financial instruments, including cash, accounts receivable, accounts payable and other current liabilities, the carrying amounts approximate their respective fair values due to the relatively short maturity of these amounts. The Fair Value Measurements and Disclosures topic of the FASB ASC 820 requires fair value to be determined based on the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market assuming an orderly transaction between market participants. The Fair Value Measurements and Disclosures topic established market (observable inputs) as the preferred source of fair value, to be followed by the Company's assumptions of fair value based on hypothetical transactions (unobservable inputs) in the absence of observable market inputs. Based upon the above, the following fair value hierarchy was created: Level 1 - Quoted market prices for identical instruments in active markets; Level 2 - Quoted prices for similar instruments in active markets, as well as quoted prices for identical or similar instruments in markets that are not considered active; and Level 3 - Unobservable inputs developed by the Company using estimates and assumptions reflective of those that would be utilized by a market participant. The market values have been determined based on market values for similar instruments adjusted for certain factors. As such, the 2016 Senior Notes, the 2013 Senior Notes, the Term B-3 Loans, and the 2012 ABL Revolver are measured in Level 2 of the above hierarchy (see summary below detailing the carrying amounts and estimated fair values of these borrowings at December 31, 2016 and March 31, 2016). December 31, 2016 March 31, 2016 (In thousands) Carrying Value Fair Value Carrying Value Fair Value 2016 Senior Notes $ 350,000 $ 367,500 $ 350,000 $ 363,125 2013 Senior Notes 400,000 413,000 400,000 408,000 Term B-3 Loans 687,000 692,153 817,500 818,522 2012 ABL Revolver — — 85,000 85,000 At December 31, 2016 and March 31, 2016, we did not have any assets or liabilities measured in Level 1 or 3.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Dec. 31, 2016
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Stockholders' Equity The Company is authorized to issue 250.0 million shares of common stock, $0.01 par value per share, and 5.0 million shares of preferred stock, $0.01 par value per share. The Board of Directors may direct the issuance of the undesignated preferred stock in one or more series and determine preferences, privileges and restrictions thereof. Each share of common stock has the right to one vote on all matters submitted to a vote of stockholders. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors, subject to prior rights of holders of all classes of outstanding stock having priority rights as to dividends. No dividends have been declared or paid on the Company's common stock through December 31, 2016 . During the three months ended December 31, 2016 and 2015 , we repurchased 780 shares and 0 shares, respectively, of restricted common stock from our employees pursuant to the provisions of various employee restricted stock awards. The repurchases for the three months ended December 31, 2016 were at an average price of $45.83 . During the nine months ended December 31, 2016 and 2015, we repurchased 25,768 shares and 39,429 shares, respectively, of restricted common stock from our employees pursuant to the provisions of various employee restricted stock awards. The repurchases for the nine months ended December 31, 2016 and 2015 were at an average price of $55.51 and $41.66 , respectively. All of the repurchased shares have been recorded as treasury stock.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	9 Months Ended
	Dec. 31, 2016
Stockholders' Equity Note [Abstract]
Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive Loss The table below presents accumulated other comprehensive loss (“AOCI”), which affects equity and results from recognized transactions and other economic events, other than transactions with owners in their capacity as owners. AOCI consisted of the following at December 31, 2016 and March 31, 2016 : December 31, March 31, (In thousands) 2016 2016 Components of Accumulated Other Comprehensive Loss Cumulative translation adjustment $ (35,382 ) $ (23,525 ) Accumulated other comprehensive loss, net of tax $ (35,382 ) $ (23,525 )

Earnings Per Share

Earnings Per Share	9 Months Ended
	Dec. 31, 2016
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share Basic earnings per share is computed based on the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share is computed based on the weighted-average number of shares of common stock outstanding plus the effect of potentially dilutive common shares outstanding during the period using the treasury stock method, which includes stock options and restricted stock units. In loss periods, the assumed exercise of in-the-money stock options and restricted stock units has an anti-dilutive effect, and therefore these instruments are excluded from the computation of diluted earnings per share. The following table sets forth the computation of basic and diluted earnings per share: Three Months Ended December 31, Nine Months Ended December 31, (In thousands, except per share data) 2016 2015 2016 2015 Numerator Net income $ 31,641 $ 27,995 $ 58,305 $ 85,971 Denominator Denominator for basic earnings per share — weighted average shares outstanding 52,999 52,824 52,960 52,727 Dilutive effect of unvested restricted stock units and options issued to employees and directors 360 379 379 379 Denominator for diluted earnings per share 53,359 53,203 53,339 53,106 Earnings per Common Share: Basic net earnings per share $ 0.60 $ 0.53 $ 1.10 $ 1.63 Diluted net earnings per share $ 0.59 $ 0.53 $ 1.09 $ 1.62 For the three months ended December 31, 2016 and 2015, there were 0.2 million and 0.2 million shares, respectively, attributable to outstanding stock-based awards that were excluded from the calculation of diluted earnings per share because their inclusion would have been anti-dilutive. For the nine months ended December 31, 2016 and 2015, there were 0.2 million and less than 0.1 million shares, respectively, attributable to outstanding stock-based awards that were excluded from the calculation of diluted earnings per share because their inclusion would have been anti-dilutive.

Share-Based Compensation

Share-Based Compensation	9 Months Ended
	Dec. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Compensation	Share-Based Compensation In connection with our initial public offering, the Board of Directors adopted the 2005 Long-Term Equity Incentive Plan (the “Plan”), which provides for grants of up to a maximum of 5.0 million shares of restricted stock, stock options, restricted stock units and other equity-based awards. In June 2014, the Board of Directors approved, and in July 2014, the stockholders ratified, an increase of an additional 1.8 million shares of our common stock for issuance under the Plan, increased the maximum number of shares subject to stock options that may be awarded to any one participant under the Plan during any fiscal 12-month period from 1.0 million to 2.5 million shares, and extended the term of the Plan by ten years to February 2025. Directors, officers and other employees of the Company and its subsidiaries, as well as others performing services for the Company, are eligible for grants under the Plan. During the three and nine months ended December 31, 2016 , pre-tax share-based compensation costs charged against income were $2.4 million and $6.3 million , respectively, and the related income tax benefit recorded was $1.3 million and $2.5 million , respectively. During the three and nine months ended December 31, 2015, pre-tax share-based compensation costs charged against income were $2.1 million and $7.1 million , respectively, and the related income tax benefit recorded was $0.7 million and $2.5 million , respectively. At December 31, 2016 , there were $10.5 million of unrecognized compensation costs related to nonvested share-based compensation arrangements under the Plan, based on management's estimate of the shares that will ultimately vest. We expect to recognize such costs over a weighted-average period of 0.9 year. The total fair value of options and restricted stock units vested during the nine months ended December 31, 2016 and 2015 was $6.0 million and $6.6 million , respectively. For the nine months ended December 31, 2016 and 2015, we issued 94,718 and 153,603 shares of restricted stock units, respectively, and received cash from the exercise of stock options of $3.4 million and $6.6 million , respectively. Accordingly, we realized $1.8 million and $3.5 million , respectively, in tax benefits from the tax deductions resulting from these restricted stock issuances and stock option exercises. At December 31, 2016 , there were 2.4 million shares available for issuance under the Plan. On May 9, 2016, the Compensation Committee of our Board of Directors granted 49,064 shares of restricted stock units and stock options to acquire 224,843 shares of our common stock to certain executive officers and employees under the Plan. All of the shares of restricted stock units vest in their entirety on the three -year anniversary of the date of grant. Upon vesting, the units will be settled in shares of our common stock. The stock options will vest 33.3% per year over three years and are exercisable for up to ten years from the date of grant. These stock options were granted at an exercise price of $57.18 per share, which is equal to the closing price for our common stock on the date of the grant. Termination of employment prior to vesting will result in forfeiture of the unvested restricted common stock units and the unvested stock options. Vested stock options will remain exercisable by the employee after termination, subject to the terms of the Plan. On September 12, 2016, we announced that Christine Sacco had been appointed as Chief Financial Officer of the Company, effective that same day. In connection with Ms. Sacco's appointment as Chief Financial Officer on September 12, 2016, the Company executed an offer letter with Ms. Sacco, which sets forth the terms of her compensation as approved by the Compensation Committee of the Board of Directors. In accordance with the terms of her offer letter, the Company granted Ms. Sacco 5,012 shares of restricted stock units and stock options to acquire 25,746 shares of our common stock under the Plan. The restricted stock units vest in their entirety on the three-year anniversary of the date of grant. Upon vesting, the units will be settled in shares of our common stock. The stock options will vest 33.3% per year over three years and are exercisable for up to ten years from the date of grant. These stock options were granted at an exercise price of $47.39 per share, which is equal to the closing price of our common stock on the date of grant. On November 14, 2016, we announced that William C. P'Pool had been appointed as Senior Vice President, General Counsel and Corporate Secretary, effective that same day. In connection with Mr. P'Pool's appointment as Senior Vice President, General Counsel and Corporate Secretary on November 14, 2016, the Company executed an offer letter with Mr. P'Pool, which sets forth the terms of his compensation as approved by the Compensation Committee of the Board of Directors. In accordance with the terms of his offer letter, the Company granted Mr. P'Pool 2,664 shares of restricted stock units and stock options to acquire 13,683 shares of our common stock under the Plan. The restricted stock units vest in their entirety on the three-year anniversary of the date of grant. Upon vesting, the units will be settled in shares of our common stock. The stock options will vest 33.3% per year over three years and are exercisable for up to ten years from the date of grant. These stock options were granted at an exercise price of $50.06 per share, which is equal to the closing price of our common stock on the date of grant. Restricted Shares Restricted shares granted to employees under the Plan generally vest in three to five years, primarily upon the attainment of certain time vesting thresholds, and may also be contingent on the attainment of certain performance goals of the Company, including revenue and earnings before income taxes, depreciation and amortization targets. The restricted stock unit awards provide for accelerated vesting if there is a change of control, as defined in the Plan. The restricted stock units granted to employees generally vest in their entirety on the three -year anniversary of the date of the grant. Upon vesting, the units will be settled in shares of our common stock. Termination of employment prior to vesting will result in forfeiture of the restricted stock units, unless otherwise accelerated by the Compensation Committee. The restricted stock units granted to directors vest in their entirety one year after the date of grant so long as membership on the Board of Directors continues through the vesting date, and will be settled by delivery to the director of one share of common stock of the Company for each vested restricted stock unit promptly following the earliest of the director's (i) death, (ii) disability or (iii) the six -month anniversary of the date on which the director's Board membership ceases for reasons other than death or disability. At our annual meeting date on August 2, 2016, each of our six independent members of the Board of Directors received a grant of 1,896 restricted stock units under the Plan. Additionally, on May 26, 2016, the Compensation Committee granted 346 restricted stock units to a newly appointed Board member. The fair value of the restricted stock units is determined using the closing price of our common stock on the date of the grant. The weighted-average grant-date fair value of restricted stock units granted during the nine months ended December 31, 2016 and 2015 was $55.44 and $42.41 , respectively. A summary of the Company's restricted stock units granted under the Plan is presented below: Restricted Stock Units Shares (in thousands) Weighted- Average Grant-Date Fair Value Nine months ended December 31, 2015 Vested and nonvested at March 31, 2015 362.3 $ 22.74 Granted 266.1 42.41 Vested and issued (153.6 ) 18.16 Forfeited (1.4 ) 33.50 Vested and nonvested at December 31, 2015 473.4 35.25 Vested at December 31, 2015 69.8 14.76 Nine months ended December 31, 2016 Vested and nonvested at March 31, 2016 467.8 $ 35.22 Granted 68.4 55.44 Vested and issued (94.7 ) 28.51 Forfeited (91.4 ) 41.71 Vested and nonvested at December 31, 2016 350.1 39.29 Vested at December 31, 2016 63.4 20.12 Options The Plan provides that the exercise price of options granted shall be no less than the fair market value of the Company's common stock on the date the options are granted. Options granted have a term of no greater than ten years from the date of grant and vest in accordance with a schedule determined at the time the option is granted, generally three to five years. The option awards provide for accelerated vesting in the event of a change in control, as defined in the Plan. Termination of employment prior to vesting will result in forfeiture of the unvested stock options. Vested stock options will remain exercisable by the employee after termination of employment, subject to the terms in the Plan. The fair value of each option award is estimated on the date of grant using the Black-Scholes Option Pricing Model that uses the assumptions noted in the table below. Expected volatilities are based on the historical volatility of our common stock and other factors, including the historical volatilities of comparable companies. We use appropriate historical data, as well as current data, to estimate option exercise and employee termination behaviors. Employees that are expected to exhibit similar exercise or termination behaviors are grouped together for the purposes of valuation. The expected terms of the options granted are derived from our historical experience, management's estimates, and consideration of information derived from the public filings of companies similar to us, and represent the period of time that options granted are expected to be outstanding. The risk-free rate represents the yield on U.S. Treasury bonds with a maturity equal to the expected term of the granted options. The weighted-average grant-date fair values of the options granted during the nine months ended December 31, 2016 and 2015 were $21.75 and $17.24 , respectively. Nine months ended December 31, 2016 2015 Expected volatility 37.8 % 40.2 % Expected dividends $ — $ — Expected term in years 6.0 6.0 Risk-free rate 1.7 % 1.7 % A summary of option activity under the Plan is as follows: Options Shares (in thousands) Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (years) Aggregate Intrinsic Value (in thousands) Nine months ended December 31, 2015 Outstanding at March 31, 2015 871.2 $ 23.40 Granted 208.2 42.13 Exercised (336.9 ) 18.99 Forfeited or expired (2.1 ) 38.21 Outstanding at December 31, 2015 740.4 30.63 7.9 $ 15,325 Exercisable at December 31, 2015 313.5 21.68 6.7 $ 9,341 Nine months ended December 31, 2016 Outstanding at March 31, 2016 727.7 $ 30.70 Granted 264.3 55.86 Exercised (107.9 ) 31.91 Forfeited or expired (92.2 ) 42.62 Outstanding at December 31, 2016 791.9 37.54 7.4 $ 12,543 Exercisable at December 31, 2016 387.0 25.70 6.3 $ 10,217 The aggregate intrinsic value of options exercised in the nine months ended December 31, 2016 was $2.4 million .

Income Taxes

Income Taxes	9 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Income taxes are recorded in our quarterly financial statements based on our estimated annual effective income tax rate, subject to adjustments for discrete events, should they occur. The effective tax rates used in the calculation of income taxes were 37.6% and 35.2% for the three months ended December 31, 2016 and 2015, respectively. The effective rates used in the calculation of income taxes were 36.7% and 35.2% for the nine months ended December 31, 2016 and 2015, respectively. The increase in the effective tax rate for the three and nine months ended December 31, 2016 was primarily due to non-deductible goodwill associated with the sale of rights to use Comet in certain geographic areas and the lower tax basis in e.p.t and Dermoplast . See Note 8 above for further information on the sale of rights to use Comet . During the nine months ended December 31, 2016, we realized a net reduction to our deferred tax liability of $37.7 million as a result of the sale of Pediacare , New Skin, Fiber Choice, Dermoplast and e.p.t brands. At December 31, 2016, a 100% owned subsidiary of the Company had a net operating loss carryforward of approximately $7.1 million ( $2.5 million , tax effected), which may be used to offset future taxable income of the consolidated group and begins to expire in 2025. The Company expects to fully utilize the loss carryover before it expires. The net operating loss carryforward is subject to an annual limitation as to usage under Internal Revenue Code Section 382 of approximately $33.6 million . The balance in our uncertain tax liability was $3.7 million at December 31, 2016 and $4.1 million at March 31, 2016. During the three months ended December 31, 2016 , we reduced our uncertain tax liability by $1.0 million related to the expiration of the statute of limitations and increased our uncertain tax liability by $0.6 million related to the current year. We recognize interest and penalties related to uncertain tax positions as a component of income tax expense. We did not incur any material interest or penalties related to income taxes in any of the periods presented.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies We are involved from time to time in legal matters and other claims incidental to our business. We review outstanding claims and proceedings internally and with external counsel as necessary to assess the probability and amount of a potential loss. These assessments are re-evaluated at each reporting period and as new information becomes available to determine whether a reserve should be established or if any existing reserve should be adjusted. The actual cost of resolving a claim or proceeding ultimately may be substantially different than the amount of the recorded reserve. In addition, because it is not permissible under GAAP to establish a litigation reserve until the loss is both probable and estimable, in some cases there may be insufficient time to establish a reserve prior to the actual incurrence of the loss (upon verdict and judgment at trial, for example, or in the case of a quickly negotiated settlement). We believe the resolution of routine legal matters and other claims incidental to our business, taking our reserves into account, will not have a material adverse effect on our business, financial condition, or results of operations. Lease Commitments We have operating leases for office facilities and equipment in New York and other locations, which expire at various dates through fiscal 2022. These amounts have been included in the table below. The following summarizes future minimum lease payments for our operating leases as of December 31, 2016 : (In thousands) Year Ending March 31, Facilities Equipment Total (a) 2017 (Remaining three months ending March 31, 2017) $ 524 $ 132 $ 656 2018 2,029 443 2,472 2019 2,023 174 2,197 2020 1,848 86 1,934 2021 903 7 910 Thereafter 59 4 63 $ 7,386 $ 846 $ 8,232 (a) Minimum lease payments have not been reduced by minimum sublease rentals of $1.0 million due to us in the future under noncancelable subleases. The following schedule shows the composition of total minimum lease payments that have been reduced by minimum sublease rentals: (In thousands) December 31, 2016 March 31, 2016 Minimum lease payments $ 8,232 $ 8,434 Less: Sublease rentals (971 ) (1,165 ) $ 7,261 $ 7,269 Rent expense for the three months ended December 31, 2016 and 2015 was $0.4 million and $0.4 million , respectively. Rent expense for the nine months ended December 31, 2016 and 2015 was $1.5 million and $1.2 million , respectively. Purchase Commitments Effective November 1, 2009, we entered into a ten year supply agreement for the exclusive manufacture of a portion of one of our Household Cleaning products. Although we are committed under the supply agreement to pay the minimum amounts set forth in the table below, the total commitment is less than 10% of the estimated purchases that we expect to make during the course of the agreement. (In thousands) Year Ending March 31, Amount 2017 (Remaining three months ending March 31, 2017) 258 2018 1,013 2019 982 2020 559 2021 — $ 2,812

Concentrations of Risk

Concentrations of Risk	9 Months Ended
	Dec. 31, 2016
Risks and Uncertainties [Abstract]
Concentrations of Risk	Concentrations of Risk Our revenues are concentrated in the areas of OTC Healthcare and Household Cleaning products. We sell our products to mass merchandisers, food and drug stores, and convenience, dollar and club stores. During the three and nine months ended December 31, 2016 , approximately 40.4% and 41.4% , respectively, of our total revenues were derived from our five top selling brands. During the three and nine months ended December 31, 2015, approximately 41.0% and 42.2% , respectively, of our total revenues were derived from our five top selling brands. Two customers, Walmart and Walgreens, accounted for more than 10% of our gross revenues for each of the periods presented. Walmart accounted for approximately 20.4% and 20.7% , respectively, of our gross revenues for the three and nine months ended December 31, 2016 . Walmart accounted for approximately 20.2% and 19.9% , respectively, of our gross revenues for the three and nine months ended December 31, 2015. Walgreens accounted for approximately 10.0% and 10.3% of gross revenues for the three and nine months ended December 31, 2016, respectively. Walgreens accounted for approximately 9.5% and 9.6% of gross revenues for the three and nine months ended December 31, 2015, respectively. At December 31, 2016 , approximately 25.7% and 10.5% of accounts receivable were owed by Walmart and Walgreens, respectively. We manage product distribution in the continental United States through a third-party distribution center in St. Louis, Missouri. A serious disruption, such as a flood or fire, to the main distribution center could damage our inventories and could materially impair our ability to distribute our products to customers in a timely manner or at a reasonable cost. We could incur significantly higher costs and experience longer lead times associated with the distribution of our products to our customers during the time that it takes us to reopen or replace our distribution center. As a result, any such disruption could have a material adverse effect on our business, sales and profitability. At December 31, 2016 , we had relationships with 112 third-party manufacturers. Of those, we had long-term contracts with 48 manufacturers that produced items that accounted for approximately 78.5% of gross sales for the nine months ended December 31, 2016 . At December 31, 2015 , we had relationships with 101 third-party manufacturers. Of those, we had long-term contracts with 47 manufacturers that produced items that accounted for approximately 79.8% of gross sales for the nine months ended December 31, 2015 . The fact that we do not have long-term contracts with certain manufacturers means that they could cease manufacturing our products at any time and for any reason or initiate arbitrary and costly price increases, which could have a material adverse effect on our business and results from operations. Although we are in the process of negotiating long-term contracts with certain key manufacturers, we may not be able to reach a timely agreement, which could have a material adverse effect on our business and results of operations.

Business Segments

Business Segments	9 Months Ended
	Dec. 31, 2016
Segment Reporting [Abstract]
Business Segments	Business Segments Segment information has been prepared in accordance with the Segment Reporting topic of the FASB ASC 280. Our current reportable segments consist of (i) North American OTC Healthcare, (ii) International OTC Healthcare and (iii) Household Cleaning. We evaluate the performance of our operating segments and allocate resources to these segments based primarily on contribution margin, which we define as gross profit less advertising and promotional expenses. The tables below summarize information about our reportable segments. Three Months Ended December 31, 2016 (In thousands) North American OTC International OTC Household Cleaning Consolidated Gross segment revenues $ 178,097 $ 18,459 $ 21,000 $ 217,556 Elimination of intersegment revenues (824 ) — — (824 ) Third-party segment revenues 177,273 18,459 21,000 216,732 Other revenues — — 31 31 Total segment revenues 177,273 18,459 21,031 216,763 Cost of sales 68,378 7,678 16,160 92,216 Gross profit 108,895 10,781 4,871 124,547 Advertising and promotion 26,800 3,502 380 30,682 Contribution margin $ 82,095 $ 7,279 $ 4,491 93,865 Other operating expenses* 24,578 Operating income 69,287 Other expense 18,554 Income before income taxes 50,733 Provision for income taxes 19,092 Net income $ 31,641 *Other operating expenses for the three months ended December 31, 2016 includes a pre-tax net gain on divestitures of $3.4 million related primarily to e.p.t and Dermoplast. The assets and corresponding contribution margin associated with the pre-tax net gain on these divestitures are included within the North American OTC Healthcare segment. Nine Months Ended December 31, 2016 (In thousands) North American OTC International OTC Household Cleaning Consolidated Gross segment revenues $ 523,988 $ 53,061 $ 65,658 $ 642,707 Elimination of intersegment revenues (2,188 ) — — (2,188 ) Third-party segment revenues 521,800 53,061 65,658 640,519 Other revenues — 6 865 871 Total segment revenues 521,800 53,067 66,523 641,390 Cost of sales 198,014 21,722 51,551 271,287 Gross profit 323,786 31,345 14,972 370,103 Advertising and promotion 76,651 8,870 1,388 86,909 Contribution margin $ 247,135 $ 22,475 $ 13,584 283,194 Other operating expenses* 130,635 Operating income 152,559 Other expense 60,511 Income before income taxes 92,048 Provision for income taxes 33,743 Net income $ 58,305 *Other operating expenses for the nine months ended December 31, 2016 includes a pre-tax net loss of $51.6 million related to divestitures. These divestitures include Pediacare , New Skin, Fiber Choice, e.p.t, Dermoplast, and license rights in certain geographic areas pertaining to Comet . The assets and corresponding contribution margin associated with the pre-tax net loss on divestitures related to Pediacare , New Skin, Fiber Choice, e.p.t and Dermoplast are included within the North American OTC Healthcare segment, while the pre-tax gain on sale of license rights related to Comet are included in the Household Cleaning segment. Three Months Ended December 31, 2015 (In thousands) North American OTC International OTC Household Cleaning Consolidated Gross segment revenues** $ 165,287 $ 13,803 $ 20,623 $ 199,713 Elimination of intersegment revenues (228 ) — — (228 ) Third-party segment revenues 165,059 13,803 20,623 199,485 Other revenues** — 9 701 710 Total segment revenues 165,059 13,812 21,324 200,195 Cost of sales** 62,655 4,964 15,792 83,411 Gross profit 102,404 8,848 5,532 116,784 Advertising and promotion 26,472 2,838 625 29,935 Contribution margin $ 75,932 $ 6,010 $ 4,907 86,849 Other operating expenses 24,206 Operating income 62,643 Other expense 19,462 Income before income taxes 43,181 Provision for income taxes 15,186 Net income $ 27,995 Nine Months Ended December 31, 2015 (In thousands) North American OTC International OTC Household Cleaning Consolidated Gross segment revenues** $ 489,265 $ 43,213 $ 65,984 $ 598,462 Elimination of intersegment revenues (2,428 ) — — (2,428 ) Third-party segment revenues 486,837 43,213 65,984 596,034 Other revenues** 15 40 2,303 2,358 Total segment revenues 486,852 43,253 68,287 598,392 Cost of sales** 182,279 16,347 50,806 249,432 Gross profit 304,573 26,906 17,481 348,960 Advertising and promotion 74,107 8,338 1,805 84,250 Contribution margin $ 230,466 $ 18,568 $ 15,676 264,710 Other operating expenses 69,664 Operating income 195,046 Other expense 62,464 Income before income taxes 132,582 Provision for income taxes 46,611 Net income $ 85,971 ** Certain immaterial amounts relating to gross segment revenues, other revenues and cost of sales for each of the three and nine months ended December 31, 2015 were reclassified between the International OTC Healthcare segment and the North American OTC Healthcare segment. There were no changes to the consolidated financial statements for any periods presented. The tables below summarize information about our segment revenues from similar product groups. Three Months Ended December 31, 2016 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 32,439 $ 444 $ — $ 32,883 Cough & Cold 29,803 4,166 — 33,969 Women's Health 30,896 580 — 31,476 Gastrointestinal 15,109 6,701 — 21,810 Eye & Ear Care 23,571 2,997 — 26,568 Dermatologicals 19,948 479 — 20,427 Oral Care 24,129 3,083 — 27,212 Other OTC 1,378 9 — 1,387 Household Cleaning — — 21,031 21,031 Total segment revenues $ 177,273 $ 18,459 $ 21,031 $ 216,763 Nine Months Ended December 31, 2016 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 90,558 $ 1,515 $ — $ 92,073 Cough & Cold 68,876 13,718 — 82,594 Women's Health 97,051 2,151 — 99,202 Gastrointestinal 50,495 17,045 — 67,540 Eye & Ear Care 72,512 8,782 — 81,294 Dermatologicals 65,598 1,717 — 67,315 Oral Care 72,308 8,120 — 80,428 Other OTC 4,402 19 — 4,421 Household Cleaning — — 66,523 66,523 Total segment revenues $ 521,800 $ 53,067 $ 66,523 $ 641,390 Three Months Ended December 31, 2015 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 30,454 $ 450 $ — $ 30,904 Cough & Cold 30,466 3,696 — 34,162 Women's Health 33,521 877 — 34,398 Gastrointestinal 17,401 5,517 — 22,918 Eye & Ear Care 21,936 2,613 — 24,549 Dermatologicals 19,734 524 — 20,258 Oral Care 9,996 126 — 10,122 Other OTC 1,551 9 — 1,560 Household Cleaning — — 21,324 21,324 Total segment revenues $ 165,059 $ 13,812 $ 21,324 $ 200,195 Nine Months Ended December 31, 2015 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 86,996 $ 1,668 $ — $ 88,664 Cough & Cold 74,681 12,948 — 87,629 Women's Health 100,036 2,381 — 102,417 Gastrointestinal 56,782 14,667 — 71,449 Eye & Ear Care 71,159 9,393 — 80,552 Dermatologicals 63,026 1,669 — 64,695 Oral Care 29,706 509 — 30,215 Other OTC 4,466 18 — 4,484 Household Cleaning — — 68,287 68,287 Total segment revenues $ 486,852 $ 43,253 $ 68,287 $ 598,392 During the three months ended December 31, 2016 and 2015, approximately 86.7% and 87.8% , respectively, of our total segment revenues were from customers in the United States. During the nine months ended December 31, 2016 and 2015, approximately 86.7% and 86.9% , respectively, of our total segment revenues were from customers in the United States. Other than the United States, no individual geographical area accounted for more than 10% of net sales in any of the periods presented. During the three months ended December 31, 2016, our Canada and Australia sales accounted for approximately 4.7% and 5.3% , respectively, of our total segment revenues, while during the three months ended December 31, 2015, approximately 5.0% and 5.0% , respectively, of our total segment revenues were attributable to sales to Canada and Australia. During the nine months ended December 31, 2016, our Canada and Australia sales accounted for approximately 4.9% and 5.4% , respectively, of our total segment revenues, while during the nine months ended December 31, 2015, approximately 5.2% and 5.9% , respectively, of our total segment revenues were attributable to sales to Canada and Australia. At December 31, 2016 and March 31, 2016, approximately 95.9% of our consolidated goodwill and intangible assets were located in the United States and approximately 4.1% were located in Australia and the United Kingdom. These consolidated goodwill and intangible assets have been allocated to the reportable segments as follows: December 31, 2016 (In thousands) North American OTC International OTC Household Cleaning Consolidated Goodwill $ 318,014 $ 21,226 $ 6,245 $ 345,485 Intangible assets Indefinite-lived 1,755,635 80,716 101,262 1,937,613 Finite-lived 196,391 1,004 21,370 218,765 Intangible assets, net 1,952,026 81,720 122,632 2,156,378 Total $ 2,270,040 $ 102,946 $ 128,877 $ 2,501,863 March 31, 2016 (In thousands) North American OTC International OTC Household Consolidated Goodwill $ 330,615 $ 22,776 $ 6,800 $ 360,191 Intangible assets Indefinite-lived 1,823,873 85,901 110,272 2,020,046 Finite-lived 277,762 2,237 22,678 302,677 Intangible assets, net 2,101,635 88,138 132,950 2,322,723 Total $ 2,432,250 $ 110,914 $ 139,750 $ 2,682,914

Condensed Consolidating Financi

Condensed Consolidating Financial Statements	9 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Condensed Consolidating Financial Statements	Condensed Consolidating Financial Statements As described in Note 10, Prestige Brands Holdings, Inc., together with certain of our 100% owned subsidiaries, has fully and unconditionally guaranteed, on a joint and several basis, the obligations of Prestige Brands, Inc. (a 100% owned subsidiary of the Company) set forth in the indentures governing the 2016 Senior Notes and the 2013 Senior Notes, including the obligation to pay principal and interest with respect to the 2016 Senior Notes and the 2013 Senior Notes. The 100% owned subsidiaries of the Company that have guaranteed the 2016 Senior Notes and the 2013 Senior Notes are as follows: Prestige Services Corp., Prestige Brands Holdings, Inc. (a Virginia corporation), Prestige Brands International, Inc., Medtech Holdings, Inc., Medtech Products Inc., The Cutex Company, The Spic and Span Company, Blacksmith Brands, Inc., Insight Pharmaceuticals Corporation, Insight Pharmaceuticals, LLC, Practical Health Products, Inc., and DenTek Holdings, Inc. (collectively, the "Subsidiary Guarantors"). A significant portion of our operating income and cash flow is generated by our subsidiaries. As a result, funds necessary to meet Prestige Brands, Inc.'s debt service obligations are provided in part by distributions or advances from our subsidiaries. Under certain circumstances, contractual and legal restrictions, as well as the financial condition and operating requirements of our subsidiaries, could limit Prestige Brands, Inc.'s ability to obtain cash from our subsidiaries for the purpose of meeting our debt service obligations, including the payment of principal and interest on the 2016 Senior Notes and the 2013 Senior Notes. Although holders of the 2016 Senior Notes and the 2013 Senior Notes will be direct creditors of the guarantors of the 2016 Senior Notes and the 2013 Senior Notes by virtue of the guarantees, we have indirect subsidiaries located primarily in the United Kingdom, the Netherlands and Australia (collectively, the "Non-Guarantor Subsidiaries") that have not guaranteed the 2016 Senior Notes or the 2013 Senior Notes, and such subsidiaries will not be obligated with respect to the 2016 Senior Notes or the 2013 Senior Notes. As a result, the claims of creditors of the Non-Guarantor Subsidiaries will effectively have priority with respect to the assets and earnings of such companies over the claims of the holders of the 2016 Senior Notes and the 2013 Senior Notes. Presented below are supplemental Condensed Consolidating Balance Sheets as of December 31, 2016 and March 31, 2016 , Condensed Consolidating Statements of Income and Comprehensive Income for the three and nine months ended December 31, 2016 and 2015 , and Condensed Consolidating Statements of Cash Flows for the nine months ended December 31, 2016 and 2015 . Such consolidating information includes separate columns for: a) Prestige Brands Holdings, Inc., the parent, b) Prestige Brands, Inc., the Issuer or the Borrower, c) Combined Subsidiary Guarantors, d) Combined Non-Guarantor Subsidiaries, and e) Elimination entries necessary to consolidate the Company and all of its subsidiaries. The Condensed Consolidating Financial Statements are presented using the equity method of accounting for investments in our 100% owned subsidiaries. Under the equity method, the investments in subsidiaries are recorded at cost and adjusted for our share of the subsidiaries' cumulative results of operations, capital contributions, distributions and other equity changes. The elimination entries principally eliminate investments in subsidiaries and intercompany balances and transactions. The financial information in this note should be read in conjunction with the Consolidated Financial Statements presented and other notes related thereto contained in this Quarterly Report on Form 10-Q. In the second quarter of fiscal 2017, the Company determined that it had incorrectly recorded certain intercompany transactions relating to the first quarter of fiscal 2017 in the condensed consolidating financial statements. This resulted in an overstatement of equity in earnings of subsidiaries for Prestige Brands, Inc. (the “Issuer”) of $44.6 million and a net understatement of equity in earnings of subsidiaries for the eliminations of $44.6 million for the three months ended June 30, 2016.This item also resulted in corresponding adjustments to the investments in subsidiaries on the condensed consolidating balance sheet as of June 30, 2016 and adjustments to net income (loss) and equity in income of subsidiaries in the condensed consolidating statement of cash flows, although net cash provided by (used in) operating activities for the three months ended June 30, 2016 remained unchanged. These errors had no impact to the Company's consolidated balance sheet, consolidated statement of income or consolidated statement of cash flows. The Company assessed the materiality of these errors on the previously issued interim financial statements in accordance with SEC Staff Accounting Bulletin No. 99 and No. 108, and concluded that the errors were not material to the consolidated financial statements for the three months ended June 30, 2016. The Company appropriately reflected the intercompany transactions in the condensed consolidating financial statements for the six months ended September 30, 2016 and plans to revise the comparative presentation of the condensed consolidating financial statements for the period ended June 30, 2016 in future filings. Condensed Consolidating Statements of Income and Comprehensive Income Three Months Ended December 31, 2016 (In thousands) Prestige Brands Holdings, Inc. Prestige Brands, Inc., the issuer Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Revenues Net sales $ — $ 29,156 $ 172,216 $ 16,184 $ (824 ) $ 216,732 Other revenues — 76 31 329 (405 ) 31 Total revenues — 29,232 172,247 16,513 (1,229 ) 216,763 Cost of Sales Cost of sales (exclusive of depreciation shown below) — 12,179 74,494 6,684 (1,141 ) 92,216 Gross profit — 17,053 97,753 9,829 (88 ) 124,547 Operating Expenses Advertising and promotion — 3,009 24,266 3,407 — 30,682 General and administrative 2,486 2,004 15,644 1,997 — 22,131 Depreciation and amortization 722 154 4,860 116 — 5,852 Gain on divestitures — — (3,405 ) — — (3,405 ) Total operating expenses 3,208 5,167 41,365 5,520 — 55,260 Operating income (loss) (3,208 ) 11,886 56,388 4,309 (88 ) 69,287 Other (income) expense Interest income (12,056 ) (21,422 ) (1,299 ) (160 ) 34,891 (46 ) Interest expense 8,495 18,598 25,099 1,299 (34,891 ) 18,600 Equity in (income) loss of subsidiaries (32,821 ) (23,629 ) (2,089 ) — 58,539 — Total other expense (income) (36,382 ) (26,453 ) 21,711 1,139 58,539 18,554 Income (loss) before income taxes 33,174 38,339 34,677 3,170 (58,627 ) 50,733 Provision for income taxes 1,533 5,087 11,391 1,081 — 19,092 Net income (loss) $ 31,641 $ 33,252 $ 23,286 $ 2,089 $ (58,627 ) $ 31,641 Comprehensive (loss) income, net of tax: Currency translation adjustments (8,736 ) (8,736 ) (8,736 ) (8,736 ) 26,208 (8,736 ) Total other comprehensive (loss) income (8,736 ) (8,736 ) (8,736 ) (8,736 ) 26,208 (8,736 ) Comprehensive (loss) income $ 22,905 $ 24,516 $ 14,550 $ (6,647 ) $ (32,419 ) $ 22,905 Condensed Consolidating Statements of Income and Comprehensive Income Nine Months Ended December 31, 2016 (In thousands) Prestige Brands Holdings, Inc. Prestige Brands, Inc., the issuer Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Revenues Net sales $ — $ 83,128 $ 512,212 $ 47,368 $ (2,189 ) $ 640,519 Other revenues — 223 865 1,309 (1,526 ) 871 Total revenues — 83,351 513,077 48,677 (3,715 ) 641,390 Cost of Sales Cost of sales (exclusive of depreciation shown below) — 35,331 220,336 19,162 (3,542 ) 271,287 Gross profit — 48,020 292,741 29,515 (173 ) 370,103 Operating Expenses Advertising and promotion — 11,505 66,689 8,715 — 86,909 General and administrative 6,224 5,954 43,260 4,945 — 60,383 Depreciation and amortization 2,474 456 15,410 360 — 18,700 Loss on divestitures — — 51,552 — — 51,552 Total operating expenses 8,698 17,915 176,911 14,020 — 217,544 Operating income (loss) (8,698 ) 30,105 115,830 15,495 (173 ) 152,559 Other (income) expense Interest income (36,100 ) (64,143 ) (3,865 ) (475 ) 104,434 (149 ) Interest expense 25,437 60,654 75,138 3,865 (104,434 ) 60,660 Equity in (income) loss of subsidiaries (59,111 ) (37,390 ) (8,766 ) — 105,267 — Total other expense (income) (69,774 ) (40,879 ) 62,507 3,390 105,267 60,511 Income (loss) before income taxes 61,076 70,984 53,323 12,105 (105,440 ) 92,048 Provision for income taxes 2,771 11,791 15,842 3,339 — 33,743 Net income (loss) $ 58,305 $ 59,193 $ 37,481 $ 8,766 $ (105,440 ) $ 58,305 Comprehensive (loss) income, net of tax: Currency translation adjustments (11,857 ) (11,857 ) (11,857 ) (11,857 ) 35,571 (11,857 ) Total other comprehensive (loss) income (11,857 ) (11,857 ) (11,857 ) (11,857 ) 35,571 (11,857 ) Comprehensive (loss) income $ 46,448 $ 47,336 $ 25,624 $ (3,091 ) $ (69,869 ) $ 46,448 Condensed Consolidating Statements of Income and Comprehensive Income Three Months Ended December 31, 2015 (In thousands) Prestige Brands Holdings, Inc. Prestige Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Revenues Net sales $ — $ 27,598 $ 159,783 $ 12,332 $ (228 ) $ 199,485 Other revenues — 98 700 356 (444 ) 710 Total revenues — 27,696 160,483 12,688 (672 ) 200,195 Cost of Sales Cost of sales (exclusive of depreciation shown below) — 11,796 68,148 4,448 (981 ) 83,411 Gross profit — 15,900 92,335 8,240 309 116,784 Operating Expenses Advertising and promotion — 1,881 25,251 2,803 — 29,935 General and administrative 1,370 1,789 13,463 1,513 — 18,135 Depreciation and amortization 1,013 151 4,794 113 — 6,071 Total operating expenses 2,383 3,821 43,508 4,429 — 54,141 Operating income (loss) (2,383 ) 12,079 48,827 3,811 309 62,643 Other (income) expense Interest income (12,141 ) (21,569 ) (1,124 ) (128 ) 34,931 (31 ) Interest expense 8,602 19,443 25,255 1,124 (34,931 ) 19,493 Equity in (income) loss of subsidiaries (27,711 ) (15,898 ) (2,033 ) — 45,642 — Total other (income) expense (31,250 ) (18,024 ) 22,098 996 45,642 19,462 Income (loss) before income taxes 28,867 30,103 26,729 2,815 (45,333 ) 43,181 Provision for income taxes 872 4,950 8,582 782 — 15,186 Net income (loss) $ 27,995 $ 25,153 $ 18,147 $ 2,033 $ (45,333 ) $ 27,995 Comprehensive (loss) income, net of tax: Currency translation adjustments 4,922 4,922 4,922 4,922 (14,766 ) 4,922 Total other comprehensive (loss) income 4,922 4,922 4,922 4,922 (14,766 ) 4,922 Comprehensive income (loss) $ 32,917 $ 30,075 $ 23,069 $ 6,955 $ (60,099 ) $ 32,917 Condensed Consolidating Statements of Income and Comprehensive Income Nine Months Ended December 31, 2015 (In thousands) Prestige Brands Holdings, Inc. Prestige Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Revenues Net sales $ — $ 83,438 $ 477,079 $ 37,945 $ (2,428 ) $ 596,034 Other revenues — 273 2,317 1,397 (1,629 ) 2,358 Total revenues — 83,711 479,396 39,342 (4,057 ) 598,392 Cost of Sales Cost of sales (exclusive of depreciation shown below) — 33,105 206,646 13,808 (4,127 ) 249,432 Gross profit — 50,606 272,750 25,534 70 348,960 Operating Expenses Advertising and promotion — 7,602 68,412 8,236 — 84,250 General and administrative 3,884 5,644 38,326 4,332 — 52,186 Depreciation and amortization 3,032 444 13,686 316 — 17,478 Total operating expenses 6,916 13,690 120,424 12,884 — 153,914 Operating income (loss) (6,916 ) 36,916 152,326 12,650 70 195,046 Other (income) expense Interest income (36,351 ) (64,584 ) (3,513 ) (366 ) 104,723 (91 ) Interest expense 26,056 61,654 75,604 3,513 (104,723 ) 62,104 Loss on extinguishment of debt — 451 — — — 451 Equity in (income) loss of subsidiaries (84,458 ) (52,599 ) (6,868 ) — 143,925 — Total other (income) expense (94,753 ) (55,078 ) 65,223 3,147 143,925 62,464 Income (loss) before income taxes 87,837 91,994 87,103 9,503 (143,855 ) 132,582 Provision for income taxes 1,866 13,867 28,243 2,635 — 46,611 Net income (loss) $ 85,971 $ 78,127 $ 58,860 $ 6,868 $ (143,855 ) $ 85,971 Comprehensive (loss) income, net of tax: Currency translation adjustments (6,562 ) (6,562 ) (6,562 ) (6,562 ) 19,686 (6,562 ) Total other comprehensive (loss) income (6,562 ) (6,562 ) (6,562 ) (6,562 ) 19,686 (6,562 ) Comprehensive income (loss) $ 79,409 $ 71,565 $ 52,298 $ 306 $ (124,169 ) $ 79,409 Condensed Consolidating Balance Sheet December 31, 2016 (In thousands) Prestige Brands Holdings, Inc. Prestige Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Assets Current assets Cash and cash equivalents $ 36,821 $ — $ 202 $ 26,266 $ — $ 63,289 Accounts receivable, net — 12,291 79,927 12,170 — 104,388 Inventories — 16,758 75,522 9,351 (705 ) 100,926 Deferred income tax assets 2,372 918 8,624 688 — 12,602 Prepaid expenses and other current assets 1,611 158 7,464 772 — 10,005 Total current assets 40,804 30,125 171,739 49,247 (705 ) 291,210 Property and equipment, net 7,595 315 4,478 477 — 12,865 Goodwill — 66,007 258,252 21,226 — 345,485 Intangible assets, net — 191,387 1,882,242 82,749 — 2,156,378 Other long-term assets 2,500 2,414 — — — 4,914 Intercompany receivables 1,451,328 2,518,756 1,670,364 14,432 (5,654,880 ) — Investment in subsidiary 1,690,523 1,553,251 76,662 — (3,320,436 ) — Total Assets $ 3,192,750 $ 4,362,255 $ 4,063,737 $ 168,131 $ (8,976,021 ) $ 2,810,852 Liabilities and Stockholders' Equity Current liabilities Accounts payable $ 2,822 $ 9,418 $ 29,964 $ 3,046 $ — $ 45,250 Accrued interest payable — 8,399 — — — 8,399 Other accrued liabilities 13,722 2,721 55,162 7,070 — 78,675 Total current liabilities 16,544 20,538 85,126 10,116 — 132,324 Long-term debt Principal amount — 1,437,000 — — — 1,437,000 Less unamortized debt costs — (21,421 ) — — — (21,421 ) Long-term debt, net — 1,415,579 — — — 1,415,579 Deferred income tax liabilities — 61,047 398,380 353 — 459,780 Other long-term liabilities — — 3,264 48 — 3,312 Intercompany payables 2,376,349 1,249,872 1,945,431 83,228 (5,654,880 ) — Total Liabilities 2,392,893 2,747,036 2,432,201 93,745 (5,654,880 ) 2,010,995 Stockholders' Equity Common stock 532 — — — — 532 Additional paid-in capital 455,684 1,280,947 1,359,921 78,774 (2,719,642 ) 455,684 Treasury stock, at cost (6,594 ) — — — — (6,594 ) Accumulated other comprehensive (loss) income, net of tax (35,382 ) (35,382 ) (35,382 ) (35,382 ) 106,146 (35,382 ) Retained earnings (accumulated deficit) 385,617 369,654 306,997 30,994 (707,645 ) 385,617 Total Stockholders' Equity 799,857 1,615,219 1,631,536 74,386 (3,321,141 ) 799,857 Total Liabilities and Stockholders' Equity $ 3,192,750 $ 4,362,255 $ 4,063,737 $ 168,131 $ (8,976,021 ) $ 2,810,852 Condensed Consolidating Balance Sheet March 31, 2016 (In thousands) Prestige Brands Holdings, Inc. Prestige Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Assets Current assets Cash and cash equivalents $ 4,440 $ — $ 2,899 $ 19,891 $ — $ 27,230 Accounts receivable, net — 12,025 74,446 8,776 — 95,247 Inventories — 9,411 72,296 10,088 (532 ) 91,263 Deferred income tax assets 316 681 8,293 818 — 10,108 Prepaid expenses and other current assets 15,311 257 8,379 1,218 — 25,165 Total current assets 20,067 22,374 166,313 40,791 (532 ) 249,013 Property and equipment, net 9,166 210 5,528 636 — 15,540 Goodwill — 66,007 271,409 22,775 — 360,191 Intangible assets, net — 191,789 2,042,640 88,294 — 2,322,723 Other long-term assets — 1,324 — — — 1,324 Intercompany receivables 1,457,011 2,703,192 1,083,488 10,738 (5,254,429 ) — Investment in subsidiary 1,641,477 1,527,718 81,545 — (3,250,740 ) — Total Assets $ 3,127,721 $ 4,512,614 $ 3,650,923 $ 163,234 $ (8,505,701 ) $ 2,948,791 Liabilities and Stockholders' Equity Current liabilities Accounts payable $ 2,914 $ 7,643 $ 24,437 $ 3,302 $ — $ 38,296 Accrued interest payable — 8,664 — — — 8,664 Other accrued liabilities 12,285 1,714 38,734 6,991 — 59,724 Total current liabilities 15,199 18,021 63,171 10,293 — 106,684 Long-term debt Principal amount — 1,652,500 — — — 1,652,500 Less unamortized debt costs — (27,191 ) — — — (27,191 ) Long-term debt, net — 1,625,309 — — — 1,625,309 Deferred income tax liabilities — 60,317 408,893 412 — 469,622 Other long-term liabilities — — 2,682 158 — 2,840 Intercompany payables 2,368,186 1,241,084 1,570,265 74,894 (5,254,429 ) — Total Liabilities 2,383,385 2,944,731 2,045,011 85,757 (5,254,429 ) 2,204,455 Stockholders' Equity Common stock 530 — — — — 530 Additional paid-in capital 445,182 1,280,947 1,359,921 78,774 (2,719,642 ) 445,182 Treasury stock, at cost (5,163 ) — — — — (5,163 ) Accumulated other comprehensive income (loss), net of tax (23,525 ) (23,525 ) (23,525 ) (23,525 ) 70,575 (23,525 ) Retained earnings (accumulated deficit) 327,312 310,461 269,516 22,228 (602,205 ) 327,312 Total Stockholders' Equity 744,336 1,567,883 1,605,912 77,477 (3,251,272 ) 744,336 Total Liabilities and Stockholders' Equity $ 3,127,721 $ 4,512,614 $ 3,650,923 $ 163,234 $ (8,505,701 ) $ 2,948,791 Condensed Consolidating Statement of Cash Flows Nine Months Ended December 31, 2016 (In thousands) Prestige Brands Holdings, Inc. Prestige Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Operating Activities Net income (loss) $ 58,305 $ 59,193 $ 37,481 $ 8,766 $ (105,440 ) $ 58,305 Adjustments to reconcile net income (loss) to net cash provided by operating activities: Depreciation and amortization 2,474 456 15,410 360 — 18,700 Loss on divestitures and sales of property and equipment — 51,807 — — 51,807 Deferred income taxes (2,056 ) 493 (11,101 ) 134 — (12,530 ) Amortization of debt origination costs — 6,129 — — — 6,129 Stock-based compensation costs 6,260 — — — — 6,260 Equity in income of subsidiaries (59,111 ) (37,390 ) (8,766 ) — 105,267 — Changes in operating assets and liabilities, net of effects from acquisitions: Accounts receivable — (266 ) (5,481 ) (6,627 ) — (12,374 ) Inventories — (7,347 ) (9,409 ) (6 ) 173 (16,589 ) Prepaid expenses and other current assets 11,200 99 (525 ) 375 — 11,149 Accounts payable (118 ) 1,775 5,981 (470 ) — 7,168 Accrued liabilities 1,437 742 20,995 (851 ) — 22,323 Net cash provided by operating activities 18,391 23,884 96,392 1,681 — 140,348 Investing Activities Purchases of property and equipment (890 ) (158 ) (785 ) (102 ) — (1,935 ) Proceeds from divestitures — — 110,717 — — 110,717 Proceeds from the sales of property and equipment — — 85 — — 85 Proceeds from DenTek working capital arbitration settlement — — 1,419 — — 1,419 Net cash provided by (used in) investing activities (890 ) (158 ) 111,436 (102 ) — 110,286 Financing Activities Term loan repayments — (130,500 ) — — — (130,500 ) Borrowings under revolving credit agreement — 20,000 — — — 20,000 Repayments under revolving credit agreement — (105,000 ) — — — (105,000 ) Payments of debt origination costs — (9 ) — — — (9 ) Proceeds from exercise of stock options 3,444 — — — — 3,444 Excess tax benefits from share-based awards 800 — — — — 800 Fair value of shares surrendered as payment of tax withholding (1,431 ) — — — — (1,431 ) Intercompany activity, net 12,067 191,783 (210,525 ) 6,675 — — Net cash (used in) provided by financing activities 14,880 (23,726 ) (210,525 ) 6,675 — (212,696 ) Effect of exchange rate changes on cash and cash equivalents — — — (1,879 ) — (1,879 ) Increase (decrease) in cash and cash equivalents 32,381 — (2,697 ) 6,375 — 36,059 Cash and cash equivalents - beginning of period 4,440 — 2,899 19,891 — 27,230 Cash and cash equivalents - end of period $ 36,821 $ — $ 202 $ 26,266 $ — $ 63,289 Condensed Consolidating Statement of Cash Flows Nine Months Ended December 31, 2015 (In thousands) Prestige Brands Holdings, Inc. Prestige Combined Subsidiary Guarantors Combined Non-Guarantor Subsidiaries Eliminations Consolidated Operating Activities Net income (loss) $ 85,971 $ 78,127 $ 58,860 $ 6,868 $ (143,855 ) $ 85,971 Adjustments to reconcile net income (loss) to net cash provided by operating activities: Depreciation and amortization 3,032 444 13,686 316 — 17,478 Deferred income taxes 148 164 31,301 (22 ) — 31,591 Amortization of debt origination costs — 5,433 — — — 5,433 Stock-based compensation costs 7,057 — — 41 — 7,098 Loss on extinguishment of debt — 451 — — — 451 Gain on sale or disposal of property and equipment — — — (36 ) — (36 ) Equity in income of subsidiaries (84,458 ) (52,599 ) (6,868 ) — 143,925 — Changes in operating assets and liabilities, net of effects from acquisitions: Accounts receivable — 1,158 2,188 (893 ) — 2,453 Inventories — (2,519 ) (3,014 ) (1,511 ) (70 ) (7,114 ) Prepaid expenses and other current assets 3,557 (305 ) 2,752 (532 ) — 5,472 Accounts payable (33 ) (1,161 ) (14,613 ) (1,746 ) — (17,553 ) Accrued liabilities (102 ) (1,636 ) 5,439 1,506 — 5,207 Net cash provided by operating activities 15,172 27,557 89,731 3,991 — 136,451 Investing Activities Purchases of property and equipment (1,741 ) (93 ) (212 ) (494 ) — (2,540 ) Proceeds from the sale of property and equipment — — — 344 — 344 Proceeds from Insight Pharmaceuticals working capital arbitration settlement — — 7,237 — — 7,237 Net cash provided by (used in) investing activities (1,741 ) (93 ) 7,025 (150 ) — 5,041 Financing Activities Term loan repayments — (50,000 ) — — — (50,000 ) Borrowings under revolving credit agreement — 15,000 — — — 15,000 Repayments under revolving credit agreement — (81,100 ) — — — (81,100 ) Payments of debt origination costs — (4,211 ) — — — (4,211 ) Proceeds from exercise of stock options 6,600 — — — — 6,600 Proceeds from restricted stock exercises 544 — — — — 544 Excess tax benefits from share-based awards 1,850 — — — — 1,850 Fair value of shares surrendered as payment of tax withholding (2,187 ) — — — — (2,187 ) Intercompany activity, net 2,127 92,847 (96,756 ) 1,782 — — Net cash (used in) provided by financing activities 8,934 (27,464 ) (96,756 ) 1,782 — (113,504 ) Effect of exchange rate changes on cash and cash equivalents — — — (333 ) — (333 ) Increase in cash and cash equivalents 22,365 — — 5,290 — 27,655 Cash and cash equivalents - beginning of period 11,387 — — 9,931 — 21,318 Cash and cash equivalents - end of period $ 33,752 $ — $ — $ 15,221 $ — $ 48,973

Subsequent Events

Subsequent Events	9 Months Ended
	Dec. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events On January 26, 2017, we completed our previously announced acquisition of Fleet pursuant to the Agreement and Plan of Merger, dated as of December 22, 2016, by and among Medtech Products, Inc., AETAGE LLC, C.B. Fleet TopCo, LLC, and Gryphon Partners 3.5, L.P. (the “Merger Agreement”). As a result of the merger contemplated by the Merger Agreement, we acquired multiple feminine hygiene, gastrointestinal care and infant care OTC brands, including Summer’s Eve , Fleet , and Pedia-Lax , as well as a “mix and fill” manufacturing facility in Lynchburg Virginia. The purchase price was $825.0 million subject to certain adjustments based on the cash, indebtedness, transaction expenses, and working capital of Fleet and its subsidiaries at the closing. The purchase price was funded by available cash on hand, additional borrowings under our asset-based revolving credit facility, and a new $740.0 million senior secured incremental term loan. The acquisition will be accounted for as a business combination. The application of purchase accounting as of the closing date is expected to have a material effect on our results of operations for periods subsequent to the acquisition. We have begun the process to determine the purchase price allocation for Fleet's assets and liabilities including estimating fair values of intangible and tangible assets. These estimates have not been completed due to the timing and complexity of obtaining information and calculating such amounts. Term Loan and ABL Refinancing On January 26, 2017, we entered into (i) Amendment No. 4 (“Term Loan Amendment No. 4”) to the 2012 Term Loan and (ii) Amendment No. 6 (“ABL Amendment No. 6” and together with the Term Loan Amendment No. 4, the “Amendments”) to the 2012 ABL Revolver. Term Loan Amendment No. 4 provides for (i) the refinancing of the Borrower’s outstanding term loans and the creation of a new class of Term B-4 Loans under the 2012 Term Loan in an aggregate principal amount of $1.427 billion , (ii) increased flexibility under the 2012 Term Loan , including but not limited to additional investment, restricted payment and debt incurrence flexibility and financial maintenance covenant relief and (iii) an interest rate on the Term B-4 Loans that is based, at the Borrower’s option, on a LIBOR rate plus a margin of 2.75% per annum, with a LIBOR floor of 0.75% , or an alternative base rate plus a margin (with a margin step-down to 2.50% per annum based upon achievement of a specified first lien net leverage ratio). In addition, Citibank, N.A. was succeeded by Barclays Bank PLC as administrative agent under the 2012 Term Loan. ABL Amendment No. 6 provides for (i) a $40.0 million increase in revolving commitments under the 2012 ABL Revolver (ii) an extension of the maturity date of revolving commitments to January 26, 2022 and (iii) increased flexibility under the 2012 ABL Revolver, including but not limited to additional investment, restricted payment and debt incurrence flexibility consistent with Term Loan Amendment No. 4. We used the net proceeds from the Term B-4 Loans and borrowings under the 2012 ABL Revolver to finance the acquisition of Fleet, to refinance outstanding term loans, and pay fees and expenses incurred in connection with the Fleet acquisition.

Business and Basis of Present27

Business and Basis of Presentation (Policies)	9 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The unaudited Consolidated Financial Statements presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. All significant intercompany transactions and balances have been eliminated in these Consolidated Financial Statements. In the opinion of management, these Consolidated Financial Statements include all adjustments, consisting of normal recurring adjustments, that are considered necessary for a fair statement of our consolidated financial position, results of operations and cash flows for the interim periods presented. Our fiscal year ends on March 31 st of each year. References in these Consolidated Financial Statements or related notes to a year (e.g., “2017”) mean our fiscal year ending or ended on March 31 st of that year. Operating results for the three and nine months ended December 31, 2016 are not necessarily indicative of results that may be expected for the fiscal year ending March 31, 2017 . These unaudited Consolidated Financial Statements and related notes should be read in conjunction with our audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2016 .
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on our knowledge of current events and actions that we may undertake in the future, actual results could differ from those estimates. As discussed below, our most significant estimates include those made in connection with the valuation of intangible assets, stock-based compensation, fair value of debt, sales returns and allowances, trade promotional allowances and inventory obsolescence, and the recognition of income taxes using an estimated annual effective tax rate.
Cash and Cash Equivalents	Cash and Cash Equivalents We consider all short-term deposits and investments with original maturities of three months or less to be cash equivalents. Substantially all of our cash is held by a large regional bank with headquarters in California. We do not believe that, as a result of this concentration, we are subject to any unusual financial risk beyond the normal risk associated with commercial banking relationships. The Federal Deposit Insurance Corporation (“FDIC”) and Securities Investor Protection Corporation (“SIPC”) insure these balances up to $250,000 and $500,000, with a $250,000 limit for cash, respectively. Substantially all of the Company's cash balances at December 31, 2016 are uninsured, and approximately 58.5% of our consolidated cash balances at December 31, 2016 are located in the United States.
Accounts Receivable	Accounts Receivable We extend non-interest-bearing trade credit to our customers in the ordinary course of business. We maintain an allowance for doubtful accounts receivable based upon historical collection experience and expected collectability of the accounts receivable. In an effort to reduce credit risk, we (i) have established credit limits for all of our customer relationships, (ii) perform ongoing credit evaluations of customers' financial condition, (iii) monitor the payment history and aging of customers' receivables, and (iv) monitor open orders against an individual customer's outstanding receivable balance.
Inventories	Inventories Inventories are stated at the lower of cost or market value, with cost determined by using the first-in, first-out method. We reduce inventories for diminution of value resulting from product obsolescence, damage or other issues affecting marketability, equal to the difference between the cost of the inventory and its estimated market value. Factors utilized in the determination of estimated market value include: (i) current sales data and historical return rates, (ii) estimates of future demand, (iii) competitive pricing pressures, (iv) new product introductions, (v) product expiration dates, and (vi) component and packaging obsolescence.
Property and Equipment	Property and Equipment Property and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives: Years Machinery 5 Computer equipment and software 3 Furniture and fixtures 7 Leasehold improvements * *Leasehold improvements are amortized over the lesser of the term of the lease or the estimated useful life of the related asset. Expenditures for maintenance and repairs are charged to expense as incurred. When an asset is sold or otherwise disposed of, we remove the cost and associated accumulated depreciation from the respective accounts and recognize the resulting gain or loss in the Consolidated Statements of Income and Comprehensive Income. Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. An impairment loss is recognized if the carrying amount of the asset exceeds its fair value.
Goodwill	Goodwill The excess of the purchase price over the fair market value of assets acquired and liabilities assumed in business combinations is classified as goodwill. Goodwill is not amortized, although the carrying value is tested for impairment at least annually in the fourth fiscal quarter of each year, or more frequently if events or changes in circumstances indicate that the asset may be impaired. Goodwill is tested for impairment at the product group level, which is one level below the operating segment level.
Intangible Assets	Intangible Assets Intangible assets, which are comprised primarily of trademarks, are stated at cost less accumulated amortization. For intangible assets with finite lives, amortization is computed using the straight-line method over estimated useful lives, typically ranging from 10 to 30 years. Indefinite-lived intangible assets are tested for impairment at least annually in the fourth fiscal quarter of each year, or more frequently if events or changes in circumstances indicate that the asset may be impaired. Intangible assets with finite lives are reviewed for impairment whenever events or changes in circumstances indicate that their carrying amounts may exceed their fair values and may not be recoverable. An impairment loss is recognized if the carrying amount of the asset exceeds its fair value.
Debt Origination Costs	Debt Origination Costs We have incurred debt origination costs in connection with the issuance of our long-term debt. These costs are amortized over the term of the related debt, using the effective interest method for our bonds and our term loan facility and the straight-line method for our revolving credit facility.
Revenue Recognition	Revenue Recognition Revenues are recognized when the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) the selling price is fixed or determinable, (iii) the product has been shipped and the customer takes ownership and assumes the risk of loss, and (iv) collection of the resulting receivable is reasonably assured. We have determined that these criteria are met and the transfer of the risk of loss generally occurs when the product is received by the customer, and, accordingly, we recognize revenue at that time. Provisions are made for estimated discounts related to customer payment terms and estimated product returns at the time of sale based on our historical experience. As is customary in the consumer products industry, we participate in the promotional programs of our customers to enhance the sale of our products. The cost of these promotional programs varies based on the actual number of units sold during a finite period of time. These promotional programs consist of direct-to-consumer incentives, such as coupons and temporary price reductions, as well as incentives to our customers, such as allowances for new distribution, including slotting fees, and cooperative advertising. Estimates of the costs of these promotional programs are based on (i) historical sales experience, (ii) the current promotional offering, (iii) forecasted data, (iv) current market conditions, and (v) communication with customer purchasing/marketing personnel. We recognize the cost of such sales incentives by recording an estimate of such cost as a reduction of revenue, at the later of (a) the date the related revenue is recognized, or (b) the date when a particular sales incentive is offered. At the completion of a promotional program, the estimated amounts are adjusted to actual results. Due to the nature of the consumer products industry, we are required to estimate future product returns. Accordingly, we record an estimate of product returns concurrent with recording sales, which is made after analyzing (i) historical return rates, (ii) current economic trends, (iii) changes in customer demand, (iv) product acceptance, (v) seasonality of our product offerings, and (vi) the impact of changes in product formulation, packaging and advertising.
Cost of Sales	Cost of Sales Cost of sales includes product costs, warehousing costs, inbound and outbound shipping costs, and handling and storage costs.
Advertising and Promotion Costs	Advertising and Promotion Costs Advertising and promotion costs are expensed as incurred. Allowances for distribution costs associated with products, including slotting fees, are recognized as a reduction of sales. Under these new distribution arrangements, the retailers allow our products to be placed on the stores' shelves in exchange for such fees.
Stock-based Compensation	Stock-based Compensation We recognize stock-based compensation by measuring the cost of services to be rendered based on the grant-date fair value of the equity award. Compensation expense is recognized over the period a grantee is required to provide service in exchange for the award, generally referred to as the requisite service period.
Income Taxes	Income Taxes Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Income Taxes topic of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740 prescribes a recognition threshold and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The guidance only allows the recognition of those tax benefits that have a greater than 50% likelihood of being sustained upon examination by the various taxing authorities. As a result, we have applied such guidance in determining our tax uncertainties. We are subject to taxation in the United States and various state and foreign jurisdictions. We classify penalties and interest related to unrecognized tax benefits as income tax expense in the Consolidated Statements of Income and Comprehensive Income.
Earnings Per Share	Earnings Per Share Basic earnings per share is calculated based on income available to common stockholders and the weighted-average number of shares outstanding during the reporting period. Diluted earnings per share is calculated based on income available to common stockholders and the weighted-average number of common and potential common shares outstanding during the reporting period. Potential common shares, composed of the incremental common shares issuable upon the exercise of outstanding stock options and unvested restricted stock units, are included in the earnings per share calculation to the extent that they are dilutive. In loss periods, the assumed exercise of in-the-money stock options and restricted stock units has an anti-dilutive effect, and therefore these instruments are excluded from the computation of diluted earnings per share.
Recently Issued Accounting Standards	Recently Issued Accounting Standards In January 2017, the FASB issued Accounting Standards Update ("ASU") 2017-04, Intangibles - Goodwill and Other (Topic 350) . The amendments in this update simplify the test for goodwill impairment by eliminating Step 2 from the impairment test, which required the entity to perform procedures to determine the fair value at the impairment testing date of its assets and liabilities following the procedure that would be required in determining fair value of assets acquired and liabilities assumed in a business combination. The amendments in this update are effective for public companies for annual or any interim goodwill impairments tests in fiscal years beginning after December 15, 2019. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements. In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805); Clarifying the Definition of a Business. The amendments in this update clarify the definition of a business to help companies evaluate whether transactions should be accounted for as acquisitions or disposals of assets or businesses. The amendments in this update are effective for public companies for annual periods beginning after December 15, 2017, including interim periods within those periods. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements. In December 2016, the FASB issued ASU 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers . The amendments in this update affect narrow aspects of the guidance issued in ASU 2014-09, Revenue from Contracts with Customers . For public business entities, the amendments in this update are effective for annual reporting periods beginning after December 15, 2017, including interim reporting periods therein. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements. In December 2016, the FASB issued ASU 2016-19, Technical Corrections and Improvements . The amendments in this update affect a wide variety of topics in the Accounting Standards Codification. For public business entities, the amendments in this update are effective for annual periods beginning after December 15, 2017, and interim periods in the annual periods beginning after December 15, 2018. The adoption of ASU 2016-19 is not expected to have a material impact on our Consolidated Financial Statements. In October 2016, the FASB issued ASU 2016-16, Intra-Entity Transfers of Assets Other Than Inventory. The amendments in this update require recognition of the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. For public business entities, the amendments in this update are effective for annual reporting periods beginning after December 15, 2017, including interim reporting periods within those annual reporting periods. The adoption of ASU 2016-16 is not expected to have a material impact on our Consolidated Financial Statements. In August 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments . The amendments in this update provide clarification and guidance on eight cash flow classification issues. For public business entities, the amendments in this update are effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The adoption of ASU 2016-15 is not expected to have a material impact on our Consolidated Financial Statements. In May 2016, the FASB issued ASU 2016-12, Revenue from Contracts with Customers . The amendments do not change the core principle of the guidance in FASB ASC 606, discussed below. Rather, the amendments in this update affect only certain narrow aspects of FASB ASC 606. The effective date and transition requirements for the amendments in this update are the same as the effective date and transition requirements of ASU 2014-09 described below. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements. In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers . The amendments in this update clarify the implementation guidance on identifying performance obligations and licensing in FASB ASC 606. The effective date and transition requirements for the amendments in this update are the same as the effective date and transition requirements of ASU 2014-09 described below. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements. In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting . The amendments in this update involve several aspects of accounting for share-based payment transactions, including income tax consequences, classification of awards, and classification on the statement of cash flows. For public business entities, the amendments in this update are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements. In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers . The amendments in this update clarify the implementation guidance on principals versus agent considerations in FASB ASC 606. The effective date and transition requirements for the amendments in this update are the same as the effective date and transition requirements of ASU 2014-09 described below. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements. In February 2016, the FASB issued ASU 2016-02, Leases. The amendments in this update include a new FASB ASC Topic 842, which supersedes Topic 840. The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. For public business entities, the amendments in this update are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted for all entities as of the beginning of interim or annual reporting periods. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements. In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes . The amendments in this update require that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The amendments in this update may be applied either prospectively to all deferred tax liabilities and assets or retrospectively to all periods presented. For public business entities, the amendments in this update are effective for financial statements issued for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early application is permitted for all entities as of the beginning of interim or annual reporting periods. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements. In July 2015, the FASB issued ASU 2015-11, Simplifying the Measurement of Inventory . The amendments in this update more closely align the measurement of inventory in GAAP with the measurement of inventory in International Financial Reporting Standards, under which an entity should measure inventory at the lower of cost or net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. For public business entities, the amendments are effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The adoption of ASU 2015-11 is not expected to have a material impact on our Consolidated Financial Statements. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers - Topic 606 , which supersedes the revenue recognition requirements in FASB ASC 605. The new guidance primarily states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. In August 2015, the FASB issued ASU 2015-14, which deferred the effective date of ASU 2014-09 from annual and interim periods beginning after December 15, 2016 to annual and interim periods beginning after December 15, 2017. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements.

Business and Basis of Present28

Business and Basis of Presentation (Tables)	9 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Property and Equipment	Property and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives: Years Machinery 5 Computer equipment and software 3 Furniture and fixtures 7 Leasehold improvements * *Leasehold improvements are amortized over the lesser of the term of the lease or the estimated useful life of the related asset. Property and equipment consist of the following: (In thousands) December 31, March 31, Components of Property and Equipment Machinery $ 8,217 $ 7,734 Computer equipment 13,238 12,793 Furniture and fixtures 2,504 2,445 Leasehold improvements 7,347 7,389 31,306 30,361 Accumulated depreciation (18,441 ) (14,821 ) Property and equipment, net $ 12,865 $ 15,540

Acquisitions (Tables)

Acquisitions (Tables)	9 Months Ended
	Dec. 31, 2016
Business Combinations [Abstract]
Allocation of Assets Acquired and Liabilities Assumed	The following table summarizes our allocation of the assets acquired and liabilities assumed as of the February 5, 2016 acquisition date. (In thousands) February 5, 2016 Cash acquired $ 1,359 Accounts receivable 9,187 Inventories 14,304 Deferred income taxes 3,303 Prepaids and other current assets 6,728 Property, plant and equipment, net 3,555 Goodwill 73,737 Intangible assets, net 206,700 Total assets acquired 318,873 Accounts payable 3,261 Accrued expenses 14,336 Deferred income tax liabilities - long term 74,352 Total liabilities assumed 91,949 Total purchase price $ 226,924

Divestitures (Tables)

Divestitures (Tables)	9 Months Ended
	Dec. 31, 2016
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Divestitures	The following table sets forth the components of the assets sold and the pre-tax loss recognized on the sale in July 2016. (In thousands) July 7, Components of assets sold: Inventory $ 2,380 Intangible assets, net 91,208 Goodwill 2,920 Assets sold 96,508 Total purchase price received 42,380 54,128 Costs to sell 2,018 Pre-tax loss on divestitures $ 56,146 The following table sets forth the components of the assets sold and the pre-tax net gain recognized on the sales of e.p.t and Dermoplast in December 2016. (In thousands) December 2016 Components of assets sold: Inventory $ 2,998 Intangible assets, net 45,870 Goodwill 6,889 Assets sold 55,757 Total purchase price received 59,614 Pre-tax net (gain) on divestitures $ (3,857 )

Accounts Receivable (Tables)

Accounts Receivable (Tables)	9 Months Ended
	Dec. 31, 2016
Receivables [Abstract]
Accounts Receivable	Accounts receivable consist of the following: (In thousands) December 31, March 31, Components of Accounts Receivable Trade accounts receivable $ 115,967 $ 105,592 Other receivables 289 1,261 116,256 106,853 Less allowances for discounts, returns and uncollectible accounts (11,868 ) (11,606 ) Accounts receivable, net $ 104,388 $ 95,247

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Dec. 31, 2016
Inventory Disclosure [Abstract]
Inventories	Inventories consist of the following: (In thousands) December 31, March 31, Components of Inventories Packaging and raw materials $ 7,944 $ 7,563 Finished goods 92,982 83,700 Inventories $ 100,926 $ 91,263

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives: Years Machinery 5 Computer equipment and software 3 Furniture and fixtures 7 Leasehold improvements * *Leasehold improvements are amortized over the lesser of the term of the lease or the estimated useful life of the related asset. Property and equipment consist of the following: (In thousands) December 31, March 31, Components of Property and Equipment Machinery $ 8,217 $ 7,734 Computer equipment 13,238 12,793 Furniture and fixtures 2,504 2,445 Leasehold improvements 7,347 7,389 31,306 30,361 Accumulated depreciation (18,441 ) (14,821 ) Property and equipment, net $ 12,865 $ 15,540

Goodwill (Tables)

Goodwill (Tables)	9 Months Ended
	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Reconciliation of the Activity Affecting Goodwill	A reconciliation of the activity affecting goodwill by operating segment is as follows: (In thousands) North American OTC Healthcare International OTC Healthcare Household Cleaning Consolidated Balance — March 31, 2016 $ 330,615 $ 22,776 $ 6,800 $ 360,191 Reductions (12,601 ) — (555 ) (13,156 ) Effects of foreign currency exchange rates — (1,550 ) — (1,550 ) Balance — December 31, 2016 $ 318,014 $ 21,226 $ 6,245 $ 345,485

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Reconciliation of the Activity Affecting Intangible Assets	A reconciliation of the activity affecting intangible assets is as follows: (In thousands) Indefinite Lived Trademarks Finite Lived Totals Gross Carrying Amounts Balance — March 31, 2016 $ 2,020,046 $ 417,880 $ 2,437,926 Reductions (77,248 ) (76,903 ) (154,151 ) Effects of foreign currency exchange rates (5,185 ) (230 ) (5,415 ) Balance — December 31, 2016 1,937,613 340,747 2,278,360 Accumulated Amortization Balance — March 31, 2016 — 115,203 115,203 Additions — 14,412 14,412 Reductions — (7,610 ) (7,610 ) Effects of foreign currency exchange rates — (23 ) (23 ) Balance — December 31, 2016 — 121,982 121,982 Intangible assets, net - December 31, 2016 $ 1,937,613 $ 218,765 $ 2,156,378 Intangible Assets, net by Reportable Segment: North American OTC Healthcare $ 1,755,635 $ 196,391 $ 1,952,026 International OTC Healthcare 80,716 1,004 81,720 Household Cleaning 101,262 21,370 122,632 Intangible assets, net - December 31, 2016 $ 1,937,613 $ 218,765 $ 2,156,378
Schedule of Expected Amortization Expense	At December 31, 2016 , finite-lived intangible assets are being amortized over a period of 10 to 30 years, and the associated amortization expense is expected to be as follows: (In thousands) Year Ending March 31, Amount 2017 (Remaining three months ending March 31, 2017) $ 4,527 2018 17,945 2019 17,945 2020 17,945 2021 17,522 Thereafter 142,881 $ 218,765

Other Accrued Liabilities (Tabl

Other Accrued Liabilities (Tables)	9 Months Ended
	Dec. 31, 2016
Payables and Accruals [Abstract]
Other Accrued Liabilities	Other accrued liabilities consist of the following: (In thousands) December 31, March 31, Accrued marketing costs $ 33,786 $ 26,373 Accrued compensation costs 7,686 9,574 Accrued broker commissions 1,277 1,497 Income taxes payable 13,327 3,675 Accrued professional fees 3,142 1,787 Deferred rent 609 836 Accrued production costs 5,216 3,324 Accrued lease termination costs 351 448 Income tax related payable 6,354 6,354 Other accrued liabilities 6,927 5,856 $ 78,675 $ 59,724

Long-Term Debt (Tables)

Long-Term Debt (Tables)	9 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Schedule of Long-term Debt	Long-term debt consists of the following, as of the dates indicated: (In thousands, except percentages) December 31, March 31, 2016 Senior Notes bearing interest at 6.375%, with interest payable on March 1 and September 1 of each year. The 2016 Senior Notes mature on March 1, 2024. $ 350,000 $ 350,000 2013 Senior Notes bearing interest at 5.375%, with interest payable on June 15 and December 15 of each year. The 2013 Senior Notes mature on December 15, 2021. 400,000 400,000 2012 Term B-3 Loans bearing interest at the Borrower's option at either a base rate with a floor of 1.75% plus applicable margin or LIBOR with a floor of 0.75% plus applicable margin, due on September 3, 2021. 687,000 817,500 2012 ABL Revolver bearing interest at the Borrower's option at either a base rate plus applicable margin or LIBOR plus applicable margin. Any unpaid balance is due on June 9, 2020. — 85,000 Total long-term debt (including current portion) 1,437,000 1,652,500 Current portion of long-term debt — — Long-term debt 1,437,000 1,652,500 Less: unamortized debt costs (21,421 ) (27,191 ) Long-term debt, net $ 1,415,579 $ 1,625,309
Aggregate Future Principal Payments	At December 31, 2016, aggregate future principal payments required in accordance with the terms of the 2012 Term Loan, 2012 ABL Revolver and the indentures governing the 2016 Senior Notes and the 2013 Senior Notes are as follows: (In thousands) Year Ending March 31, Amount 2017 (remaining three months ending March 31, 2017) $ — 2018 — 2019 — 2020 — 2021 — Thereafter 1,437,000 $ 1,437,000

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Dec. 31, 2016
Fair Value Disclosures [Abstract]
Summary of Carry Amounts and Fair Value Measurements	As such, the 2016 Senior Notes, the 2013 Senior Notes, the Term B-3 Loans, and the 2012 ABL Revolver are measured in Level 2 of the above hierarchy (see summary below detailing the carrying amounts and estimated fair values of these borrowings at December 31, 2016 and March 31, 2016). December 31, 2016 March 31, 2016 (In thousands) Carrying Value Fair Value Carrying Value Fair Value 2016 Senior Notes $ 350,000 $ 367,500 $ 350,000 $ 363,125 2013 Senior Notes 400,000 413,000 400,000 408,000 Term B-3 Loans 687,000 692,153 817,500 818,522 2012 ABL Revolver — — 85,000 85,000

Accumulated Other Comprehensi39

Accumulated Other Comprehensive Loss (Tables)	9 Months Ended
	Dec. 31, 2016
Stockholders' Equity Note [Abstract]
Schedule of Accumulated Other Comprehensive Income	The table below presents accumulated other comprehensive loss (“AOCI”), which affects equity and results from recognized transactions and other economic events, other than transactions with owners in their capacity as owners. AOCI consisted of the following at December 31, 2016 and March 31, 2016 : December 31, March 31, (In thousands) 2016 2016 Components of Accumulated Other Comprehensive Loss Cumulative translation adjustment $ (35,382 ) $ (23,525 ) Accumulated other comprehensive loss, net of tax $ (35,382 ) $ (23,525 )

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Dec. 31, 2016
Earnings Per Share [Abstract]
Computation of Basic and Diluted Earnings Per Share	The following table sets forth the computation of basic and diluted earnings per share: Three Months Ended December 31, Nine Months Ended December 31, (In thousands, except per share data) 2016 2015 2016 2015 Numerator Net income $ 31,641 $ 27,995 $ 58,305 $ 85,971 Denominator Denominator for basic earnings per share — weighted average shares outstanding 52,999 52,824 52,960 52,727 Dilutive effect of unvested restricted stock units and options issued to employees and directors 360 379 379 379 Denominator for diluted earnings per share 53,359 53,203 53,339 53,106 Earnings per Common Share: Basic net earnings per share $ 0.60 $ 0.53 $ 1.10 $ 1.63 Diluted net earnings per share $ 0.59 $ 0.53 $ 1.09 $ 1.62

Share-Based Compensation (Table

Share-Based Compensation (Tables)	9 Months Ended
	Dec. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Restricted Shares	A summary of the Company's restricted stock units granted under the Plan is presented below: Restricted Stock Units Shares (in thousands) Weighted- Average Grant-Date Fair Value Nine months ended December 31, 2015 Vested and nonvested at March 31, 2015 362.3 $ 22.74 Granted 266.1 42.41 Vested and issued (153.6 ) 18.16 Forfeited (1.4 ) 33.50 Vested and nonvested at December 31, 2015 473.4 35.25 Vested at December 31, 2015 69.8 14.76 Nine months ended December 31, 2016 Vested and nonvested at March 31, 2016 467.8 $ 35.22 Granted 68.4 55.44 Vested and issued (94.7 ) 28.51 Forfeited (91.4 ) 41.71 Vested and nonvested at December 31, 2016 350.1 39.29 Vested at December 31, 2016 63.4 20.12
Fair Value of Options Granted	Nine months ended December 31, 2016 2015 Expected volatility 37.8 % 40.2 % Expected dividends $ — $ — Expected term in years 6.0 6.0 Risk-free rate 1.7 % 1.7 %
Stock Option Activity	A summary of option activity under the Plan is as follows: Options Shares (in thousands) Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (years) Aggregate Intrinsic Value (in thousands) Nine months ended December 31, 2015 Outstanding at March 31, 2015 871.2 $ 23.40 Granted 208.2 42.13 Exercised (336.9 ) 18.99 Forfeited or expired (2.1 ) 38.21 Outstanding at December 31, 2015 740.4 30.63 7.9 $ 15,325 Exercisable at December 31, 2015 313.5 21.68 6.7 $ 9,341 Nine months ended December 31, 2016 Outstanding at March 31, 2016 727.7 $ 30.70 Granted 264.3 55.86 Exercised (107.9 ) 31.91 Forfeited or expired (92.2 ) 42.62 Outstanding at December 31, 2016 791.9 37.54 7.4 $ 12,543 Exercisable at December 31, 2016 387.0 25.70 6.3 $ 10,217

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases	The following summarizes future minimum lease payments for our operating leases as of December 31, 2016 : (In thousands) Year Ending March 31, Facilities Equipment Total (a) 2017 (Remaining three months ending March 31, 2017) $ 524 $ 132 $ 656 2018 2,029 443 2,472 2019 2,023 174 2,197 2020 1,848 86 1,934 2021 903 7 910 Thereafter 59 4 63 $ 7,386 $ 846 $ 8,232 (a) Minimum lease payments have not been reduced by minimum sublease rentals of $1.0 million due to us in the future under noncancelable subleases. The following schedule shows the composition of total minimum lease payments that have been reduced by minimum sublease rentals: (In thousands) December 31, 2016 March 31, 2016 Minimum lease payments $ 8,232 $ 8,434 Less: Sublease rentals (971 ) (1,165 ) $ 7,261 $ 7,269
Purchase Commitments Minimum Amounts Set Forth	Although we are committed under the supply agreement to pay the minimum amounts set forth in the table below, the total commitment is less than 10% of the estimated purchases that we expect to make during the course of the agreement. (In thousands) Year Ending March 31, Amount 2017 (Remaining three months ending March 31, 2017) 258 2018 1,013 2019 982 2020 559 2021 — $ 2,812

Business Segments (Tables)

Business Segments (Tables)	9 Months Ended
	Dec. 31, 2016
Segment Reporting [Abstract]
Information about our Operating and Reportable Segments	The tables below summarize information about our reportable segments. Three Months Ended December 31, 2016 (In thousands) North American OTC International OTC Household Cleaning Consolidated Gross segment revenues $ 178,097 $ 18,459 $ 21,000 $ 217,556 Elimination of intersegment revenues (824 ) — — (824 ) Third-party segment revenues 177,273 18,459 21,000 216,732 Other revenues — — 31 31 Total segment revenues 177,273 18,459 21,031 216,763 Cost of sales 68,378 7,678 16,160 92,216 Gross profit 108,895 10,781 4,871 124,547 Advertising and promotion 26,800 3,502 380 30,682 Contribution margin $ 82,095 $ 7,279 $ 4,491 93,865 Other operating expenses* 24,578 Operating income 69,287 Other expense 18,554 Income before income taxes 50,733 Provision for income taxes 19,092 Net income $ 31,641 *Other operating expenses for the three months ended December 31, 2016 includes a pre-tax net gain on divestitures of $3.4 million related primarily to e.p.t and Dermoplast. The assets and corresponding contribution margin associated with the pre-tax net gain on these divestitures are included within the North American OTC Healthcare segment. Nine Months Ended December 31, 2016 (In thousands) North American OTC International OTC Household Cleaning Consolidated Gross segment revenues $ 523,988 $ 53,061 $ 65,658 $ 642,707 Elimination of intersegment revenues (2,188 ) — — (2,188 ) Third-party segment revenues 521,800 53,061 65,658 640,519 Other revenues — 6 865 871 Total segment revenues 521,800 53,067 66,523 641,390 Cost of sales 198,014 21,722 51,551 271,287 Gross profit 323,786 31,345 14,972 370,103 Advertising and promotion 76,651 8,870 1,388 86,909 Contribution margin $ 247,135 $ 22,475 $ 13,584 283,194 Other operating expenses* 130,635 Operating income 152,559 Other expense 60,511 Income before income taxes 92,048 Provision for income taxes 33,743 Net income $ 58,305 *Other operating expenses for the nine months ended December 31, 2016 includes a pre-tax net loss of $51.6 million related to divestitures. These divestitures include Pediacare , New Skin, Fiber Choice, e.p.t, Dermoplast, and license rights in certain geographic areas pertaining to Comet . The assets and corresponding contribution margin associated with the pre-tax net loss on divestitures related to Pediacare , New Skin, Fiber Choice, e.p.t and Dermoplast are included within the North American OTC Healthcare segment, while the pre-tax gain on sale of license rights related to Comet are included in the Household Cleaning segment. Three Months Ended December 31, 2015 (In thousands) North American OTC International OTC Household Cleaning Consolidated Gross segment revenues** $ 165,287 $ 13,803 $ 20,623 $ 199,713 Elimination of intersegment revenues (228 ) — — (228 ) Third-party segment revenues 165,059 13,803 20,623 199,485 Other revenues** — 9 701 710 Total segment revenues 165,059 13,812 21,324 200,195 Cost of sales** 62,655 4,964 15,792 83,411 Gross profit 102,404 8,848 5,532 116,784 Advertising and promotion 26,472 2,838 625 29,935 Contribution margin $ 75,932 $ 6,010 $ 4,907 86,849 Other operating expenses 24,206 Operating income 62,643 Other expense 19,462 Income before income taxes 43,181 Provision for income taxes 15,186 Net income $ 27,995 Nine Months Ended December 31, 2015 (In thousands) North American OTC International OTC Household Cleaning Consolidated Gross segment revenues** $ 489,265 $ 43,213 $ 65,984 $ 598,462 Elimination of intersegment revenues (2,428 ) — — (2,428 ) Third-party segment revenues 486,837 43,213 65,984 596,034 Other revenues** 15 40 2,303 2,358 Total segment revenues 486,852 43,253 68,287 598,392 Cost of sales** 182,279 16,347 50,806 249,432 Gross profit 304,573 26,906 17,481 348,960 Advertising and promotion 74,107 8,338 1,805 84,250 Contribution margin $ 230,466 $ 18,568 $ 15,676 264,710 Other operating expenses 69,664 Operating income 195,046 Other expense 62,464 Income before income taxes 132,582 Provision for income taxes 46,611 Net income $ 85,971 ** Certain immaterial amounts relating to gross segment revenues, other revenues and cost of sales for each of the three and nine months ended December 31, 2015 were reclassified between the International OTC Healthcare segment and the North American OTC Healthcare segment. There were no changes to the consolidated financial statements for any periods presented.
Information about our Revenues from Similar Product Groups	The tables below summarize information about our segment revenues from similar product groups. Three Months Ended December 31, 2016 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 32,439 $ 444 $ — $ 32,883 Cough & Cold 29,803 4,166 — 33,969 Women's Health 30,896 580 — 31,476 Gastrointestinal 15,109 6,701 — 21,810 Eye & Ear Care 23,571 2,997 — 26,568 Dermatologicals 19,948 479 — 20,427 Oral Care 24,129 3,083 — 27,212 Other OTC 1,378 9 — 1,387 Household Cleaning — — 21,031 21,031 Total segment revenues $ 177,273 $ 18,459 $ 21,031 $ 216,763 Nine Months Ended December 31, 2016 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 90,558 $ 1,515 $ — $ 92,073 Cough & Cold 68,876 13,718 — 82,594 Women's Health 97,051 2,151 — 99,202 Gastrointestinal 50,495 17,045 — 67,540 Eye & Ear Care 72,512 8,782 — 81,294 Dermatologicals 65,598 1,717 — 67,315 Oral Care 72,308 8,120 — 80,428 Other OTC 4,402 19 — 4,421 Household Cleaning — — 66,523 66,523 Total segment revenues $ 521,800 $ 53,067 $ 66,523 $ 641,390 Three Months Ended December 31, 2015 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 30,454 $ 450 $ — $ 30,904 Cough & Cold 30,466 3,696 — 34,162 Women's Health 33,521 877 — 34,398 Gastrointestinal 17,401 5,517 — 22,918 Eye & Ear Care 21,936 2,613 — 24,549 Dermatologicals 19,734 524 — 20,258 Oral Care 9,996 126 — 10,122 Other OTC 1,551 9 — 1,560 Household Cleaning — — 21,324 21,324 Total segment revenues $ 165,059 $ 13,812 $ 21,324 $ 200,195 Nine Months Ended December 31, 2015 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 86,996 $ 1,668 $ — $ 88,664 Cough & Cold 74,681 12,948 — 87,629 Women's Health 100,036 2,381 — 102,417 Gastrointestinal 56,782 14,667 — 71,449 Eye & Ear Care 71,159 9,393 — 80,552 Dermatologicals 63,026 1,669 — 64,695 Oral Care 29,706 509 — 30,215 Other OTC 4,466 18 — 4,484 Household Cleaning — — 68,287 68,287 Total segment revenues $ 486,852 $ 43,253 $ 68,287 $ 598,392
Allocation of Long-Term Assets to Segments	These consolidated goodwill and intangible assets have been allocated to the reportable segments as follows: December 31, 2016 (In thousands) North American OTC International OTC Household Cleaning Consolidated Goodwill $ 318,014 $ 21,226 $ 6,245 $ 345,485 Intangible assets Indefinite-lived 1,755,635 80,716 101,262 1,937,613 Finite-lived 196,391 1,004 21,370 218,765 Intangible assets, net 1,952,026 81,720 122,632 2,156,378 Total $ 2,270,040 $ 102,946 $ 128,877 $ 2,501,863 March 31, 2016 (In thousands) North American OTC International OTC Household Consolidated Goodwill $ 330,615 $ 22,776 $ 6,800 $ 360,191 Intangible assets Indefinite-lived 1,823,873 85,901 110,272 2,020,046 Finite-lived 277,762 2,237 22,678 302,677 Intangible assets, net 2,101,635 88,138 132,950 2,322,723 Total $ 2,432,250 $ 110,914 $ 139,750 $ 2,682,914

Condensed Consolidating Finan44

Condensed Consolidating Financial Statements (Tables)	9 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Condensed Consolidating Statements of Income and Comprehensive Income	Condensed Consolidating Statements of Income and Comprehensive Income Three Months Ended December 31, 2016 (In thousands) Prestige Brands Holdings, Inc. Prestige Brands, Inc., the issuer Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Revenues Net sales $ — $ 29,156 $ 172,216 $ 16,184 $ (824 ) $ 216,732 Other revenues — 76 31 329 (405 ) 31 Total revenues — 29,232 172,247 16,513 (1,229 ) 216,763 Cost of Sales Cost of sales (exclusive of depreciation shown below) — 12,179 74,494 6,684 (1,141 ) 92,216 Gross profit — 17,053 97,753 9,829 (88 ) 124,547 Operating Expenses Advertising and promotion — 3,009 24,266 3,407 — 30,682 General and administrative 2,486 2,004 15,644 1,997 — 22,131 Depreciation and amortization 722 154 4,860 116 — 5,852 Gain on divestitures — — (3,405 ) — — (3,405 ) Total operating expenses 3,208 5,167 41,365 5,520 — 55,260 Operating income (loss) (3,208 ) 11,886 56,388 4,309 (88 ) 69,287 Other (income) expense Interest income (12,056 ) (21,422 ) (1,299 ) (160 ) 34,891 (46 ) Interest expense 8,495 18,598 25,099 1,299 (34,891 ) 18,600 Equity in (income) loss of subsidiaries (32,821 ) (23,629 ) (2,089 ) — 58,539 — Total other expense (income) (36,382 ) (26,453 ) 21,711 1,139 58,539 18,554 Income (loss) before income taxes 33,174 38,339 34,677 3,170 (58,627 ) 50,733 Provision for income taxes 1,533 5,087 11,391 1,081 — 19,092 Net income (loss) $ 31,641 $ 33,252 $ 23,286 $ 2,089 $ (58,627 ) $ 31,641 Comprehensive (loss) income, net of tax: Currency translation adjustments (8,736 ) (8,736 ) (8,736 ) (8,736 ) 26,208 (8,736 ) Total other comprehensive (loss) income (8,736 ) (8,736 ) (8,736 ) (8,736 ) 26,208 (8,736 ) Comprehensive (loss) income $ 22,905 $ 24,516 $ 14,550 $ (6,647 ) $ (32,419 ) $ 22,905 Condensed Consolidating Statements of Income and Comprehensive Income Nine Months Ended December 31, 2016 (In thousands) Prestige Brands Holdings, Inc. Prestige Brands, Inc., the issuer Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Revenues Net sales $ — $ 83,128 $ 512,212 $ 47,368 $ (2,189 ) $ 640,519 Other revenues — 223 865 1,309 (1,526 ) 871 Total revenues — 83,351 513,077 48,677 (3,715 ) 641,390 Cost of Sales Cost of sales (exclusive of depreciation shown below) — 35,331 220,336 19,162 (3,542 ) 271,287 Gross profit — 48,020 292,741 29,515 (173 ) 370,103 Operating Expenses Advertising and promotion — 11,505 66,689 8,715 — 86,909 General and administrative 6,224 5,954 43,260 4,945 — 60,383 Depreciation and amortization 2,474 456 15,410 360 — 18,700 Loss on divestitures — — 51,552 — — 51,552 Total operating expenses 8,698 17,915 176,911 14,020 — 217,544 Operating income (loss) (8,698 ) 30,105 115,830 15,495 (173 ) 152,559 Other (income) expense Interest income (36,100 ) (64,143 ) (3,865 ) (475 ) 104,434 (149 ) Interest expense 25,437 60,654 75,138 3,865 (104,434 ) 60,660 Equity in (income) loss of subsidiaries (59,111 ) (37,390 ) (8,766 ) — 105,267 — Total other expense (income) (69,774 ) (40,879 ) 62,507 3,390 105,267 60,511 Income (loss) before income taxes 61,076 70,984 53,323 12,105 (105,440 ) 92,048 Provision for income taxes 2,771 11,791 15,842 3,339 — 33,743 Net income (loss) $ 58,305 $ 59,193 $ 37,481 $ 8,766 $ (105,440 ) $ 58,305 Comprehensive (loss) income, net of tax: Currency translation adjustments (11,857 ) (11,857 ) (11,857 ) (11,857 ) 35,571 (11,857 ) Total other comprehensive (loss) income (11,857 ) (11,857 ) (11,857 ) (11,857 ) 35,571 (11,857 ) Comprehensive (loss) income $ 46,448 $ 47,336 $ 25,624 $ (3,091 ) $ (69,869 ) $ 46,448 Condensed Consolidating Statements of Income and Comprehensive Income Three Months Ended December 31, 2015 (In thousands) Prestige Brands Holdings, Inc. Prestige Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Revenues Net sales $ — $ 27,598 $ 159,783 $ 12,332 $ (228 ) $ 199,485 Other revenues — 98 700 356 (444 ) 710 Total revenues — 27,696 160,483 12,688 (672 ) 200,195 Cost of Sales Cost of sales (exclusive of depreciation shown below) — 11,796 68,148 4,448 (981 ) 83,411 Gross profit — 15,900 92,335 8,240 309 116,784 Operating Expenses Advertising and promotion — 1,881 25,251 2,803 — 29,935 General and administrative 1,370 1,789 13,463 1,513 — 18,135 Depreciation and amortization 1,013 151 4,794 113 — 6,071 Total operating expenses 2,383 3,821 43,508 4,429 — 54,141 Operating income (loss) (2,383 ) 12,079 48,827 3,811 309 62,643 Other (income) expense Interest income (12,141 ) (21,569 ) (1,124 ) (128 ) 34,931 (31 ) Interest expense 8,602 19,443 25,255 1,124 (34,931 ) 19,493 Equity in (income) loss of subsidiaries (27,711 ) (15,898 ) (2,033 ) — 45,642 — Total other (income) expense (31,250 ) (18,024 ) 22,098 996 45,642 19,462 Income (loss) before income taxes 28,867 30,103 26,729 2,815 (45,333 ) 43,181 Provision for income taxes 872 4,950 8,582 782 — 15,186 Net income (loss) $ 27,995 $ 25,153 $ 18,147 $ 2,033 $ (45,333 ) $ 27,995 Comprehensive (loss) income, net of tax: Currency translation adjustments 4,922 4,922 4,922 4,922 (14,766 ) 4,922 Total other comprehensive (loss) income 4,922 4,922 4,922 4,922 (14,766 ) 4,922 Comprehensive income (loss) $ 32,917 $ 30,075 $ 23,069 $ 6,955 $ (60,099 ) $ 32,917 Condensed Consolidating Statements of Income and Comprehensive Income Nine Months Ended December 31, 2015 (In thousands) Prestige Brands Holdings, Inc. Prestige Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Revenues Net sales $ — $ 83,438 $ 477,079 $ 37,945 $ (2,428 ) $ 596,034 Other revenues — 273 2,317 1,397 (1,629 ) 2,358 Total revenues — 83,711 479,396 39,342 (4,057 ) 598,392 Cost of Sales Cost of sales (exclusive of depreciation shown below) — 33,105 206,646 13,808 (4,127 ) 249,432 Gross profit — 50,606 272,750 25,534 70 348,960 Operating Expenses Advertising and promotion — 7,602 68,412 8,236 — 84,250 General and administrative 3,884 5,644 38,326 4,332 — 52,186 Depreciation and amortization 3,032 444 13,686 316 — 17,478 Total operating expenses 6,916 13,690 120,424 12,884 — 153,914 Operating income (loss) (6,916 ) 36,916 152,326 12,650 70 195,046 Other (income) expense Interest income (36,351 ) (64,584 ) (3,513 ) (366 ) 104,723 (91 ) Interest expense 26,056 61,654 75,604 3,513 (104,723 ) 62,104 Loss on extinguishment of debt — 451 — — — 451 Equity in (income) loss of subsidiaries (84,458 ) (52,599 ) (6,868 ) — 143,925 — Total other (income) expense (94,753 ) (55,078 ) 65,223 3,147 143,925 62,464 Income (loss) before income taxes 87,837 91,994 87,103 9,503 (143,855 ) 132,582 Provision for income taxes 1,866 13,867 28,243 2,635 — 46,611 Net income (loss) $ 85,971 $ 78,127 $ 58,860 $ 6,868 $ (143,855 ) $ 85,971 Comprehensive (loss) income, net of tax: Currency translation adjustments (6,562 ) (6,562 ) (6,562 ) (6,562 ) 19,686 (6,562 ) Total other comprehensive (loss) income (6,562 ) (6,562 ) (6,562 ) (6,562 ) 19,686 (6,562 ) Comprehensive income (loss) $ 79,409 $ 71,565 $ 52,298 $ 306 $ (124,169 ) $ 79,409
Condensed Consolidating Balance Sheet	Condensed Consolidating Balance Sheet December 31, 2016 (In thousands) Prestige Brands Holdings, Inc. Prestige Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Assets Current assets Cash and cash equivalents $ 36,821 $ — $ 202 $ 26,266 $ — $ 63,289 Accounts receivable, net — 12,291 79,927 12,170 — 104,388 Inventories — 16,758 75,522 9,351 (705 ) 100,926 Deferred income tax assets 2,372 918 8,624 688 — 12,602 Prepaid expenses and other current assets 1,611 158 7,464 772 — 10,005 Total current assets 40,804 30,125 171,739 49,247 (705 ) 291,210 Property and equipment, net 7,595 315 4,478 477 — 12,865 Goodwill — 66,007 258,252 21,226 — 345,485 Intangible assets, net — 191,387 1,882,242 82,749 — 2,156,378 Other long-term assets 2,500 2,414 — — — 4,914 Intercompany receivables 1,451,328 2,518,756 1,670,364 14,432 (5,654,880 ) — Investment in subsidiary 1,690,523 1,553,251 76,662 — (3,320,436 ) — Total Assets $ 3,192,750 $ 4,362,255 $ 4,063,737 $ 168,131 $ (8,976,021 ) $ 2,810,852 Liabilities and Stockholders' Equity Current liabilities Accounts payable $ 2,822 $ 9,418 $ 29,964 $ 3,046 $ — $ 45,250 Accrued interest payable — 8,399 — — — 8,399 Other accrued liabilities 13,722 2,721 55,162 7,070 — 78,675 Total current liabilities 16,544 20,538 85,126 10,116 — 132,324 Long-term debt Principal amount — 1,437,000 — — — 1,437,000 Less unamortized debt costs — (21,421 ) — — — (21,421 ) Long-term debt, net — 1,415,579 — — — 1,415,579 Deferred income tax liabilities — 61,047 398,380 353 — 459,780 Other long-term liabilities — — 3,264 48 — 3,312 Intercompany payables 2,376,349 1,249,872 1,945,431 83,228 (5,654,880 ) — Total Liabilities 2,392,893 2,747,036 2,432,201 93,745 (5,654,880 ) 2,010,995 Stockholders' Equity Common stock 532 — — — — 532 Additional paid-in capital 455,684 1,280,947 1,359,921 78,774 (2,719,642 ) 455,684 Treasury stock, at cost (6,594 ) — — — — (6,594 ) Accumulated other comprehensive (loss) income, net of tax (35,382 ) (35,382 ) (35,382 ) (35,382 ) 106,146 (35,382 ) Retained earnings (accumulated deficit) 385,617 369,654 306,997 30,994 (707,645 ) 385,617 Total Stockholders' Equity 799,857 1,615,219 1,631,536 74,386 (3,321,141 ) 799,857 Total Liabilities and Stockholders' Equity $ 3,192,750 $ 4,362,255 $ 4,063,737 $ 168,131 $ (8,976,021 ) $ 2,810,852 Condensed Consolidating Balance Sheet March 31, 2016 (In thousands) Prestige Brands Holdings, Inc. Prestige Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Assets Current assets Cash and cash equivalents $ 4,440 $ — $ 2,899 $ 19,891 $ — $ 27,230 Accounts receivable, net — 12,025 74,446 8,776 — 95,247 Inventories — 9,411 72,296 10,088 (532 ) 91,263 Deferred income tax assets 316 681 8,293 818 — 10,108 Prepaid expenses and other current assets 15,311 257 8,379 1,218 — 25,165 Total current assets 20,067 22,374 166,313 40,791 (532 ) 249,013 Property and equipment, net 9,166 210 5,528 636 — 15,540 Goodwill — 66,007 271,409 22,775 — 360,191 Intangible assets, net — 191,789 2,042,640 88,294 — 2,322,723 Other long-term assets — 1,324 — — — 1,324 Intercompany receivables 1,457,011 2,703,192 1,083,488 10,738 (5,254,429 ) — Investment in subsidiary 1,641,477 1,527,718 81,545 — (3,250,740 ) — Total Assets $ 3,127,721 $ 4,512,614 $ 3,650,923 $ 163,234 $ (8,505,701 ) $ 2,948,791 Liabilities and Stockholders' Equity Current liabilities Accounts payable $ 2,914 $ 7,643 $ 24,437 $ 3,302 $ — $ 38,296 Accrued interest payable — 8,664 — — — 8,664 Other accrued liabilities 12,285 1,714 38,734 6,991 — 59,724 Total current liabilities 15,199 18,021 63,171 10,293 — 106,684 Long-term debt Principal amount — 1,652,500 — — — 1,652,500 Less unamortized debt costs — (27,191 ) — — — (27,191 ) Long-term debt, net — 1,625,309 — — — 1,625,309 Deferred income tax liabilities — 60,317 408,893 412 — 469,622 Other long-term liabilities — — 2,682 158 — 2,840 Intercompany payables 2,368,186 1,241,084 1,570,265 74,894 (5,254,429 ) — Total Liabilities 2,383,385 2,944,731 2,045,011 85,757 (5,254,429 ) 2,204,455 Stockholders' Equity Common stock 530 — — — — 530 Additional paid-in capital 445,182 1,280,947 1,359,921 78,774 (2,719,642 ) 445,182 Treasury stock, at cost (5,163 ) — — — — (5,163 ) Accumulated other comprehensive income (loss), net of tax (23,525 ) (23,525 ) (23,525 ) (23,525 ) 70,575 (23,525 ) Retained earnings (accumulated deficit) 327,312 310,461 269,516 22,228 (602,205 ) 327,312 Total Stockholders' Equity 744,336 1,567,883 1,605,912 77,477 (3,251,272 ) 744,336 Total Liabilities and Stockholders' Equity $ 3,127,721 $ 4,512,614 $ 3,650,923 $ 163,234 $ (8,505,701 ) $ 2,948,791
Condensed Consolidating Statement of Cash Flows	Condensed Consolidating Statement of Cash Flows Nine Months Ended December 31, 2016 (In thousands) Prestige Brands Holdings, Inc. Prestige Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Operating Activities Net income (loss) $ 58,305 $ 59,193 $ 37,481 $ 8,766 $ (105,440 ) $ 58,305 Adjustments to reconcile net income (loss) to net cash provided by operating activities: Depreciation and amortization 2,474 456 15,410 360 — 18,700 Loss on divestitures and sales of property and equipment — 51,807 — — 51,807 Deferred income taxes (2,056 ) 493 (11,101 ) 134 — (12,530 ) Amortization of debt origination costs — 6,129 — — — 6,129 Stock-based compensation costs 6,260 — — — — 6,260 Equity in income of subsidiaries (59,111 ) (37,390 ) (8,766 ) — 105,267 — Changes in operating assets and liabilities, net of effects from acquisitions: Accounts receivable — (266 ) (5,481 ) (6,627 ) — (12,374 ) Inventories — (7,347 ) (9,409 ) (6 ) 173 (16,589 ) Prepaid expenses and other current assets 11,200 99 (525 ) 375 — 11,149 Accounts payable (118 ) 1,775 5,981 (470 ) — 7,168 Accrued liabilities 1,437 742 20,995 (851 ) — 22,323 Net cash provided by operating activities 18,391 23,884 96,392 1,681 — 140,348 Investing Activities Purchases of property and equipment (890 ) (158 ) (785 ) (102 ) — (1,935 ) Proceeds from divestitures — — 110,717 — — 110,717 Proceeds from the sales of property and equipment — — 85 — — 85 Proceeds from DenTek working capital arbitration settlement — — 1,419 — — 1,419 Net cash provided by (used in) investing activities (890 ) (158 ) 111,436 (102 ) — 110,286 Financing Activities Term loan repayments — (130,500 ) — — — (130,500 ) Borrowings under revolving credit agreement — 20,000 — — — 20,000 Repayments under revolving credit agreement — (105,000 ) — — — (105,000 ) Payments of debt origination costs — (9 ) — — — (9 ) Proceeds from exercise of stock options 3,444 — — — — 3,444 Excess tax benefits from share-based awards 800 — — — — 800 Fair value of shares surrendered as payment of tax withholding (1,431 ) — — — — (1,431 ) Intercompany activity, net 12,067 191,783 (210,525 ) 6,675 — — Net cash (used in) provided by financing activities 14,880 (23,726 ) (210,525 ) 6,675 — (212,696 ) Effect of exchange rate changes on cash and cash equivalents — — — (1,879 ) — (1,879 ) Increase (decrease) in cash and cash equivalents 32,381 — (2,697 ) 6,375 — 36,059 Cash and cash equivalents - beginning of period 4,440 — 2,899 19,891 — 27,230 Cash and cash equivalents - end of period $ 36,821 $ — $ 202 $ 26,266 $ — $ 63,289 Condensed Consolidating Statement of Cash Flows Nine Months Ended December 31, 2015 (In thousands) Prestige Brands Holdings, Inc. Prestige Combined Subsidiary Guarantors Combined Non-Guarantor Subsidiaries Eliminations Consolidated Operating Activities Net income (loss) $ 85,971 $ 78,127 $ 58,860 $ 6,868 $ (143,855 ) $ 85,971 Adjustments to reconcile net income (loss) to net cash provided by operating activities: Depreciation and amortization 3,032 444 13,686 316 — 17,478 Deferred income taxes 148 164 31,301 (22 ) — 31,591 Amortization of debt origination costs — 5,433 — — — 5,433 Stock-based compensation costs 7,057 — — 41 — 7,098 Loss on extinguishment of debt — 451 — — — 451 Gain on sale or disposal of property and equipment — — — (36 ) — (36 ) Equity in income of subsidiaries (84,458 ) (52,599 ) (6,868 ) — 143,925 — Changes in operating assets and liabilities, net of effects from acquisitions: Accounts receivable — 1,158 2,188 (893 ) — 2,453 Inventories — (2,519 ) (3,014 ) (1,511 ) (70 ) (7,114 ) Prepaid expenses and other current assets 3,557 (305 ) 2,752 (532 ) — 5,472 Accounts payable (33 ) (1,161 ) (14,613 ) (1,746 ) — (17,553 ) Accrued liabilities (102 ) (1,636 ) 5,439 1,506 — 5,207 Net cash provided by operating activities 15,172 27,557 89,731 3,991 — 136,451 Investing Activities Purchases of property and equipment (1,741 ) (93 ) (212 ) (494 ) — (2,540 ) Proceeds from the sale of property and equipment — — — 344 — 344 Proceeds from Insight Pharmaceuticals working capital arbitration settlement — — 7,237 — — 7,237 Net cash provided by (used in) investing activities (1,741 ) (93 ) 7,025 (150 ) — 5,041 Financing Activities Term loan repayments — (50,000 ) — — — (50,000 ) Borrowings under revolving credit agreement — 15,000 — — — 15,000 Repayments under revolving credit agreement — (81,100 ) — — — (81,100 ) Payments of debt origination costs — (4,211 ) — — — (4,211 ) Proceeds from exercise of stock options 6,600 — — — — 6,600 Proceeds from restricted stock exercises 544 — — — — 544 Excess tax benefits from share-based awards 1,850 — — — — 1,850 Fair value of shares surrendered as payment of tax withholding (2,187 ) — — — — (2,187 ) Intercompany activity, net 2,127 92,847 (96,756 ) 1,782 — — Net cash (used in) provided by financing activities 8,934 (27,464 ) (96,756 ) 1,782 — (113,504 ) Effect of exchange rate changes on cash and cash equivalents — — — (333 ) — (333 ) Increase in cash and cash equivalents 22,365 — — 5,290 — 27,655 Cash and cash equivalents - beginning of period 11,387 — — 9,931 — 21,318 Cash and cash equivalents - end of period $ 33,752 $ — $ — $ 15,221 $ — $ 48,973

Business and Basis of Present45

Business and Basis of Presentation (Other Balance Sheet and Income Statement Items) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Ownership percentage, subsidiaries	100.00%		100.00%
Concentration Risk [Line Items]
Warehousing, shipping and handling, and storage costs	$ 10.7	$ 10.1	$ 32.1	$ 29.2
UNITED STATES | Geographic concentration risk | Cash
Concentration Risk [Line Items]
Percentage of deposits located in the United States			58.50%

Business and Basis of Present46

Business and Basis of Presentation (Property and Equipment) (Details)	9 Months Ended
	Dec. 31, 2016
Machinery
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	5 years
Computer equipment and software
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	3 years
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	7 years

Business and Basis of Present47

Business and Basis of Presentation (Intangible Assets) (Details)	9 Months Ended
	Dec. 31, 2016
Minimum
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful lives	10 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful lives	30 years

Acquisitions (Narrative) (Detai

Acquisitions (Narrative) (Details) - USD ($) $ in Thousands	Feb. 05, 2016	Dec. 31, 2016	Dec. 31, 2016	Mar. 31, 2016
Business Acquisition [Line Items]
Goodwill		$ 345,485	$ 345,485	$ 360,191
DenTek Oral Care, Inc.
Business Acquisition [Line Items]
Purchase price	$ 226,900
Non-amortizable intangible assets	179,800
Amortizable intangible assets	$ 26,900
Purchased amortizable intangible assets, weighted average useful life	18 years 6 months
Purchased amortizable intangible assets, weighted average remaining period			17 years 8 months
Reduction to Goodwill		$ 2,800
Goodwill	$ 73,737

Acquisitions (Allocation of Ass

Acquisitions (Allocation of Assets Acquired and Liabilities Assumed) (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Mar. 31, 2016	Feb. 05, 2016
Purchase Price
Goodwill	$ 345,485	$ 360,191
DenTek Oral Care, Inc.
Purchase Price
Cash acquired			$ 1,359
Accounts receivable			9,187
Inventories			14,304
Deferred income taxes			3,303
Prepaids and other current assets			6,728
Property, plant and equipment, net			3,555
Goodwill			73,737
Intangible assets, net			206,700
Total assets acquired			318,873
Accounts payable			3,261
Accrued expenses			14,336
Deferred income tax liabilities - long term			74,352
Total liabilities assumed			91,949
Total purchase price			$ 226,924

Divestitures (Divestitures) (De

Divestitures (Divestitures) (Details) - USD ($) $ in Thousands	Jul. 07, 2016	Dec. 31, 2016	Dec. 31, 2016	Dec. 31, 2015
Long Lived Assets Held-for-sale [Line Items]
Proceeds from divestitures			$ 110,717	$ 0
Disposed of by sale | Pediacare, New Skin and Fiber Choice | Cough and Cold, Dermatologicals, and Gastrointestinal Products Group | North American OTC Healthcare
Long Lived Assets Held-for-sale [Line Items]
Disposal group, consideration, excluding costs of inventory	$ 40,000
Proceeds from divestitures	40,100
Cost of inventory	$ 2,600
Holdback term	18 months
Gain on sale of assets	$ 54,128
Disposed of by sale | Dermoplast | Cough and Cold, Dermatologicals, and Gastrointestinal Products Group | North American OTC Healthcare
Long Lived Assets Held-for-sale [Line Items]
Proceeds from divestitures		$ 48,400
Deposit for agreement to purchase	$ 1,250
Disposed of by sale | e.p.t and Dermoplast | Cough and Cold, Dermatologicals, and Gastrointestinal Products Group | North American OTC Healthcare
Long Lived Assets Held-for-sale [Line Items]
Proceeds from divestitures		59,600
Gain on sale of assets		$ 3,857

Divestitures (Assets Held for S

Divestitures (Assets Held for Sold) (Details) - USD ($) $ in Thousands	Jul. 07, 2016	Dec. 31, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Pre-tax loss (gain) on sales			$ (3,405)	$ 0	$ 51,552	$ 0
Disposed of by sale | North American OTC Healthcare
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Pre-tax loss (gain) on sales			51,600
Pediacare, New Skin and Fiber Choice | Disposed of by sale | Cough and Cold, Dermatologicals, and Gastrointestinal Products Group | North American OTC Healthcare
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Inventory	$ 2,380
Intangible assets, net	91,208
Goodwill	2,920
Assets sold	96,508
Total purchase price received	42,380
(Gain) loss on sale of assets	(54,128)
Costs to sell	2,018
Pre-tax loss (gain) on sales	$ 56,146				56,146
e.p.t and Dermoplast | Disposed of by sale | North American OTC Healthcare
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Pre-tax loss (gain) on sales			(3,400)
e.p.t and Dermoplast | Disposed of by sale | Cough and Cold, Dermatologicals, and Gastrointestinal Products Group | North American OTC Healthcare
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Inventory		$ 2,998	2,998		2,998
Intangible assets, net		45,870	45,870		45,870
Goodwill		6,889	6,889		6,889
Assets sold		55,757	55,757		55,757
Total purchase price received		59,614	$ 59,614		$ 59,614
(Gain) loss on sale of assets		$ (3,857)

Accounts Receivable (Components

Accounts Receivable (Components of Accounts Receivable) (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Mar. 31, 2016
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	$ 116,256	$ 106,853
Less allowances for discounts, returns and uncollectible accounts	(11,868)	(11,606)
Accounts receivable, net	104,388	95,247
Trade accounts receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	115,967	105,592
Other receivables
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	$ 289	$ 1,261

Inventories (Components of Inv

Inventories (Components of Inventories) (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Mar. 31, 2016
Inventory Disclosure [Abstract]
Packaging and raw materials	$ 7,944	$ 7,563
Finished goods	92,982	83,700
Inventories	100,926	91,263
Inventory valuation reserves related to obsolete and slow-moving inventory	$ 4,100	$ 4,800

Property and Equipment (Compone

Property and Equipment (Components of Property and Equipment) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Mar. 31, 2016
Components of Property and Equipment
Property and equipment, gross	$ 31,306		$ 31,306		$ 30,361
Accumulated depreciation	(18,441)		(18,441)		(14,821)
Property and equipment, net	12,865		12,865		15,540
Depreciation expense	1,300	$ 1,200	4,300	$ 3,700
Machinery
Components of Property and Equipment
Property and equipment, gross	8,217		8,217		7,734
Computer equipment
Components of Property and Equipment
Property and equipment, gross	13,238		13,238		12,793
Furniture and fixtures
Components of Property and Equipment
Property and equipment, gross	2,504		2,504		2,445
Leasehold improvements
Components of Property and Equipment
Property and equipment, gross	$ 7,347		$ 7,347		$ 7,389

Goodwill (Schedule of Segment G

Goodwill (Schedule of Segment Goodwill) (Details) - USD ($) $ in Thousands	1 Months Ended	9 Months Ended
	Aug. 31, 2016	Dec. 31, 2016
Goodwill [Roll Forward]
Balance — March 31, 2016		$ 360,191
Reductions		(13,156)
Effects of foreign currency exchange rates		(1,550)
Balance — December 31, 2016		345,485
North American OTC Healthcare
Goodwill [Roll Forward]
Balance — March 31, 2016		330,615
Reductions		(12,601)
Effects of foreign currency exchange rates		0
Balance — December 31, 2016		318,014
International OTC Healthcare
Goodwill [Roll Forward]
Balance — March 31, 2016		22,776
Reductions		0
Effects of foreign currency exchange rates		(1,550)
Balance — December 31, 2016		21,226
Household Cleaning
Goodwill [Roll Forward]
Balance — March 31, 2016		6,800
Reductions	$ (600)	(555)
Effects of foreign currency exchange rates		0
Balance — December 31, 2016		$ 6,245

Goodwill (Narrative) (Details)

Goodwill (Narrative) (Details) - USD ($) $ in Thousands	Jul. 07, 2016	Dec. 31, 2016	Aug. 31, 2016	Dec. 31, 2016	Dec. 31, 2015	Mar. 31, 2016
Goodwill [Line Items]
Reduced Goodwill amount				$ 13,156
Proceeds from sale of business				110,717	$ 0
Goodwill impairment						$ 0
Household Cleaning
Goodwill [Line Items]
Reduced Goodwill amount			$ 600	555
North American OTC Healthcare
Goodwill [Line Items]
Reduced Goodwill amount				12,601
Cough and Cold, Dermatologicals, and Gastrointestinal Products Group | Disposed of by sale | North American OTC Healthcare | Pediacare, New Skin and Fiber Choice
Goodwill [Line Items]
Reduced Goodwill amount	$ 2,900
Disposal group, consideration, excluding costs of inventory	40,000
Proceeds from sale of business	$ 40,100
Cough and Cold, Dermatologicals, and Gastrointestinal Products Group | Disposed of by sale | North American OTC Healthcare | Dermoplast
Goodwill [Line Items]
Reduced Goodwill amount		$ 5,500
Proceeds from sale of business		48,400
Cough and Cold, Dermatologicals, and Gastrointestinal Products Group | Disposed of by sale | North American OTC Healthcare | e.p.t.
Goodwill [Line Items]
Reduced Goodwill amount		1,400
DenTek Oral Care, Inc.
Goodwill [Line Items]
Proceeds from previous acquisitions		1,400		$ 1,419	$ 0
Reduction to Goodwill		2,800
Adjustment to purchase price		$ 1,400

Intangible Assets (Schedule of

Intangible Assets (Schedule of Reconciliation of Activity Affecting Intangible Assets) (Details) $ in Thousands	3 Months Ended	9 Months Ended
	Dec. 31, 2016USD ($)	Dec. 31, 2016USD ($)	Mar. 31, 2016USD ($)
Indefinite-Lived Intangible Assets [Abstract]
Indefinite Lived Trademarks, beginning balance		$ 2,020,046
Indefinite Lived Trademarks, ending balance	$ 1,937,613	1,937,613
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]
Finite Lived Trademarks and Customer Relationships, accumulated amortization, beginning balance		115,203
Accumulated amortization, additions	4,500	14,412
Accumulated amortization, reclassified to assets held for sale		(7,610)
Accumulated amortization, effects of foreign exchange rates		(23)
Finite Lived Trademarks and Customer Relationships, accumulated amortization, ending balance	121,982	121,982
Intangible Assets, Gross [Abstract]
Totals, gross, beginning balance		2,437,926
Totals, reclassified to assets held for sale		(154,151)
Totals, effects of foreign currency exchange rate		(5,415)
Totals, gross, ending balance	2,278,360	2,278,360
Finite-Lived Intangible Assets, Net [Abstract]
Intangible assets, net	218,765	218,765	$ 302,677
Intangible Assets, Net [Abstract]
Intangible assets, net	2,156,378	2,156,378	2,322,723
North American OTC Healthcare
Intangible Assets, Net [Abstract]
Intangible assets, net	1,952,026	1,952,026	2,101,635
International OTC Healthcare
Intangible Assets, Net [Abstract]
Intangible assets, net	81,720	81,720	88,138
Household Cleaning
Intangible Assets, Net [Abstract]
Intangible assets, net	122,632	122,632	132,950
Finite Lived Trademarks and Customer Relationships
Finite-Lived Intangible Assets, Gross [Abstract]
Finite Lived Trademarks and Customer Relationships, beginning balance		417,880
Finite-Lived Trademarks and Customer Relationships, reclassified to assets held for sale		(76,903)
Finite Lived Trademarks and Customer Relationships, effects of foreign currency exchange rate		(230)
Finite Lived Trademarks and Customer Relationships, ending balance	340,747	340,747
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]
Finite Lived Trademarks and Customer Relationships, accumulated amortization, beginning balance		115,203
Accumulated amortization, additions		14,412
Accumulated amortization, reclassified to assets held for sale		(7,610)
Accumulated amortization, effects of foreign exchange rates		(23)
Finite Lived Trademarks and Customer Relationships, accumulated amortization, ending balance	121,982	121,982
Finite-Lived Intangible Assets, Net [Abstract]
Intangible assets, net	218,765	218,765
Finite Lived Trademarks and Customer Relationships | North American OTC Healthcare
Finite-Lived Intangible Assets, Net [Abstract]
Intangible assets, net	196,391	196,391	277,762
Finite Lived Trademarks and Customer Relationships | International OTC Healthcare
Finite-Lived Intangible Assets, Net [Abstract]
Intangible assets, net	1,004	1,004	2,237
Finite Lived Trademarks and Customer Relationships | Household Cleaning
Finite-Lived Intangible Assets, Net [Abstract]
Intangible assets, net	21,370	21,370	$ 22,678
Indefinite Lived Trademarks
Indefinite-Lived Intangible Assets [Abstract]
Indefinite Lived Trademarks, beginning balance		2,020,046
Indefinite-Lived Trademarks, reclassified to assets held for sale		(77,248)
Indefinite Lived Trademarks, effects of foreign currency exchange rate		(5,185)
Indefinite Lived Trademarks, ending balance	1,937,613	1,937,613
Indefinite Lived Trademarks | North American OTC Healthcare
Indefinite-Lived Intangible Assets [Abstract]
Indefinite Lived Trademarks, beginning balance		1,823,873
Indefinite Lived Trademarks, ending balance	1,755,635	1,755,635
Indefinite Lived Trademarks | International OTC Healthcare
Indefinite-Lived Intangible Assets [Abstract]
Indefinite Lived Trademarks, beginning balance		85,901
Indefinite Lived Trademarks, ending balance	80,716	80,716
Indefinite Lived Trademarks | Household Cleaning
Indefinite-Lived Intangible Assets [Abstract]
Indefinite Lived Trademarks, beginning balance		110,272
Indefinite Lived Trademarks, ending balance	$ 101,262	$ 101,262

Intangible Assets (Narrative) (

Intangible Assets (Narrative) (Details) - USD ($) $ in Thousands	Jul. 07, 2016	Dec. 31, 2016	Aug. 31, 2016	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Proceeds from sale of business							$ 110,717	$ 0
Pre-tax gain (loss) on sale					$ 3,405	$ 0	$ (51,552)	$ 0
Purchased amortizable intangible assets, weighted average remaining period							12 years 1 month 6 days
Amortization expense					4,500		$ 14,412
Minimum
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful lives							10 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful lives							30 years
North American OTC Healthcare | Disposed of by sale
Finite-Lived Intangible Assets [Line Items]
Pre-tax gain (loss) on sale					$ (51,600)
Cough and Cold, Dermatologicals, and Gastrointestinal Products Group | North American OTC Healthcare | Pediacare, New Skin and Fiber Choice | Disposed of by sale
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets, period decrease	$ 37,200
Disposal group, consideration, excluding costs of inventory	40,000
Proceeds from sale of business	40,100
Finite-lived intangible assets, reclassified to assets held for sale	54,000
Pre-tax gain (loss) on sale	$ (56,146)						$ (56,146)
Cough and Cold, Dermatologicals, and Gastrointestinal Products Group | North American OTC Healthcare | Dermoplast | Disposed of by sale
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets, period decrease		$ 31,000
Proceeds from sale of business		48,400
Cough and Cold, Dermatologicals, and Gastrointestinal Products Group | North American OTC Healthcare | e.p.t. | Disposed of by sale
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets, period decrease		$ 14,800
Trademarks
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets, period decrease			$ 9,000
Comet Brand
Finite-Lived Intangible Assets [Line Items]
Proceeds from divestitures			11,000	$ 10,000			$ 1,000
Gain on sale of intangible assets			$ 1,200

Intangible Assets (Expected Amo

Intangible Assets (Expected Amortization Expense) (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Mar. 31, 2016
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2017 (Remaining three months ending March 31, 2017)	$ 4,527
2,018	17,945
2,019	17,945
2,020	17,945
2,021	17,522
Thereafter	142,881
Intangible assets, net	$ 218,765	$ 302,677

Other Accrued Liabilities (Summ

Other Accrued Liabilities (Summary of Accrued Liabilities and Accounts Payable) (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Mar. 31, 2016
Payables and Accruals [Abstract]
Accrued marketing costs	$ 33,786	$ 26,373
Accrued compensation costs	7,686	9,574
Accrued broker commissions	1,277	1,497
Income taxes payable	13,327	3,675
Accrued professional fees	3,142	1,787
Deferred rent	609	836
Accrued production costs	5,216	3,324
Accrued lease termination costs	351	448
Income tax related payable	6,354	6,354
Other accrued liabilities	6,927	5,856
Total other accrued liabilities	$ 78,675	$ 59,724

Long-Term Debt (2012 Term Loan

Long-Term Debt (2012 Term Loan and 2012 ABL Revolver) (Details) - USD ($)

Feb. 04, 2016

Jun. 09, 2015

Sep. 03, 2014

Feb. 21, 2013

Jan. 31, 2012

Dec. 31, 2016

Dec. 31, 2015

Mar. 31, 2013

Dec. 31, 2016

Dec. 31, 2015

Mar. 31, 2015

Mar. 31, 2016

May 08, 2015

Debt Instrument [Line Items]

Loss on extinguishment of debt

$ 0

$ 0

$ 0

$ 451,000

Term Loan and ABL Revolver 2012

Debt Instrument [Line Items]

Debt issuance costs capitalized

$ 20,600,000

2012 ABL Revolver | Revolving Credit Facility

Debt Instrument [Line Items]

Debt instrument, maturity term

5 years

Line of credit facility, maximum borrowing capacity

$ 50,000,000

135,000,000

135,000,000

Line of credit facility, increase in borrowing capacity

$ 85,000,000

$ 85,000,000

Debt instrument, interest rate, increase/(decrease) (percent)

(0.25%)

Line of credit facility, commitment fee percentage

0.50%

Line of credit facility, conditional commitment fee percentage

0.375%

Line of credit facility, increase in accordion feature

$ 35,000,000

Long-term debt, weighted average interest rate

2.70%

2.70%

2012 ABL Revolver | Revolving Credit Facility | LIBOR

Debt Instrument [Line Items]

Debt instrument, basis spread on variable rate, fixed component (percent)

1.00%

2012 ABL Revolver | Revolving Credit Facility | LIBOR | Minimum

Debt Instrument [Line Items]

Debt instrument, conditional variable rate (percent)

2.00%

2012 ABL Revolver | Revolving Credit Facility | LIBOR | Maximum

Debt Instrument [Line Items]

Debt instrument, conditional variable rate (percent)

2.25%

2012 ABL Revolver | Revolving Credit Facility | Base Rate | Minimum

Debt Instrument [Line Items]

Debt instrument, conditional variable rate (percent)

1.00%

2012 ABL Revolver | Revolving Credit Facility | Base Rate | Maximum

Debt Instrument [Line Items]

Debt instrument, conditional variable rate (percent)

1.25%

2012 ABL Revolver | Revolving Credit Facility | Federal Funds Rate

Debt Instrument [Line Items]

Debt instrument, basis spread on variable rate, fixed component (percent)

0.50%

2012 ABL Revolver Amendment 3 | Revolving Credit Facility

Debt Instrument [Line Items]

Line of credit facility, increase in borrowing capacity

$ 40,000,000

2012 ABL Revolver Amendment 5 | Revolving Credit Facility

Debt Instrument [Line Items]

Temporary suspension of financial reporting covenant, period

60 days

Senior Notes | 2012 Senior Notes

Debt Instrument [Line Items]

Debt instrument, face amount

$ 660,000,000

Debt instrument, stated interest rate (percent)

8.125%

Term Loans | 2012 Term Loan

Debt Instrument [Line Items]

Debt instrument, maturity term

7 years

Debt instrument, discount, percentage

1.50%

Proceeds from issuance of long-term debt

$ 650,100,000

Term Loans | Amendment 1, 2012 Term Loan

Debt Instrument [Line Items]

Loss on extinguishment of debt

$ 1,400,000

Term Loans | Amendment 1, 2012 Term Loan | LIBOR

Debt Instrument [Line Items]

Debt instrument, basis spread on variable rate (percent)

2.75%

Debt instrument, reference rate floor (percent)

1.00%

Term Loans | Amendment 1, 2012 Term Loan | Base Rate

Debt Instrument [Line Items]

Debt instrument, reference rate floor (percent)

2.00%

Term Loans | Amendment 2, 2012 Term Loan

Debt Instrument [Line Items]

Debt instrument, reference rate floor (percent)

1.00%

Term Loans | Amendment 2, 2012 Term Loan | LIBOR

Debt Instrument [Line Items]

Debt instrument, basis spread on variable rate (percent)

3.125%

Term Loans | Amendment 2, 2012 Term Loan | Base Rate

Debt Instrument [Line Items]

Debt instrument, reference rate floor (percent)

2.00%

Term Loans | Amendment 3, 2012 Term Loan

Debt Instrument [Line Items]

Debt instrument, average interest rate during period (percent)

4.70%

Term Loans | Amendment 3, 2012 Term Loan | LIBOR

Debt Instrument [Line Items]

Debt instrument, basis spread on variable rate, fixed component (percent)

1.00%

Term Loans | Amendment 3, 2012 Term Loan | LIBOR | Minimum

Debt Instrument [Line Items]

Debt instrument, basis spread on variable rate (percent)

0.75%

Term Loans | Amendment 3, 2012 Term Loan | Base Rate

Debt Instrument [Line Items]

Debt instrument, basis spread on variable rate, fixed component (percent)

1.75%

Term Loans | Amendment 3, 2012 Term Loan | Federal Funds Rate

Debt Instrument [Line Items]

Debt instrument, basis spread on variable rate, fixed component (percent)

0.50%

Term B-2 | Amendment 2, 2012 Term Loan

Debt Instrument [Line Items]

Debt instrument, face amount

$ 720,000,000

Term B-2 | Amendment 2, 2012 Term Loan | LIBOR

Debt Instrument [Line Items]

Debt instrument, basis spread on variable rate (percent)

3.50%

Debt instrument, reference rate floor (percent)

1.00%

Term B-2 | Amendment 2, 2012 Term Loan | Base Rate

Debt Instrument [Line Items]

Debt instrument, reference rate floor (percent)

2.00%

Debt instrument, step down interest rate (percent)

3.25%

Term B-2 | Amendment 3, 2012 Term Loan

Debt Instrument [Line Items]

Debt instrument, face amount

$ 645,000,000

Loans Payable, Term B-3 | 2012 Senior Notes | LIBOR

Debt Instrument [Line Items]

Debt instrument, reference rate floor (percent)

0.75%

0.75%

0.75%

Loans Payable, Term B-3 | 2012 Senior Notes | Base Rate

Debt Instrument [Line Items]

Debt instrument, reference rate floor (percent)

1.75%

1.75%

1.75%

Loans Payable, Term B-3 | Amendment 3, 2012 Term Loan

Debt Instrument [Line Items]

Debt instrument, face amount

852,500,000

Loans Payable, Term B-1 | Amendment 3, 2012 Term Loan

Debt Instrument [Line Items]

Debt instrument, face amount

$ 207,500,000

Long-Term Debt (Senior Notes) (

Long-Term Debt (Senior Notes) (Details) - Senior Notes - USD ($)	Dec. 31, 2016	Mar. 31, 2016	Feb. 19, 2016	Dec. 17, 2013
2013 Senior Notes
Debt Instrument [Line Items]
Debt instrument, face amount				$ 400,000,000
Debt instrument, stated interest rate (percent)	5.375%	5.375%		5.375%
Debt issuance costs capitalized				$ 7,200,000
2016 Senior Notes
Debt Instrument [Line Items]
Debt instrument, face amount			$ 350,000,000
Debt instrument, stated interest rate (percent)	6.375%	6.375%	6.375%
Debt issuance costs capitalized			$ 5,500,000

Long-Term Debt (Redemptions and

Long-Term Debt (Redemptions and Restrictions) (Details) - USD ($)	Feb. 19, 2016	Dec. 31, 2016	Mar. 31, 2016
Debt Instrument [Line Items]
Unamortized discount (premium) and debt issuance costs, net		$ 21,421,000	$ 27,191,000
2012 ABL Revolver | Revolving Credit Facility
Debt Instrument [Line Items]
Long-term debt outstanding		0
Line of credit facility, remaining borrowing capacity		135,000,000
2012 ABL Revolver | Revolving Credit Facility | Other long-term assets
Debt Instrument [Line Items]
Unamortized debt costs related to 2012 ABL Revolver		$ 1,000,000	1,300,000
Senior Notes | 2013 Senior Notes
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage		101.00%
Unamortized discount (premium) and debt issuance costs, net		$ 4,800,000	5,400,000
Senior Notes | 2016 Senior Notes
Debt Instrument [Line Items]
Unamortized discount (premium) and debt issuance costs, net		5,000,000	5,400,000
Term Loans | 2012 Term Loan
Debt Instrument [Line Items]
Unamortized discount (premium) and debt issuance costs, net		$ 11,600,000	$ 16,400,000
Debt Instrument, Redemption, Period One | Senior Notes | 2013 Senior Notes
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage		100.00%
Redemption price, percentage of principal amount, using proceeds of equity offerings		105.375%
Debt Instrument, Redemption, Period Two | Senior Notes | 2016 Senior Notes
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage	100.00%
Maximum | Debt Instrument, Redemption, Period One | Senior Notes | 2013 Senior Notes
Debt Instrument [Line Items]
Redemption price, percentage of principal amount redeemed		35.00%
Maximum | Debt Instrument, Redemption, Period Two | Senior Notes | 2016 Senior Notes
Debt Instrument [Line Items]
Redemption price, percentage of principal amount redeemed	40.00%
Indirect Guarantee of Indebtedness | Senior Notes | 2016 Senior Notes
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage	101.00%

Long-Term Debt (Schedule of Lon

Long-Term Debt (Schedule of Long-term Debt) (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Mar. 31, 2016	Feb. 19, 2016	Dec. 17, 2013	Feb. 21, 2013
Debt Instrument [Line Items]
Long-term debt, gross	$ 1,437,000	$ 1,652,500
Current portion of long-term debt	0	0
Long-term debt	1,437,000	1,652,500
Less: unamortized debt costs	(21,421)	(27,191)
Long-term debt, net	1,415,579	1,625,309
2012 ABL Revolver | Revolving Credit Facility
Debt Instrument [Line Items]
Long-term debt, gross	$ 0	$ 85,000
Senior Notes | 2016 Senior Notes
Debt Instrument [Line Items]
Debt instrument, stated interest rate (percent)	6.375%	6.375%	6.375%
Long-term debt, gross	$ 350,000	$ 350,000
Less: unamortized debt costs	$ (5,000)	$ (5,400)
Senior Notes | 2013 Senior Notes
Debt Instrument [Line Items]
Debt instrument, stated interest rate (percent)	5.375%	5.375%		5.375%
Long-term debt, gross	$ 400,000	$ 400,000
Less: unamortized debt costs	(4,800)	(5,400)
Senior Notes | 2012 Senior Notes
Debt Instrument [Line Items]
Debt instrument, stated interest rate (percent)					8.125%
Loans Payable, Term B-3 | 2012 Senior Notes
Debt Instrument [Line Items]
Long-term debt, gross	$ 687,000	$ 817,500
Loans Payable, Term B-3 | 2012 Senior Notes | Base Rate
Debt Instrument [Line Items]
Debt instrument, reference rate floor (percent)	1.75%	1.75%
Loans Payable, Term B-3 | 2012 Senior Notes | LIBOR
Debt Instrument [Line Items]
Debt instrument, reference rate floor (percent)	0.75%	0.75%

Long-Term Debt (Maturities of L

Long-Term Debt (Maturities of Long-term Debt) (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Mar. 31, 2016
Debt Disclosure [Abstract]
2017 (remaining three months ending March 31, 2017)	$ 0
2,018	0
2,019	0
2,020	0
2,021	0
Thereafter	1,437,000
Long-term debt, gross	$ 1,437,000	$ 1,652,500

Fair Value Measurements (Summar

Fair Value Measurements (Summary of Carrying Amounts and Estimated Fair Values) (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Mar. 31, 2016
Senior Notes | 2016 Senior Notes | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	$ 350,000	$ 350,000
Senior Notes | 2013 Senior Notes | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	400,000	400,000
Term B-3 Loans | 2012 Term Loan | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	687,000	817,500
Revolving Credit Facility | 2012 ABL Revolver | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
2012 ABL Revolver	0	85,000
Fair Value, Measurements, Recurring | Senior Notes | 2016 Senior Notes | Fair Value | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	367,500	363,125
Fair Value, Measurements, Recurring | Senior Notes | 2013 Senior Notes | Fair Value | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	413,000	408,000
Fair Value, Measurements, Recurring | Term B-3 Loans | 2012 Term Loan | Fair Value | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	692,153	818,522
Fair Value, Measurements, Recurring | Revolving Credit Facility | 2012 ABL Revolver | Fair Value | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
2012 ABL Revolver	$ 0	$ 85,000

Stockholders' Equity (Narrative

Stockholders' Equity (Narrative) (Details)	3 Months Ended		9 Months Ended
	Dec. 31, 2016vote$ / sharesshares	Dec. 31, 2015shares	Dec. 31, 2016USD ($)vote$ / sharesshares	Dec. 31, 2015$ / sharesshares	Mar. 31, 2016$ / sharesshares
Class of Stock [Line Items]
Common stock, shares authorized (in shares) | shares	250,000,000		250,000,000		250,000,000
Common stock, par value (in USD per share) | $ / shares	$ 0.01		$ 0.01		$ 0.01
Preferred stock, shares authorized (in shares) | shares	5,000,000		5,000,000		5,000,000
Preferred stock, par value (in USD per share) | $ / shares	$ 0.01		$ 0.01		$ 0.01
Voting rights, number of votes per common share owned | vote	1		1
Dividends declared on common stock | $			$ 0
Restricted Shares
Class of Stock [Line Items]
Restricted stock repurchased during period (in shares) | shares	780	0	25,768	39,429
Restricted stock acquired, average cost per share (in USD per share) | $ / shares	$ 45.83		$ 55.51	$ 41.66

Accumulated Other Comprehensi68

Accumulated Other Comprehensive Loss (Components of AOCI) (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Mar. 31, 2016
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive loss, net of tax	$ (35,382)	$ (23,525)
Accumulated foreign currency adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Cumulative translation adjustment	$ (35,382)	$ (23,525)

Earnings Per Share (Computation

Earnings Per Share (Computation of Basis and Diluted Earnings Per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Numerator
Net income	$ 31,641	$ 27,995	$ 58,305	$ 85,971
Denominator
Denominator for basic earnings per share — weighted average shares outstanding (in shares)	52,999	52,824	52,960	52,727
Dilutive effect of unvested restricted stock units and options issued to employees and directors (in shares)	360	379	379	379
Denominator for diluted earnings per share (in shares)	53,359	53,203	53,339	53,106
Earnings per Common Share:
Basic net earnings per share (in USD per share)	$ 0.60	$ 0.53	$ 1.10	$ 1.63
Diluted net earnings per share (in USD per share)	$ 0.59	$ 0.53	$ 1.09	$ 1.62

Earnings Per Share (Antidilutiv

Earnings Per Share (Antidilutive Securities) (Details) - shares shares in Millions	3 Months Ended		9 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Outstanding Stock Awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (less than $0.1 million YTD 2015) (in shares)	0.2	0.2	0.2	0.1

Share-Based Compensation (Narra

Share-Based Compensation (Narrative) (Details) $ / shares in Units, $ in Millions	Nov. 14, 2016$ / sharesshares	Sep. 12, 2016$ / sharesshares	Aug. 02, 2016shares	May 26, 2016shares	May 09, 2016$ / sharesshares	May 31, 2014shares	Jun. 30, 2014shares	Dec. 31, 2016USD ($)directorshares	Dec. 31, 2015USD ($)	Dec. 31, 2016USD ($)director$ / sharesshares	Dec. 31, 2015USD ($)$ / sharesshares
Share-based Compensation, Aggregate Disclosures:
Number of shares authorized for grant under 2005 Long-Term Equity Incentive Plan (in shares)								5,000,000		5,000,000
Number of additional shares authorized (in shares)							1,800,000
Maximum number of shares per participant, 12 month period (in shares)						1,000,000	2,500,000
Extension of plan term							10 years
Share-based compensation costs charged against income | $								$ 2.4	$ 2.1	$ 6.3	$ 7.1
Tax benefit recognized from share-based compensation expense | $								1.3	$ 0.7	2.5	2.5
Unrecognized compensation costs related to nonvested awards | $								$ 10.5		$ 10.5
Unrecognized compensation costs related to nonvested awards, weighted average period for recognition										10 months 24 days
Total fair value of vested shares | $										$ 6	6.6
Cash received from exercise of stock options | $										3.4	6.6
Tax benefit realized from exercise of stock options | $										$ 1.8	$ 3.5
Shares available for issuance under the Plan (in shares)								2,400,000		2,400,000
Stock options granted (in shares)										264,300	208,200
Restricted Shares
Board of directors, number of directors | director								6		6
Options, Additional Disclosures:
Options granted, weighted-average grant-date fair value (in USD per share) | $ / shares										$ 21.75	$ 17.24
Options exercised, aggregate intrinsic value | $										$ 2.4
Restricted Stock Units (RSUs)
Share-based Compensation, Aggregate Disclosures:
Shares issued in period (in shares)										94,718	153,603
Granted in period to each independent director (in shares)			1,896		49,064					68,400	266,100
Award vesting period					3 years
Restricted Shares
Period following director's term in which RSUs may be settled			6 months
Granted, weighted-average grant-date fair value (in USD per share) | $ / shares										$ 55.44	$ 42.41
Stock Options
Share-based Compensation, Aggregate Disclosures:
Stock options granted (in shares)					224,843
Award vesting period					3 years
Expected term in years					10 years
Stock options granted, exercise price (in USD per share) | $ / shares					$ 57.18
Stock Options | Minimum
Share-based Compensation, Aggregate Disclosures:
Award vesting period										3 years
Stock Options | Maximum
Share-based Compensation, Aggregate Disclosures:
Award vesting period										5 years
Options, Additional Disclosures:
Award exercisability period, from date of grant										10 years
Restricted Shares | Minimum
Share-based Compensation, Aggregate Disclosures:
Award vesting period										3 years
Restricted Shares | Maximum
Share-based Compensation, Aggregate Disclosures:
Award vesting period										5 years
Chief Financial Officer | Restricted Stock Units (RSUs)
Share-based Compensation, Aggregate Disclosures:
Granted in period to each independent director (in shares)		5,012
Award vesting period					3 years
Chief Financial Officer | Stock Options
Share-based Compensation, Aggregate Disclosures:
Stock options granted (in shares)		25,746
Expected term in years		10 years
Stock options granted, exercise price (in USD per share) | $ / shares		$ 47.39
Senior Vice President | Restricted Stock Units (RSUs)
Share-based Compensation, Aggregate Disclosures:
Granted in period to each independent director (in shares)	2,664
Award vesting period	3 years
Senior Vice President | Stock Options
Share-based Compensation, Aggregate Disclosures:
Stock options granted (in shares)	13,683
Expected term in years	10 years
Stock options granted, exercise price (in USD per share) | $ / shares	$ 50.06
Employee | Restricted Shares
Share-based Compensation, Aggregate Disclosures:
Award vesting period										3 years
Director | Restricted Stock Units (RSUs)
Share-based Compensation, Aggregate Disclosures:
Granted in period to each independent director (in shares)				346
Restricted Shares
Number of common shares into which each RSU may be converted (in shares)			1
Director | Restricted Shares
Share-based Compensation, Aggregate Disclosures:
Award vesting period										1 year
First year anniversary | Stock Options
Share-based Compensation, Aggregate Disclosures:
Annual award vesting percentage					33.30%
First year anniversary | Chief Financial Officer | Stock Options
Share-based Compensation, Aggregate Disclosures:
Annual award vesting percentage		33.30%
First year anniversary | Senior Vice President | Stock Options
Share-based Compensation, Aggregate Disclosures:
Annual award vesting percentage	33.30%
Second year anniversary | Stock Options
Share-based Compensation, Aggregate Disclosures:
Annual award vesting percentage					33.30%
Second year anniversary | Chief Financial Officer | Stock Options
Share-based Compensation, Aggregate Disclosures:
Annual award vesting percentage		33.30%
Second year anniversary | Senior Vice President | Stock Options
Share-based Compensation, Aggregate Disclosures:
Annual award vesting percentage	33.30%
Third year anniversary | Stock Options
Share-based Compensation, Aggregate Disclosures:
Annual award vesting percentage					33.30%
Third year anniversary | Chief Financial Officer | Stock Options
Share-based Compensation, Aggregate Disclosures:
Annual award vesting percentage		33.30%
Third year anniversary | Senior Vice President | Stock Options
Share-based Compensation, Aggregate Disclosures:
Annual award vesting percentage	33.30%

Share-Based Compensation (Restr

Share-Based Compensation (Restricted Stock Units Activity) (Details) - Restricted Stock Units (RSUs) - $ / shares	Aug. 02, 2016	May 09, 2016	Dec. 31, 2016	Dec. 31, 2015
Shares
Outstanding, beginning of period (in shares)			467,800	362,300
Granted (in shares)	1,896	49,064	68,400	266,100
Vested and issued (in shares)			(94,700)	(153,600)
Forfeited (in shares)			(91,400)	(1,400)
Outstanding, end of period (in shares)			350,100	473,400
Vested, end of period (in shares)			63,400	69,800
Weighted- Average Grant-Date Fair Value
Outstanding, beginning of period, weighted-average grant-date fair value (in USD per share)			$ 35.22	$ 22.74
Granted, weighted-average grant-date fair value (in USD per share)			55.44	42.41
Vested and issued, weighted-average grant-date fair value (in USD per share)			28.51	18.16
Forfeited, weighted-average grant-date fair value (in USD per share)			41.71	33.50
Outstanding, end of period, weighted-average grant-date fair value (in USD per share)			39.29	35.25
Vested, end of period, weighted-average grant-date fair value (in USD per share)			$ 20.12	$ 14.76

Share-Based Compensation (Stock

Share-Based Compensation (Stock Option Valuation Assumptions) (Details) - Stock Options - USD ($)	9 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	37.80%	40.20%
Expected dividends	$ 0	$ 0
Expected term in years	6 years	6 years
Risk-free rate	1.70%	1.70%

Share-Based Compensation (Sto74

Share-Based Compensation (Stock Option Activity) (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Shares
Outstanding, beginning of period (in shares)	727,700	871,200
Granted (in shares)	264,300	208,200
Exercised (in shares)	(107,900)	(336,900)
Forfeited or expired (in shares)	(92,200)	(2,100)
Outstanding, end of period (in shares)	791,900	740,400
Exercisable, end of period (in shares)	387,000	313,500
Weighted- Average Exercise Price
Outstanding, beginning of period, weighted-average exercise price (in USD per share)	$ 30.70	$ 23.40
Granted, weighted-average exercise price (in USD per share)	55.86	42.13
Exercised, weighted-average exercise price (in USD per share)	31.91	18.99
Forfeited or expired, weighted-average exercise price (in USD per share)	42.62	38.21
Outstanding, end of period, weighted-average exercise price (in USD per share)	37.54	30.63
Exercisable, end of period, weighted-average exercise price (in USD per share)	$ 25.70	$ 21.68
Options, Additional Disclosures:
Outstanding, end of period, weighted-average remaining contractual term	7 years 4 months 24 days	7 years 10 months 24 days
Exercisable, end of period, weighted-average remaining contractual term	6 years 3 months 18 days	6 years 8 months 12 days
Outstanding, end of period, aggregate intrinsic value	$ 12,543	$ 15,325
Exercisable, end of period, aggregate intrinsic value	$ 10,217	$ 9,341

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Effective income tax rate (percent)	37.60%	35.20%	36.70%	35.20%
Realized reduction in deferred tax liabilities from sale of assets			$ 37.7
Ownership percentage, subsidiaries	100.00%		100.00%
Net operating loss carryforwards	$ 7.1		$ 7.1
Deferred tax assets, operating loss carryforwards	2.5		2.5
Operating loss carryforwards, limitation on use, annual amount	33.6		33.6
Uncertain tax liability	3.7		$ 3.7		$ 4.1
Reduction in uncertain tax liability from lapse	1
Increase in uncertain tax liability for the current period	$ 0.6

Commitments and Contingencies76

Commitments and Contingencies (Future Minimum Rental Payments) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Mar. 31, 2016
Operating Leased Assets [Line Items]
2017 (Remaining three months ending March 31, 2017)	$ 656		$ 656
2,018	2,472		2,472
2,019	2,197		2,197
2,020	1,934		1,934
2,021	910		910
Thereafter	63		63
Total future minimum payments due	8,232		8,232		$ 8,434
Less: Sublease rentals	(971)		(971)		(1,165)
Minimum lease payments, less minimum sublease rentals	7,261		7,261		$ 7,269
Rent expense	400	$ 400	1,500	$ 1,200
Facilities
Operating Leased Assets [Line Items]
2017 (Remaining three months ending March 31, 2017)	524		524
2,018	2,029		2,029
2,019	2,023		2,023
2,020	1,848		1,848
2,021	903		903
Thereafter	59		59
Total future minimum payments due	7,386		7,386
Equipment
Operating Leased Assets [Line Items]
2017 (Remaining three months ending March 31, 2017)	132		132
2,018	443		443
2,019	174		174
2,020	86		86
2,021	7		7
Thereafter	4		4
Total future minimum payments due	$ 846		$ 846

Commitments and Contingencies77

Commitments and Contingencies (Long-term Supply Agreement) (Details) - Third-party Manufacturing - USD ($) $ in Thousands	Nov. 01, 2009	Dec. 31, 2016
Long-term Purchase Commitment [Line Items]
Supply agreement, term	10 years
2017 (Remaining three months ending March 31, 2017)		$ 258
2,018		1,013
2,019		982
2,020		559
2,021		0
Total purchase commitment		$ 2,812

Concentrations of Risk (Narrati

Concentrations of Risk (Narrative) (Details)	3 Months Ended		9 Months Ended
	Dec. 31, 2016manufacturer	Dec. 31, 2015manufacturer	Dec. 31, 2016manufacturercustomer	Dec. 31, 2015manufacturer
Concentration Risk [Line Items]
Number of third-party manufacturers	112	101	112	101
Sales | Product Concentration Risk | Top 5 Customers
Concentration Risk [Line Items]
Concentration risk, percentage	40.40%	41.00%	41.40%	42.20%
Sales | Customer Concentration Risk | Walmart and Walgreen
Concentration Risk [Line Items]
Number of customers exceeding concentration risk benchmark | customer			2
Sales | Customer Concentration Risk | Walmart
Concentration Risk [Line Items]
Concentration risk, percentage	20.40%	20.20%	20.70%	19.90%
Sales | Customer Concentration Risk | Walgreens
Concentration Risk [Line Items]
Concentration risk, percentage	10.00%	9.50%	10.30%	9.60%
Sales | Supplier Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage			78.50%	79.80%
Number of third-party manufacturers with long-term contracts			48	47
Accounts Receivable | Customer Concentration Risk | Walmart
Concentration Risk [Line Items]
Concentration risk, percentage			25.70%
Accounts Receivable | Customer Concentration Risk | Walgreens
Concentration Risk [Line Items]
Concentration risk, percentage			10.50%

Business Segments (Information

Business Segments (Information on Operating and Reportable Segments) (Details) - USD ($) $ in Thousands	Jul. 07, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Segment Reporting Information, Profit (Loss):
Gross segment revenues		$ 216,732	$ 199,485	$ 640,519	$ 596,034
Other revenues		31	710	871	2,358
Total revenues		216,763	200,195	641,390	598,392
Cost of sales		92,216	83,411	271,287	249,432
Gross profit		124,547	116,784	370,103	348,960
Advertising and promotion		30,682	29,935	86,909	84,250
Contribution margin		93,865	86,849	283,194	264,710
Other operating expenses		24,578	24,206	130,635	69,664
Operating income		69,287	62,643	152,559	195,046
Other expense		18,554	19,462	60,511	62,464
Income before income taxes		50,733	43,181	92,048	132,582
Provision for income taxes		19,092	15,186	33,743	46,611
Net income		31,641	27,995	58,305	85,971
Pre-tax gain (loss) on sale		3,405	0	(51,552)	0
North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Gross segment revenues		177,273	165,059	521,800	486,837
Other revenues		0	0	0	15
Total revenues		177,273	165,059	521,800	486,852
Cost of sales		68,378	62,655	198,014	182,279
Gross profit		108,895	102,404	323,786	304,573
Advertising and promotion		26,800	26,472	76,651	74,107
Contribution margin		82,095	75,932	247,135	230,466
International OTC Healthcare
Segment Reporting Information, Profit (Loss):
Gross segment revenues		18,459	13,803	53,061	43,213
Other revenues		0	9	6	40
Total revenues		18,459	13,812	53,067	43,253
Cost of sales		7,678	4,964	21,722	16,347
Gross profit		10,781	8,848	31,345	26,906
Advertising and promotion		3,502	2,838	8,870	8,338
Contribution margin		7,279	6,010	22,475	18,568
Household Cleaning
Segment Reporting Information, Profit (Loss):
Gross segment revenues		21,000	20,623	65,658	65,984
Other revenues		31	701	865	2,303
Total revenues		21,031	21,324	66,523	68,287
Cost of sales		16,160	15,792	51,551	50,806
Gross profit		4,871	5,532	14,972	17,481
Advertising and promotion		380	625	1,388	1,805
Contribution margin		4,491	4,907	13,584	15,676
Operating Segments
Segment Reporting Information, Profit (Loss):
Gross segment revenues		217,556	199,713	642,707	598,462
Operating Segments | North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Gross segment revenues		178,097	165,287	523,988	489,265
Total revenues		177,273	165,059	521,800	486,852
Operating Segments | International OTC Healthcare
Segment Reporting Information, Profit (Loss):
Gross segment revenues		18,459	13,803	53,061	43,213
Total revenues		18,459	13,812	53,067	43,253
Operating Segments | Household Cleaning
Segment Reporting Information, Profit (Loss):
Gross segment revenues		21,000	20,623	65,658	65,984
Total revenues		21,031	21,324	66,523	68,287
Intersegment Eliminations
Segment Reporting Information, Profit (Loss):
Gross segment revenues		(824)	(228)	(2,188)	(2,428)
Intersegment Eliminations | North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Gross segment revenues		(824)	(228)	(2,188)	(2,428)
Intersegment Eliminations | International OTC Healthcare
Segment Reporting Information, Profit (Loss):
Gross segment revenues		0	0	0	0
Intersegment Eliminations | Household Cleaning
Segment Reporting Information, Profit (Loss):
Gross segment revenues		0	$ 0	0	$ 0
Disposed of by sale | North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Pre-tax gain (loss) on sale		(51,600)
Disposed of by sale | e.p.t and Dermoplast | North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Pre-tax gain (loss) on sale		$ 3,400
Disposed of by sale | Pediacare, New Skin and Fiber Choice | Cough and Cold, Dermatologicals, and Gastrointestinal Products Group | North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Pre-tax gain (loss) on sale	$ (56,146)			$ (56,146)

Business Segments (Revenue by P

Business Segments (Revenue by Product) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	$ 216,763	$ 200,195	$ 641,390	$ 598,392
Analgesics
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	32,883	30,904	92,073	88,664
Cough & Cold
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	33,969	34,162	82,594	87,629
Women's Health
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	31,476	34,398	99,202	102,417
Gastrointestinal
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	21,810	22,918	67,540	71,449
Eye & Ear Care
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	26,568	24,549	81,294	80,552
Dermatologicals
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	20,427	20,258	67,315	64,695
Oral Care
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	27,212	10,122	80,428	30,215
Other OTC
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	1,387	1,560	4,421	4,484
Household Cleaning
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	21,031	21,324	66,523	68,287
North American OTC Healthcare
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	177,273	165,059	521,800	486,852
International OTC Healthcare
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	18,459	13,812	53,067	43,253
Household Cleaning
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	21,031	21,324	66,523	68,287
Operating Segments | North American OTC Healthcare
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	177,273	165,059	521,800	486,852
Operating Segments | North American OTC Healthcare | Analgesics
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	32,439	30,454	90,558	86,996
Operating Segments | North American OTC Healthcare | Cough & Cold
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	29,803	30,466	68,876	74,681
Operating Segments | North American OTC Healthcare | Women's Health
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	30,896	33,521	97,051	100,036
Operating Segments | North American OTC Healthcare | Gastrointestinal
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	15,109	17,401	50,495	56,782
Operating Segments | North American OTC Healthcare | Eye & Ear Care
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	23,571	21,936	72,512	71,159
Operating Segments | North American OTC Healthcare | Dermatologicals
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	19,948	19,734	65,598	63,026
Operating Segments | North American OTC Healthcare | Oral Care
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	24,129	9,996	72,308	29,706
Operating Segments | North American OTC Healthcare | Other OTC
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	1,378	1,551	4,402	4,466
Operating Segments | International OTC Healthcare
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	18,459	13,812	53,067	43,253
Operating Segments | International OTC Healthcare | Analgesics
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	444	450	1,515	1,668
Operating Segments | International OTC Healthcare | Cough & Cold
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	4,166	3,696	13,718	12,948
Operating Segments | International OTC Healthcare | Women's Health
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	580	877	2,151	2,381
Operating Segments | International OTC Healthcare | Gastrointestinal
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	6,701	5,517	17,045	14,667
Operating Segments | International OTC Healthcare | Eye & Ear Care
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	2,997	2,613	8,782	9,393
Operating Segments | International OTC Healthcare | Dermatologicals
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	479	524	1,717	1,669
Operating Segments | International OTC Healthcare | Oral Care
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	3,083	126	8,120	509
Operating Segments | International OTC Healthcare | Other OTC
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	9	9	19	18
Operating Segments | Household Cleaning
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	21,031	21,324	66,523	68,287
Operating Segments | Household Cleaning | Analgesics
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	0	0	0	0
Operating Segments | Household Cleaning | Cough & Cold
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	0	0	0	0
Operating Segments | Household Cleaning | Women's Health
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	0	0	0	0
Operating Segments | Household Cleaning | Gastrointestinal
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	0	0	0	0
Operating Segments | Household Cleaning | Eye & Ear Care
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	0	0	0	0
Operating Segments | Household Cleaning | Dermatologicals
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	0	0	0	0
Operating Segments | Household Cleaning | Oral Care
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	0	0	0	0
Operating Segments | Household Cleaning | Other OTC
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	0	0	0	0
Operating Segments | Household Cleaning | Household Cleaning
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	$ 21,031	$ 21,324	$ 66,523	$ 68,287

Business Segments (Assets by Se

Business Segments (Assets by Segment) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Mar. 31, 2016
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	$ 345,485		$ 345,485		$ 360,191
Indefinite-lived	1,937,613		1,937,613		2,020,046
Finite-lived	218,765		218,765		302,677
Intangible assets, net	2,156,378		2,156,378		2,322,723
Intangible assets, net (including goodwill)	2,501,863		2,501,863		2,682,914
Finite Lived Intangibles
Segment Reporting, Asset Reconciling Item [Line Items]
Finite-lived	218,765		218,765
Indefinite Lived Intangibles
Segment Reporting, Asset Reconciling Item [Line Items]
Indefinite-lived	1,937,613		1,937,613		2,020,046
North American OTC Healthcare
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	318,014		318,014		330,615
Intangible assets, net	1,952,026		1,952,026		2,101,635
Intangible assets, net (including goodwill)	2,270,040		2,270,040		2,432,250
North American OTC Healthcare | Finite Lived Intangibles
Segment Reporting, Asset Reconciling Item [Line Items]
Finite-lived	196,391		196,391		277,762
North American OTC Healthcare | Indefinite Lived Intangibles
Segment Reporting, Asset Reconciling Item [Line Items]
Indefinite-lived	1,755,635		1,755,635		1,823,873
International OTC Healthcare
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	21,226		21,226		22,776
Intangible assets, net	81,720		81,720		88,138
Intangible assets, net (including goodwill)	102,946		102,946		110,914
International OTC Healthcare | Finite Lived Intangibles
Segment Reporting, Asset Reconciling Item [Line Items]
Finite-lived	1,004		1,004		2,237
International OTC Healthcare | Indefinite Lived Intangibles
Segment Reporting, Asset Reconciling Item [Line Items]
Indefinite-lived	80,716		80,716		85,901
Household Cleaning
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	6,245		6,245		6,800
Intangible assets, net	122,632		122,632		132,950
Intangible assets, net (including goodwill)	128,877		128,877		139,750
Household Cleaning | Finite Lived Intangibles
Segment Reporting, Asset Reconciling Item [Line Items]
Finite-lived	21,370		21,370		22,678
Household Cleaning | Indefinite Lived Intangibles
Segment Reporting, Asset Reconciling Item [Line Items]
Indefinite-lived	$ 101,262		$ 101,262		$ 110,272
Sales | UNITED STATES | Geographic concentration risk
Segment Reporting, Asset Reconciling Item [Line Items]
Concentration risk, percentage	86.70%	87.80%	86.70%	86.90%
Sales | CANADA | Geographic concentration risk
Segment Reporting, Asset Reconciling Item [Line Items]
Concentration risk, percentage	4.70%	5.00%	4.90%	5.20%
Sales | AUSTRALIA | Geographic concentration risk
Segment Reporting, Asset Reconciling Item [Line Items]
Concentration risk, percentage	5.30%	5.00%	5.40%	5.90%
Goodwill and Intangible Assets | UNITED STATES | Geographic concentration risk
Segment Reporting, Asset Reconciling Item [Line Items]
Concentration risk, percentage			95.90%		95.90%
Goodwill and Intangible Assets | Australia and United Kingdom | Geographic concentration risk
Segment Reporting, Asset Reconciling Item [Line Items]
Concentration risk, percentage			4.10%		4.10%

Condensed Consolidating Finan82

Condensed Consolidating Financial Statements (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended			9 Months Ended
	Dec. 31, 2016	Jun. 30, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Equity in (income) loss of subsidiaries	$ 0		$ 0	$ 0	$ 0
Eliminations
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Equity in (income) loss of subsidiaries	$ (58,539)		$ (45,642)	$ (105,267)	$ (143,925)
Restatement adjustment | Overstatement of equity in earnings of subsidiaries
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Equity in (income) loss of subsidiaries		$ (44,600)
Restatement adjustment | Eliminations | Overstatement of equity in earnings of subsidiaries
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Equity in (income) loss of subsidiaries		$ 44,600

Condensed Consolidating Finan83

Condensed Consolidating Financial Statements (Condensed Consolidating Statements of Income and Comprehensive Income) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Revenues
Net sales	$ 216,732	$ 199,485	$ 640,519	$ 596,034
Other revenues	31	710	871	2,358
Total revenues	216,763	200,195	641,390	598,392
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	92,216	83,411	271,287	249,432
Gross profit	124,547	116,784	370,103	348,960
Operating Expenses
Advertising and promotion	30,682	29,935	86,909	84,250
General and administrative	22,131	18,135	60,383	52,186
Depreciation and amortization	5,852	6,071	18,700	17,478
(Gain) loss on divestitures	(3,405)	0	51,552	0
Total operating expenses	55,260	54,141	217,544	153,914
Operating income (loss)	69,287	62,643	152,559	195,046
Other (income) expense
Interest income	(46)	(31)	(149)	(91)
Interest expense	18,600	19,493	60,660	62,104
Loss on extinguishment of debt	0	0	0	451
Equity in (income) loss of subsidiaries	0	0	0	0
Total other expense	18,554	19,462	60,511	62,464
Provision for income taxes	19,092	15,186	33,743	46,611
Income before income taxes	50,733	43,181	92,048	132,582
Net income	31,641	27,995	58,305	85,971
Comprehensive (loss) income, net of tax:
Currency translation adjustments	(8,736)	4,922	(11,857)	(6,562)
Total other comprehensive (loss) income	(8,736)	4,922	(11,857)	(6,562)
Comprehensive income	22,905	32,917	46,448	79,409
Prestige Brands Holdings, Inc.
Revenues
Net sales	0	0	0	0
Other revenues	0	0	0	0
Total revenues	0	0	0	0
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	0	0	0	0
Gross profit	0	0	0	0
Operating Expenses
Advertising and promotion	0	0	0	0
General and administrative	2,486	1,370	6,224	3,884
Depreciation and amortization	722	1,013	2,474	3,032
(Gain) loss on divestitures	0		0
Total operating expenses	3,208	2,383	8,698	6,916
Operating income (loss)	(3,208)	(2,383)	(8,698)	(6,916)
Other (income) expense
Interest income	(12,056)	(12,141)	(36,100)	(36,351)
Interest expense	8,495	8,602	25,437	26,056
Loss on extinguishment of debt				0
Equity in (income) loss of subsidiaries	(32,821)	(27,711)	(59,111)	(84,458)
Total other expense	(36,382)	(31,250)	(69,774)	(94,753)
Provision for income taxes	1,533	872	2,771	1,866
Income before income taxes	33,174	28,867	61,076	87,837
Net income	31,641	27,995	58,305	85,971
Comprehensive (loss) income, net of tax:
Currency translation adjustments	(8,736)	4,922	(11,857)	(6,562)
Total other comprehensive (loss) income	(8,736)	4,922	(11,857)	(6,562)
Comprehensive income	22,905	32,917	46,448	79,409
Prestige Brands, Inc., the issuer
Revenues
Net sales	29,156	27,598	83,128	83,438
Other revenues	76	98	223	273
Total revenues	29,232	27,696	83,351	83,711
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	12,179	11,796	35,331	33,105
Gross profit	17,053	15,900	48,020	50,606
Operating Expenses
Advertising and promotion	3,009	1,881	11,505	7,602
General and administrative	2,004	1,789	5,954	5,644
Depreciation and amortization	154	151	456	444
(Gain) loss on divestitures	0		0
Total operating expenses	5,167	3,821	17,915	13,690
Operating income (loss)	11,886	12,079	30,105	36,916
Other (income) expense
Interest income	(21,422)	(21,569)	(64,143)	(64,584)
Interest expense	18,598	19,443	60,654	61,654
Loss on extinguishment of debt				451
Equity in (income) loss of subsidiaries	(23,629)	(15,898)	(37,390)	(52,599)
Total other expense	(26,453)	(18,024)	(40,879)	(55,078)
Provision for income taxes	5,087	4,950	11,791	13,867
Income before income taxes	38,339	30,103	70,984	91,994
Net income	33,252	25,153	59,193	78,127
Comprehensive (loss) income, net of tax:
Currency translation adjustments	(8,736)	4,922	(11,857)	(6,562)
Total other comprehensive (loss) income	(8,736)	4,922	(11,857)	(6,562)
Comprehensive income	24,516	30,075	47,336	71,565
Combined Subsidiary Guarantors
Revenues
Net sales	172,216	159,783	512,212	477,079
Other revenues	31	700	865	2,317
Total revenues	172,247	160,483	513,077	479,396
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	74,494	68,148	220,336	206,646
Gross profit	97,753	92,335	292,741	272,750
Operating Expenses
Advertising and promotion	24,266	25,251	66,689	68,412
General and administrative	15,644	13,463	43,260	38,326
Depreciation and amortization	4,860	4,794	15,410	13,686
(Gain) loss on divestitures	(3,405)		51,552
Total operating expenses	41,365	43,508	176,911	120,424
Operating income (loss)	56,388	48,827	115,830	152,326
Other (income) expense
Interest income	(1,299)	(1,124)	(3,865)	(3,513)
Interest expense	25,099	25,255	75,138	75,604
Loss on extinguishment of debt				0
Equity in (income) loss of subsidiaries	(2,089)	(2,033)	(8,766)	(6,868)
Total other expense	21,711	22,098	62,507	65,223
Provision for income taxes	11,391	8,582	15,842	28,243
Income before income taxes	34,677	26,729	53,323	87,103
Net income	23,286	18,147	37,481	58,860
Comprehensive (loss) income, net of tax:
Currency translation adjustments	(8,736)	4,922	(11,857)	(6,562)
Total other comprehensive (loss) income	(8,736)	4,922	(11,857)	(6,562)
Comprehensive income	14,550	23,069	25,624	52,298
Combined Non- Guarantor Subsidiaries
Revenues
Net sales	16,184	12,332	47,368	37,945
Other revenues	329	356	1,309	1,397
Total revenues	16,513	12,688	48,677	39,342
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	6,684	4,448	19,162	13,808
Gross profit	9,829	8,240	29,515	25,534
Operating Expenses
Advertising and promotion	3,407	2,803	8,715	8,236
General and administrative	1,997	1,513	4,945	4,332
Depreciation and amortization	116	113	360	316
(Gain) loss on divestitures	0		0
Total operating expenses	5,520	4,429	14,020	12,884
Operating income (loss)	4,309	3,811	15,495	12,650
Other (income) expense
Interest income	(160)	(128)	(475)	(366)
Interest expense	1,299	1,124	3,865	3,513
Loss on extinguishment of debt				0
Equity in (income) loss of subsidiaries	0	0	0	0
Total other expense	1,139	996	3,390	3,147
Provision for income taxes	1,081	782	3,339	2,635
Income before income taxes	3,170	2,815	12,105	9,503
Net income	2,089	2,033	8,766	6,868
Comprehensive (loss) income, net of tax:
Currency translation adjustments	(8,736)	4,922	(11,857)	(6,562)
Total other comprehensive (loss) income	(8,736)	4,922	(11,857)	(6,562)
Comprehensive income	(6,647)	6,955	(3,091)	306
Eliminations
Revenues
Net sales	(824)	(228)	(2,189)	(2,428)
Other revenues	(405)	(444)	(1,526)	(1,629)
Total revenues	(1,229)	(672)	(3,715)	(4,057)
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	(1,141)	(981)	(3,542)	(4,127)
Gross profit	(88)	309	(173)	70
Operating Expenses
Advertising and promotion	0	0	0	0
General and administrative	0	0	0	0
Depreciation and amortization	0	0	0	0
(Gain) loss on divestitures	0		0
Total operating expenses	0	0	0	0
Operating income (loss)	(88)	309	(173)	70
Other (income) expense
Interest income	34,891	34,931	104,434	104,723
Interest expense	(34,891)	(34,931)	(104,434)	(104,723)
Loss on extinguishment of debt				0
Equity in (income) loss of subsidiaries	58,539	45,642	105,267	143,925
Total other expense	58,539	45,642	105,267	143,925
Provision for income taxes	0	0	0	0
Income before income taxes	(58,627)	(45,333)	(105,440)	(143,855)
Net income	(58,627)	(45,333)	(105,440)	(143,855)
Comprehensive (loss) income, net of tax:
Currency translation adjustments	26,208	(14,766)	35,571	19,686
Total other comprehensive (loss) income	26,208	(14,766)	35,571	19,686
Comprehensive income	$ (32,419)	$ (60,099)	$ (69,869)	$ (124,169)

Condensed Consolidating Finan84

Condensed Consolidating Financial Statements (Condensed Consolidating Balance Sheet) (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Mar. 31, 2016	Dec. 31, 2015	Mar. 31, 2015
Current assets
Cash and cash equivalents	$ 63,289	$ 27,230	$ 48,973	$ 21,318
Accounts receivable, net	104,388	95,247
Inventories	100,926	91,263
Deferred income tax assets	12,602	10,108
Prepaid expenses and other current assets	10,005	25,165
Total current assets	291,210	249,013
Property and equipment, net	12,865	15,540
Goodwill	345,485	360,191
Intangible assets, net	2,156,378	2,322,723
Other long-term assets	4,914	1,324
Intercompany receivables	0	0
Investment in subsidiary	0	0
Total Assets	2,810,852	2,948,791
Current liabilities
Accounts payable	45,250	38,296
Accrued interest payable	8,399	8,664
Other accrued liabilities	78,675	59,724
Total current liabilities	132,324	106,684
Long-term debt
Principal amount	1,437,000	1,652,500
Less unamortized debt costs	(21,421)	(27,191)
Long-term debt, net	1,415,579	1,625,309
Deferred income tax liabilities	459,780	469,622
Other long-term liabilities	3,312	2,840
Intercompany payables	0	0
Total Liabilities	2,010,995	2,204,455
Stockholders' Equity
Common stock	532	530
Additional paid-in capital	455,684	445,182
Treasury stock, at cost	(6,594)	(5,163)
Accumulated other comprehensive (loss) income, net of tax	(35,382)	(23,525)
Retained earnings (accumulated deficit)	385,617	327,312
Total Stockholders' Equity	799,857	744,336
Total Liabilities and Stockholders' Equity	2,810,852	2,948,791
Prestige Brands Holdings, Inc.
Current assets
Cash and cash equivalents	36,821	4,440	33,752	11,387
Accounts receivable, net	0	0
Inventories	0	0
Deferred income tax assets	2,372	316
Prepaid expenses and other current assets	1,611	15,311
Total current assets	40,804	20,067
Property and equipment, net	7,595	9,166
Goodwill	0	0
Intangible assets, net	0	0
Other long-term assets	2,500	0
Intercompany receivables	1,451,328	1,457,011
Investment in subsidiary	1,690,523	1,641,477
Total Assets	3,192,750	3,127,721
Current liabilities
Accounts payable	2,822	2,914
Accrued interest payable	0	0
Other accrued liabilities	13,722	12,285
Total current liabilities	16,544	15,199
Long-term debt
Principal amount	0	0
Less unamortized debt costs	0	0
Long-term debt, net	0	0
Deferred income tax liabilities	0	0
Other long-term liabilities	0	0
Intercompany payables	2,376,349	2,368,186
Total Liabilities	2,392,893	2,383,385
Stockholders' Equity
Common stock	532	530
Additional paid-in capital	455,684	445,182
Treasury stock, at cost	(6,594)	(5,163)
Accumulated other comprehensive (loss) income, net of tax	(35,382)	(23,525)
Retained earnings (accumulated deficit)	385,617	327,312
Total Stockholders' Equity	799,857	744,336
Total Liabilities and Stockholders' Equity	3,192,750	3,127,721
Prestige Brands, Inc., the issuer
Current assets
Cash and cash equivalents	0	0	0	0
Accounts receivable, net	12,291	12,025
Inventories	16,758	9,411
Deferred income tax assets	918	681
Prepaid expenses and other current assets	158	257
Total current assets	30,125	22,374
Property and equipment, net	315	210
Goodwill	66,007	66,007
Intangible assets, net	191,387	191,789
Other long-term assets	2,414	1,324
Intercompany receivables	2,518,756	2,703,192
Investment in subsidiary	1,553,251	1,527,718
Total Assets	4,362,255	4,512,614
Current liabilities
Accounts payable	9,418	7,643
Accrued interest payable	8,399	8,664
Other accrued liabilities	2,721	1,714
Total current liabilities	20,538	18,021
Long-term debt
Principal amount	1,437,000	1,652,500
Less unamortized debt costs	(21,421)	(27,191)
Long-term debt, net	1,415,579	1,625,309
Deferred income tax liabilities	61,047	60,317
Other long-term liabilities	0	0
Intercompany payables	1,249,872	1,241,084
Total Liabilities	2,747,036	2,944,731
Stockholders' Equity
Common stock	0	0
Additional paid-in capital	1,280,947	1,280,947
Treasury stock, at cost	0	0
Accumulated other comprehensive (loss) income, net of tax	(35,382)	(23,525)
Retained earnings (accumulated deficit)	369,654	310,461
Total Stockholders' Equity	1,615,219	1,567,883
Total Liabilities and Stockholders' Equity	4,362,255	4,512,614
Combined Subsidiary Guarantors
Current assets
Cash and cash equivalents	202	2,899	0	0
Accounts receivable, net	79,927	74,446
Inventories	75,522	72,296
Deferred income tax assets	8,624	8,293
Prepaid expenses and other current assets	7,464	8,379
Total current assets	171,739	166,313
Property and equipment, net	4,478	5,528
Goodwill	258,252	271,409
Intangible assets, net	1,882,242	2,042,640
Other long-term assets	0	0
Intercompany receivables	1,670,364	1,083,488
Investment in subsidiary	76,662	81,545
Total Assets	4,063,737	3,650,923
Current liabilities
Accounts payable	29,964	24,437
Accrued interest payable	0	0
Other accrued liabilities	55,162	38,734
Total current liabilities	85,126	63,171
Long-term debt
Principal amount	0	0
Less unamortized debt costs	0	0
Long-term debt, net	0	0
Deferred income tax liabilities	398,380	408,893
Other long-term liabilities	3,264	2,682
Intercompany payables	1,945,431	1,570,265
Total Liabilities	2,432,201	2,045,011
Stockholders' Equity
Common stock	0	0
Additional paid-in capital	1,359,921	1,359,921
Treasury stock, at cost	0	0
Accumulated other comprehensive (loss) income, net of tax	(35,382)	(23,525)
Retained earnings (accumulated deficit)	306,997	269,516
Total Stockholders' Equity	1,631,536	1,605,912
Total Liabilities and Stockholders' Equity	4,063,737	3,650,923
Combined Non- Guarantor Subsidiaries
Current assets
Cash and cash equivalents	26,266	19,891	15,221	9,931
Accounts receivable, net	12,170	8,776
Inventories	9,351	10,088
Deferred income tax assets	688	818
Prepaid expenses and other current assets	772	1,218
Total current assets	49,247	40,791
Property and equipment, net	477	636
Goodwill	21,226	22,775
Intangible assets, net	82,749	88,294
Other long-term assets	0	0
Intercompany receivables	14,432	10,738
Investment in subsidiary	0	0
Total Assets	168,131	163,234
Current liabilities
Accounts payable	3,046	3,302
Accrued interest payable	0	0
Other accrued liabilities	7,070	6,991
Total current liabilities	10,116	10,293
Long-term debt
Principal amount	0	0
Less unamortized debt costs	0	0
Long-term debt, net	0	0
Deferred income tax liabilities	353	412
Other long-term liabilities	48	158
Intercompany payables	83,228	74,894
Total Liabilities	93,745	85,757
Stockholders' Equity
Common stock	0	0
Additional paid-in capital	78,774	78,774
Treasury stock, at cost	0	0
Accumulated other comprehensive (loss) income, net of tax	(35,382)	(23,525)
Retained earnings (accumulated deficit)	30,994	22,228
Total Stockholders' Equity	74,386	77,477
Total Liabilities and Stockholders' Equity	168,131	163,234
Eliminations
Current assets
Cash and cash equivalents	0	0	$ 0	$ 0
Accounts receivable, net	0	0
Inventories	(705)	(532)
Deferred income tax assets	0	0
Prepaid expenses and other current assets	0	0
Total current assets	(705)	(532)
Property and equipment, net	0	0
Goodwill	0	0
Intangible assets, net	0	0
Other long-term assets	0	0
Intercompany receivables	(5,654,880)	(5,254,429)
Investment in subsidiary	(3,320,436)	(3,250,740)
Total Assets	(8,976,021)	(8,505,701)
Current liabilities
Accounts payable	0	0
Accrued interest payable	0	0
Other accrued liabilities	0	0
Total current liabilities	0	0
Long-term debt
Principal amount	0	0
Less unamortized debt costs	0	0
Long-term debt, net	0	0
Deferred income tax liabilities	0	0
Other long-term liabilities	0	0
Intercompany payables	(5,654,880)	(5,254,429)
Total Liabilities	(5,654,880)	(5,254,429)
Stockholders' Equity
Common stock	0	0
Additional paid-in capital	(2,719,642)	(2,719,642)
Treasury stock, at cost	0	0
Accumulated other comprehensive (loss) income, net of tax	106,146	70,575
Retained earnings (accumulated deficit)	(707,645)	(602,205)
Total Stockholders' Equity	(3,321,141)	(3,251,272)
Total Liabilities and Stockholders' Equity	$ (8,976,021)	$ (8,505,701)

Condensed Consolidating Finan85

Condensed Consolidating Financial Statements (Condensed Consolidating Statement of Cash Flows) (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Dec. 31, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Operating Activities
Net income (loss)		$ 31,641	$ 27,995	$ 58,305	$ 85,971
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization				18,700	17,478
Loss on divestitures and sales of property and equipment				51,807	0
Deferred income taxes				(12,530)	31,591
Amortization of debt origination costs				6,129	5,433
Stock-based compensation costs				6,260	7,098
Loss on extinguishment of debt		0	0	0	451
Gain on sale or disposal of property and equipment				0	(36)
Equity in income of subsidiaries				0	0
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable				(12,374)	2,453
Inventories				(16,589)	(7,114)
Prepaid expenses and other current assets				11,149	5,472
Accounts payable				7,168	(17,553)
Accrued liabilities				22,323	5,207
Net cash provided by operating activities				140,348	136,451
Investing Activities
Purchases of property and equipment				(1,935)	(2,540)
Proceeds from sale of business				110,717	0
Proceeds from the sales of property and equipment				85	344
Net cash provided by investing activities				110,286	5,041
Financing Activities
Term loan repayments				(130,500)	(50,000)
Borrowings under revolving credit agreement				20,000	15,000
Repayments under revolving credit agreement				(105,000)	(81,100)
Payments of debt origination costs				(9)	(4,211)
Proceeds from exercise of stock options				3,444	6,600
Proceeds from restricted stock exercises				0	544
Excess tax benefits from share-based awards				800	1,850
Fair value of shares surrendered as payment of tax withholding				(1,431)	(2,187)
Intercompany activity, net				0	0
Net cash used in financing activities				(212,696)	(113,504)
Effects of exchange rate changes on cash and cash equivalents				(1,879)	(333)
Increase in cash and cash equivalents				36,059	27,655
Cash and cash equivalents - beginning of period				27,230	21,318
Cash and cash equivalents - end of period	$ 63,289	63,289	48,973	63,289	48,973
Prestige Brands Holdings, Inc.
Operating Activities
Net income (loss)		31,641	27,995	58,305	85,971
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization				2,474	3,032
Loss on divestitures and sales of property and equipment
Deferred income taxes				(2,056)	148
Amortization of debt origination costs				0	0
Stock-based compensation costs				6,260	7,057
Loss on extinguishment of debt					0
Gain on sale or disposal of property and equipment					0
Equity in income of subsidiaries				(59,111)	(84,458)
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable				0	0
Inventories				0	0
Prepaid expenses and other current assets				11,200	3,557
Accounts payable				(118)	(33)
Accrued liabilities				1,437	(102)
Net cash provided by operating activities				18,391	15,172
Investing Activities
Purchases of property and equipment				(890)	(1,741)
Proceeds from sale of business				0
Proceeds from the sales of property and equipment				0	0
Net cash provided by investing activities				(890)	(1,741)
Financing Activities
Term loan repayments				0	0
Borrowings under revolving credit agreement				0	0
Repayments under revolving credit agreement				0	0
Payments of debt origination costs				0	0
Proceeds from exercise of stock options				3,444	6,600
Proceeds from restricted stock exercises					544
Excess tax benefits from share-based awards				800	1,850
Fair value of shares surrendered as payment of tax withholding				(1,431)	(2,187)
Intercompany activity, net				12,067	2,127
Net cash used in financing activities				14,880	8,934
Effects of exchange rate changes on cash and cash equivalents				0	0
Increase in cash and cash equivalents				32,381	22,365
Cash and cash equivalents - beginning of period				4,440	11,387
Cash and cash equivalents - end of period	36,821	36,821	33,752	36,821	33,752
Prestige Brands, Inc., the issuer
Operating Activities
Net income (loss)		33,252	25,153	59,193	78,127
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization				456	444
Loss on divestitures and sales of property and equipment				0
Deferred income taxes				493	164
Amortization of debt origination costs				6,129	5,433
Stock-based compensation costs				0	0
Loss on extinguishment of debt					451
Gain on sale or disposal of property and equipment					0
Equity in income of subsidiaries				(37,390)	(52,599)
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable				(266)	1,158
Inventories				(7,347)	(2,519)
Prepaid expenses and other current assets				99	(305)
Accounts payable				1,775	(1,161)
Accrued liabilities				742	(1,636)
Net cash provided by operating activities				23,884	27,557
Investing Activities
Purchases of property and equipment				(158)	(93)
Proceeds from sale of business				0
Proceeds from the sales of property and equipment				0	0
Net cash provided by investing activities				(158)	(93)
Financing Activities
Term loan repayments				(130,500)	(50,000)
Borrowings under revolving credit agreement				20,000	15,000
Repayments under revolving credit agreement				(105,000)	(81,100)
Payments of debt origination costs				(9)	(4,211)
Proceeds from exercise of stock options				0	0
Proceeds from restricted stock exercises					0
Excess tax benefits from share-based awards				0	0
Fair value of shares surrendered as payment of tax withholding				0	0
Intercompany activity, net				191,783	92,847
Net cash used in financing activities				(23,726)	(27,464)
Effects of exchange rate changes on cash and cash equivalents				0	0
Increase in cash and cash equivalents				0	0
Cash and cash equivalents - beginning of period				0	0
Cash and cash equivalents - end of period	0	0	0	0	0
Combined Subsidiary Guarantors
Operating Activities
Net income (loss)		23,286	18,147	37,481	58,860
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization				15,410	13,686
Loss on divestitures and sales of property and equipment				51,807
Deferred income taxes				(11,101)	31,301
Amortization of debt origination costs				0	0
Stock-based compensation costs				0	0
Loss on extinguishment of debt					0
Gain on sale or disposal of property and equipment					0
Equity in income of subsidiaries				(8,766)	(6,868)
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable				(5,481)	2,188
Inventories				(9,409)	(3,014)
Prepaid expenses and other current assets				(525)	2,752
Accounts payable				5,981	(14,613)
Accrued liabilities				20,995	5,439
Net cash provided by operating activities				96,392	89,731
Investing Activities
Purchases of property and equipment				(785)	(212)
Proceeds from sale of business				110,717
Proceeds from the sales of property and equipment				85	0
Net cash provided by investing activities				111,436	7,025
Financing Activities
Term loan repayments				0	0
Borrowings under revolving credit agreement				0	0
Repayments under revolving credit agreement				0	0
Payments of debt origination costs				0	0
Proceeds from exercise of stock options				0	0
Proceeds from restricted stock exercises					0
Excess tax benefits from share-based awards				0	0
Fair value of shares surrendered as payment of tax withholding				0	0
Intercompany activity, net				(210,525)	(96,756)
Net cash used in financing activities				(210,525)	(96,756)
Effects of exchange rate changes on cash and cash equivalents				0	0
Increase in cash and cash equivalents				(2,697)	0
Cash and cash equivalents - beginning of period				2,899	0
Cash and cash equivalents - end of period	202	202	0	202	0
Combined Non- Guarantor Subsidiaries
Operating Activities
Net income (loss)		2,089	2,033	8,766	6,868
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization				360	316
Loss on divestitures and sales of property and equipment				0
Deferred income taxes				134	(22)
Amortization of debt origination costs				0	0
Stock-based compensation costs				0	41
Loss on extinguishment of debt					0
Gain on sale or disposal of property and equipment					(36)
Equity in income of subsidiaries				0	0
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable				(6,627)	(893)
Inventories				(6)	(1,511)
Prepaid expenses and other current assets				375	(532)
Accounts payable				(470)	(1,746)
Accrued liabilities				(851)	1,506
Net cash provided by operating activities				1,681	3,991
Investing Activities
Purchases of property and equipment				(102)	(494)
Proceeds from sale of business				0
Proceeds from the sales of property and equipment				0	344
Net cash provided by investing activities				(102)	(150)
Financing Activities
Term loan repayments				0	0
Borrowings under revolving credit agreement				0	0
Repayments under revolving credit agreement				0	0
Payments of debt origination costs				0	0
Proceeds from exercise of stock options				0	0
Proceeds from restricted stock exercises					0
Excess tax benefits from share-based awards				0	0
Fair value of shares surrendered as payment of tax withholding				0	0
Intercompany activity, net				6,675	1,782
Net cash used in financing activities				6,675	1,782
Effects of exchange rate changes on cash and cash equivalents				(1,879)	(333)
Increase in cash and cash equivalents				6,375	5,290
Cash and cash equivalents - beginning of period				19,891	9,931
Cash and cash equivalents - end of period	26,266	26,266	15,221	26,266	15,221
Eliminations
Operating Activities
Net income (loss)		(58,627)	(45,333)	(105,440)	(143,855)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization				0	0
Loss on divestitures and sales of property and equipment				0
Deferred income taxes				0	0
Amortization of debt origination costs				0	0
Stock-based compensation costs				0	0
Loss on extinguishment of debt					0
Gain on sale or disposal of property and equipment					0
Equity in income of subsidiaries				105,267	143,925
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable				0	0
Inventories				173	(70)
Prepaid expenses and other current assets				0	0
Accounts payable				0	0
Accrued liabilities				0	0
Net cash provided by operating activities				0	0
Investing Activities
Purchases of property and equipment				0	0
Proceeds from sale of business				0
Proceeds from the sales of property and equipment				0	0
Net cash provided by investing activities				0	0
Financing Activities
Term loan repayments				0	0
Borrowings under revolving credit agreement				0	0
Repayments under revolving credit agreement				0	0
Payments of debt origination costs				0	0
Proceeds from exercise of stock options				0	0
Proceeds from restricted stock exercises					0
Excess tax benefits from share-based awards				0	0
Fair value of shares surrendered as payment of tax withholding				0	0
Intercompany activity, net				0	0
Net cash used in financing activities				0	0
Effects of exchange rate changes on cash and cash equivalents				0	0
Increase in cash and cash equivalents				0	0
Cash and cash equivalents - beginning of period				0	0
Cash and cash equivalents - end of period	0	$ 0	$ 0	0	0
DenTek Oral Care, Inc.
Investing Activities
Proceeds from previous acquisitions	$ 1,400			1,419	0
DenTek Oral Care, Inc. | Prestige Brands Holdings, Inc.
Investing Activities
Proceeds from previous acquisitions				0
DenTek Oral Care, Inc. | Prestige Brands, Inc., the issuer
Investing Activities
Proceeds from previous acquisitions				0
DenTek Oral Care, Inc. | Combined Subsidiary Guarantors
Investing Activities
Proceeds from previous acquisitions				1,419
DenTek Oral Care, Inc. | Combined Non- Guarantor Subsidiaries
Investing Activities
Proceeds from previous acquisitions				0
DenTek Oral Care, Inc. | Eliminations
Investing Activities
Proceeds from previous acquisitions				0
Insight Pharmaceuticals
Investing Activities
Proceeds from previous acquisitions				$ 0	7,237
Insight Pharmaceuticals | Prestige Brands Holdings, Inc.
Investing Activities
Proceeds from previous acquisitions					0
Insight Pharmaceuticals | Prestige Brands, Inc., the issuer
Investing Activities
Proceeds from previous acquisitions					0
Insight Pharmaceuticals | Combined Subsidiary Guarantors
Investing Activities
Proceeds from previous acquisitions					7,237
Insight Pharmaceuticals | Combined Non- Guarantor Subsidiaries
Investing Activities
Proceeds from previous acquisitions					0
Insight Pharmaceuticals | Eliminations
Investing Activities
Proceeds from previous acquisitions					$ 0

Subsequent Events (Narrative) (

Subsequent Events (Narrative) (Details) - USD ($)	Jan. 26, 2017	Sep. 03, 2014
Loans payable, Term B-4 | Term Loans | Subsequent event
Subsequent Event [Line Items]
Debt instrument, face amount	$ 1,427,000,000
LIBOR | Loans payable, Term B-4 | Term Loans | Subsequent event
Subsequent Event [Line Items]
Debt instrument, basis spread on variable rate (percent)	2.75%
Debt instrument, variable rate, minimum	0.75%
Revolving Credit Facility | Loans payable, Term B-4 | Subsequent event
Subsequent Event [Line Items]
Debt instrument, conditional variable rate (percent)	2.50%
Revolving Credit Facility | 2012 ABL Revolver Amendment 3
Subsequent Event [Line Items]
Line of credit facility, increase in borrowing capacity		$ 40,000,000
Revolving Credit Facility | 2012 ABL Revolver Amendment 3 | Subsequent event
Subsequent Event [Line Items]
Line of credit facility, increase in borrowing capacity	$ 40,000,000
Merger Agreement | Subsequent event
Subsequent Event [Line Items]
Purchase price	825,000,000
Merger Agreement | Term Loans | Subsequent event
Subsequent Event [Line Items]
Debt instrument, face amount	$ 740,000,000